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ABSTRACT 
 While it is clear that most drugs of abuse act to increase extracellular 
dopamine levels in the nucleus accumbens (NAc), the molecular mechanisms 
mediating this process vary depending on the molecular target each drug acts 
on.  The rewarding properties of most drugs of abuse including cocaine, 
amphetamine, and heroin have been well established for some time; however, 
the molecular mechanisms by which ethanol acts to mediate reward have not 
been fully elucidated.  In this thesis, I have examined the role of nicotinic 
acetylcholine receptors (nAChRs), known molecular targets for nicotine 
addiction, in mediating the initial rewarding properties of alcohol.  Using a mouse 
model of voluntary ethanol consumption called Drinking in the Dark (DID), in 
combination with nAChR pharmacology and mouse genetics, we have provided 
further evidence for the role of nAChRs in mediating the initial rewarding 
properties of ethanol.  Because of the vast number of possible functional nAChR 
subtypes present in the brain, I sought to investigate which subtype of nAChR 
may be responsible for ethanol reinforcement.  To accomplish this, I used two 
complementary nAChR mouse models.  The first is a knock-out line that does not 
express the α4 subunit (α4 KO) and the second is a knock-in line that expresses 
α4* nAChRs that are hypersensitive to agonist (Leu9′Ala). We have also shown, 
for the first time, that a specific nAChR subtype, those that contain the α4 subunit 
(α4*), mediate voluntary ethanol consumption and reward.  Next, I examined the 
role of α4* nAChRs in modulating voluntary ethanol consumption after systemic 
viii 
administration of the FDA approved smoking cessation drug varenicline, a partial 
agonist of α4* nAChRs.  We showed that varenicline and nicotine both reduced 
acute ethanol consumption in an α4* nAChR dependent mechanism.  Taken 
together, our data indicate that activation of α4* nAChRs is necessary and 
sufficient for reduction of ethanol consumption and further supports the 
hypothesis that α4* nAChRs are molecular targets for alcohol cessation 
therapies. 
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CHAPTER I.  
BRAIN MECHANISMS THAT MODULATE DRUG AND ALCOHOL ADDICTION 
I.A. Introduction 
 Addiction is a chronic brain disorder, just as is dementia, epilepsy, and 
multiple sclerosis.  It affects people of all cultures, ages, socio-economic status, 
and gender.  According to the National Institute On Drug Abuse website, 
addiction is said to be, “An equal opportunity destroyer,” and that, “No population 
group is immune to substance abuse and its damage.”  However, unlike other 
diseases, the social stigma of drug addiction is very negative.  People suffering 
from addictions are often labeled as addicts and drug users, and this stigma 
often prevents them from seeking and receiving treatment. 
 In reality, addiction is a chronic disease that involves several factors.   
Similar to other chronic diseases, addiction can run in families, be influenced by 
environmental factors and behaviors, respond to treatment, and include life-long 
lifestyle changes (McLellan et al., 2000).  While the most commonly thought of 
addiction disorder would be an addiction to a substance such as drugs or 
alcohol, addictions can occur to anything that produces a high or alters ones 
senses.  For example, acts that produce feelings of pleasure, such as overeating, 
pathological gambling, and internet use can result in behavioral addictions (Grant 
et al., 2010; Holden, 2010). 
 Currently, there are several terms used to describe ‘addiction’ and they 
are often used interchangeably.  While manifestation of addictions can change 
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(i.e., alcohol, cocaine, nicotine, gambling, etc.), addictions can be classified as 
either ‘substance abuse’ or ‘substance dependence’.  According to the current 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), substance 
abuse occurs, “When an individual persists in use of alcohol or other drugs 
despite problems related to use of the substance.”  Accordingly, the symptoms 
that must be present to be diagnosed with a substance abuse disorder, also 
defined by the DSM-IV are, “(1) recurrent use resulting in a failure to fulfill major 
obligations at work, school or home; (2) recurrent use in situations which are 
physically hazardous (e.g., driving while intoxicated); (3) legal problems resulting 
from recurrent use; or (4) continued use despite significant social or interpersonal 
problems caused by the substance use.”  However, with prolonged and 
persistence substance abuse, the diagnosis changes from ‘abuse’ to 
‘dependence’.  This occurs when a person (1) has a diagnosed substance abuse 
disorder, (2) continues use despite related problems, (3) has an increase in 
tolerance, and (4) has withdrawal symptoms.  Together, substance abuse and 
substance dependence are considered to be ‘substance use disorders’. 
 To further complicate the matter, the term ‘addiction’ is often interchanged 
with ‘substance dependence’ and is essentially the same.  Drug addiction is 
defined as a chronically relapsing disorder characterized by the compulsion to 
seek and take the drug, loss of control in limiting intake and the emergence of a 
negative emotional state during drug withdrawal (Koob and Le Moal, 1997).  
Recently, drug addiction has been described as a cycle comprising both impulse 
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control and compulsive disorders.  The addiction cycle begins with impulsivity, 
which is associated with the positive reinforcement that drives a motivated 
behavior, and then develops into compulsivity in later stages, which is driven by 
negative reinforcement (Koob, 2004).  Additionally, this cycle can be broken into 
three stages of addiction: binge/intoxication, withdrawal/negative affect, and 
preoccupation/anticipation (Koob et al., 2009).  To fully understand a complex 
disease such as addiction, it is necessary to elucidate the molecular, cellular, and 
circuit level mechanisms of each stage to determine what causes a person to 
develop from a drug user, to abuser, to addict.  Fortunately, there exist several 
animal models of addiction that mimic each stage of the addiction cycle and allow 
researchers to elucidate the molecular mechanisms at each stage. 
THESIS OVERVIEW 
 This thesis will examine one type of addiction, alcohol dependence or 
more commonly referred to as alcoholism (as referred to in the rest of this 
thesis), during the binge/intoxication stage, from the molecular to behavioral 
level.  To understand and study addiction disorders, it is first necessary to 
become familiar with the brain reward pathways and how drugs of abuse can 
hijack the endogenous machinery resulting in feelings of reward.  This first 
chapter will introduce current theories on the molecular mechanisms of drug 
addiction.  I will give a brief background on alcoholism and the currently available 
therapeutic options followed by a discussion of the dopamine reward pathway.  
Next, I will discuss what is known about how alcohol (also referred to as ethanol) 
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interacts with the dopamine reward pathway, the known primary targets of 
ethanol and discuss mouse models of alcoholism. Finally, I will give an 
introduction to neuronal nicotinic acetylcholine receptors (nAChRs) and what is 
currently known about the role of nAChRs in ethanol reward, which will be the 
focus of the rest of my thesis. 
 The second chapter will explore the role of wild type (WT) nAChRs in an 
assay designed to measure acute voluntary ethanol consumption, termed 
Drinking in the Dark (DID).  Because the role of nAChRs in voluntary ethanol 
intake was unknown, we sought to measure ethanol intake in WT mice after 
acute injections of several different nAChR agonists and antagonists.  We also 
evaluated the effect of nAChR drugs on the activation of dopaminergic (DAergic) 
neurons of the ventral tegmental area (VTA).  Our results indicate that the 
nAChR antagonist mecamylamine, as well as two nAChR agonists, nicotine and 
cytisine, can decrease acute ethanol intake.  Additionally, we showed that while 
nicotine and ethanol can both activate DAergic neurons of the VTA, 
mecamylamine can block the ethanol induced activation of dopamine (DA) 
neurons.  This result suggests that ethanol activates DAergic neurons of the VTA 
via neuronal nAChRs and that nAChRs modulate acute ethanol voluntary intake 
(Hendrickson et al., 2009).   
 Because of the vast number of possible functional nAChR subtypes 
present in the brain (Grady et al., 2007), the next area we sought to investigate 
was which subtype of nAChR may be responsible for ethanol reinforcement.  
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Several reports have shown that the two most commonly co-abused drugs are 
nicotine, the primary psychoactive ingredient found in tobacco products, and 
alcohol (Falk et al., 2006; Funk et al., 2006).  The molecular mechanisms of 
nicotine addiction are well established and studies have shown that nAChRs 
containing the alpha 4 subunit (termed α4* nAChRs) are necessary and sufficient 
for nicotine addiction (Tapper et al., 2004).  Thus, due to the common co-abuse 
of nicotine and alcohol, it is thought that these two drugs may have similar or 
overlapping molecular targets in the brain.  Therefore, we sought to determine if 
this subtype of nAChR might also play a role in alcohol addiction.  To accomplish 
this, we used two complementary nAChR mouse models.  The first is a knock-out 
line that does not express the α4 subunit (α4 KO) and the second is a knock-in 
line that expresses α4* nAChRs that are hypersensitive to agonist (Leu9′Ala). 
The third chapter of this thesis will examine the contribution of α4* nAChRs to 
ethanol reward using several alcohol assays including voluntary consumption, 
ethanol conditioned place preference and ethanol induced activation of the VTA 
in both the α4 KO and Leu9′Ala nAChR mouse models.  Combining these two 
mouse lines, our results show both the necessity and sufficiency of α4* nAChRs 
in ethanol reward.  
 One of the main goals in alcohol addiction research, aside from 
elucidating the molecular mechanisms contributing to alcohol abuse, is 
identifying possible molecular targets for alcohol therapeutics.  Currently, there 
are alcohol cessation drugs available; however, there exists a large variability in 
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response such that only 20 % - 30 % of patients respond to treatment (Spanagel, 
2009).  Chapter four of this thesis will examine α4* nAChRs as molecular targets 
for alcohol cessation therapies.  First, we show that ethanol induces c-Fos 
expression in a selective region of the brain, the posterior VTA.  Additionally, the 
DAergic neurons that were activated by ethanol have higher gene expression of 
specific nAChR subunit genes, namely the α4, α6 and β3 subunits.  Next, using 
the two aforementioned nAChR mouse models, we examined the role of α4* 
nAChRs in modulating voluntary ethanol consumption after systemic 
administration of the FDA approved smoking cessation drug varenicline (Coe et 
al., 2005; Jorenby et al., 2006), a partial agonist of α4* nAChRs.  We showed 
that varenicline reduced acute ethanol consumption in an α4* nAChR dependent 
mechanism.  Finally, we show that an infusion of varenicline directly to the 
posterior VTA, but not the anterior VTA, decreases voluntary ethanol intake 
(Hendrickson et al., 2010).   
 The fifth chapter of this thesis expands on chapter four by showing that an 
additional nAChR agonist, nicotine, also decreases ethanol intake in an α4* 
nAChR dependent manner (Hendrickson et al., 2011).  Taken together, our data 
indicate that activation of α4* nAChRs is necessary and sufficient for reduction of 
ethanol consumption and further supports the hypothesis that α4* nAChRs are 
molecular targets for alcohol cessation therapies.   
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 The sixth and final chapter of this thesis will be a discussion of the 
research presented including the contribution to the field as well as future 
directions and concluding remarks.   
 
I.B. Alcoholism: Background and current therapies 
 Approximately 4 % of US adults, over 12.5 million people, are dependent 
on alcohol (Hasin et al., 2007) and alcoholism is the third leading cause of 
preventable mortality in the US (Mokdad et al., 2004).  The estimated economic 
cost of alcoholism in the US, due to health care costs as well as productivity 
impacts such as lost wages, was $220 billion in 2005, which was significantly 
higher than cancer ($196 billion) or obesity ($133 billion) (CASA, 2005).  
Worldwide, about 2 billion people consume alcohol, with 76.3 million who have 
diagnosable alcohol use disorders.  Additionally, when analyzing the global 
burden of this disease, alcohol causes 1.8 million deaths (3.2 % of the worldwide 
total) and accounts for 4 % of the total Disability-Adjusted Life Years (DALYs) 
(World Health Organization. Dept. of Mental Health and Substance Abuse., 
2004).   
 However, while alcohol use is common in most populations, not every 
person that uses alcohol will become addicted to it.  Why do some people lose 
control over their alcohol use or drink irresponsibly at times while others are able 
to drink responsibly?  What causes one person’s alcohol consumption to 
escalate to the point of a physical dependence on alcohol, such that they 
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experience withdrawal symptoms when they discontinue alcohol use?  These are 
just a few of the questions that the neuroscience field is currently working on. 
 One area of alcoholism research seeks to understand the genetic, circuit, 
cellular and molecular mechanisms that underlie the transition from drug use to 
drug addiction.  This would most closely align with the first addiction cycle, as 
discussed previously, which is associated with positive reinforcement and 
motivated behaviors, i.e., the binge/intoxication stage.  Research on this stage of 
addiction focuses on the acute response of the drug in specific brain regions that 
are known to modulate reward, the dopaminergic mesolimbic pathway, which is 
the focus of this thesis and described in more detail in the next section.  Other 
areas of alcohol research that study chronic alcohol consumption, alcohol 
withdrawal, and alcohol craving and relapse are analogous to the second and 
third stages of addiction and focus this research on brain regions including the 
central and extended amygdala, bed nucleus of the stria terminalis (BNST) and 
the nucleus accumbens. 
 While several areas of alcoholism research exist, the end goal of the 
majority of research is to identify new and improved treatment options for those 
suffering from alcoholism.  Currently, there are three FDA approved medications 
for treating alcoholism.  The first, disulfriam, was approved in 1954, and is 
classified as an anti-relapse medication (Christensen et al., 1991).  It is an 
acetaldehyde dehydrogenase inhibitor, which after drinking alcohol allows the 
buildup of acetaldehyde in the blood, causing symptoms including headache, 
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nausea, vomiting, weakness, mental confusion, or anxiety (Christensen et al., 
1991).  However, in recent years, many doctors have stopped prescribing this 
drug because of the severe symptoms it causes and the fact that if a patient 
wished to drink again, they could simply not take their medication.  Naltrexone, 
available since 1994, is a competitive opioid receptor antagonist that works by 
decreasing the euphoric effects produced by alcohol.  It is considered to be an 
anti-relapsing drug because it decreases heavy drinking in patients with 
alcoholism and prevents relapse to heaving drinking (O'Malley et al., 1992; 
Volpicelli et al., 1992).  The third drug, acamprosate, is a partial agonist of NMDA 
glutamate receptors and an antagonist of metabotropic glutamate receptors and 
is thought to act as an anti-craving medication by inhibiting glutamate signaling 
(Mason, 2003; Mason et al., 2006).  While European studies have reported 
modest benefits with acamprosate, these studies have not been reproducible in 
the US (Pettinati et al., 2006).   
 Unfortunately, while these medications have been effective for some, only 
20-30 % of treated patients respond to the anti-craving and anti-relapsing 
compounds (Spanagel, 2009).  Interestingly, new studies have shown that 
people with different genetic profiles may drink for different reasons, and also 
that they may respond better to one type of medication versus another. For 
example, populations with a specific type of mu opioid receptor respond to 
naltrexone better than others, and this group has been described as ‘feel good 
drinkers’ (Anton et al., 2008; Oslin et al., 2006).  Another population of alcoholics 
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report that they drink to relieve feelings of stress and anxiety (Kuehn, 2009) for 
which new medications are currently being tested (George et al., 2008).  This 
large variability in patient response is a driving force in identifying new molecular 
targets for improved pharmacotheraputic drugs.  Consequently, the main focus of 
alcoholism treatments has been to restore the balance to the different 
biochemical pathways in the brain that are disrupted during alcohol dependence.    
 
I.C. Brain reward mechanisms 
 Species that learned to respond to natural rewards, like when and where 
they could obtain food and opportunities for mating, ensured their survival and 
achieving these goals function as rewards (Hyman et al., 2006).  Consequently, 
many neural substrates that modulate reward systems are conserved across 
species from Drosophila, mice, and rats, to humans and include dopamine (DA), 
G-proteins, protein kinases, amine transporters, and transcription factors 
including the cAMP response element-binding protein (CREB) (Kelley and 
Berridge, 2002).  Later, humans found that this endogenous system can be 
exogenously altered with various drugs.  We now know that responses to natural 
rewards and addictive drugs have many similarities and shared pathways.  In 
fact, one study has shown a cross-sensitization between the natural reward 
sugar, and the drug amphetamine (Avena and Hoebel, 2003).   
 One common effect of natural rewards and most drugs of abuse is an 
enhancement of activity in the mesolimbic dopamine system (discussed in more 
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detail below), leading to an increase of dopamine release in the nucleus 
accumbens (Di Chiara and Imperato, 1986; Koob and Bloom, 1988; Wise, 1998).  
While it is widely accepted that the epicenter of reward in the brain, whether 
natural or drug, is the mesolimbic dopamine system, much controversy exists 
regarding the role of dopamine in modulating goal-directed behavior.  Mesolimbic 
dopamine has been proposed to play a role in functions such as movement, 
motivation, reward, learning, arousal, attention and emotion (Gonzales et al., 
2004).  This makes sense because each of these individual behavioral 
components is necessary for the outward, measurable behavior of reward (i.e., 
an organism must locate a reward, pay attention and learn where to find it, like it 
and have a desire to return to it).   
MESOCORTICOLIMBIC DOPAMINE PATHWAY 
 It widely accepted that the mesocorticolimbic dopamine system plays a 
central role in modulating the rewarding effects of drugs of abuse (Koob, 1992; 
Wise and Bozarth, 1987).  Olds and Milner first identified this pathway in 1954.  
Using brain stimulation reward (BSR) they discovered that rats returned to the 
same region of a testing apparatus where they had received electrical stimulation 
to the septal area of the brain (Olds and Milner, 1954).  Upon further examination 
using mapping and lesion studies, it was determined that the most sensitive sites 
in the brain (i.e., lowest stimulation threshold) were along the medial forebrain 
bundle (MFB) which connects the ventral tegmental area (VTA) to the basal 
forebrain (Corbett and Wise, 1980; Olds and Milner, 1954; Wise, 1981).  Next, 
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using pharmacology, studies showed that dopaminergic receptor blockade 
attenuated brain stimulation reward (Liebman, 1983; Wise, 1978), suggesting 
that specific neurotransmitter systems were involved in reward mechanisms 
(Wise, 1987). 
  Flash-forward almost 60 years and what was once commonly referred to 
as the ‘reward circuit’ is now known as the mesolimbic dopamine pathway.  This 
pathway consists of dopaminergic neurons whose cell bodies originate in the 
ventral tegmental area (VTA), a region of the midbrain, and project to regions of 
the limbic system including the nucleus accumbens (NAc), amygdala and 
hippocampus.  An additional dopaminergic pathway, the mesocortical pathway, 
also originates in the VTA and project to regions of the prefrontal cortex.  These 
pathways are shown in a simplified diagramed in Fig. I-1. 
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Figure I-1.  The Mesocorticolimbic Dopamine Pathway in a rodent brain.  DAergic neurons 
originate in the VTA and project to the NAc making the mesolimbic pathway and to the prefrontal 
cortex, making the mesocortical pathway.  The majority of GABAergic neurons in the VTA are 
interneurons while a small subset also project from the VTA to the NAc as well as other forebrain 
regions.  The VTA receives ACh, glutamate and GABAergic inputs from the PPTg and LTD and 
glutamate inputs from the prefrontal cortex.  
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THE VENTRAL TEGMENTAL AREA 
 The VTA is known to at least partially mediate the rewarding effects of 
nicotine, opiates, ethanol and cannabinoids (Ikemoto, 2007).  For example, rats 
and mice will self-administer opiates (Bozarth and Wise, 1981), cannabinoids 
(Zangen et al., 2006), cocaine (Rodd et al., 2005), nicotine (David et al., 2006) or 
ethanol (Gatto et al., 1994; Rodd-Henricks et al., 2000) directly into the VTA.  
Additionally, intravenous nicotine self-administration is attenuated by either 
selective lesions of VTA dopaminergic neurons in rats (Corrigall et al., 1992) or 
by a local VTA infusion of a nicotinic receptor antagonist (Corrigall et al., 1994).  
 The ventral tegmental area is located in the midbrain, medial to the 
substantia nigra and ventral to the red nucleus (Paxinos, 2000).  It is referred to 
as an ‘area’ and not considered to be a ‘nucleus’ because the cryoarchitecture of 
the region is not well defined such that the boundaries of the VTA are determined 
by its neighboring structures (Fields et al., 2007; Ikemoto, 2007).  Within the VTA 
are two main cell populations, the A10 DAergic projection neurons, which 
comprise ~60% of cells in this region (Swanson, 1982), as well as local 
GABAergic interneurons (Carr and Sesack, 2000; Margolis et al., 2006b).   The 
VTA receives inputs from regions throughout the CNS (Geisler and Zahm, 2005) 
including glutamatergic projections from the prefrontal cortex (Sesack and Pickel, 
1992), as well as glutamatergic, cholinergic and GABAergic projections from two 
groups of mesopontine tegmental area neurons, the pedunculopontine tegmental 
nucleus (PPTg) and the laterodorsal tegmental nucleus (LDT) (Cornwall et al., 
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1990; Oakman et al., 1995; Semba and Fibiger, 1992).  Other regions projects to 
the VTA include the NAc, amygdala, ventral pallidum, superior colliculus and 
lateral hypothalamus (Fields et al., 2007). Additionally, the lateral habenula, a 
small nucleus that is a part of the epithalamus, has been shown to project to 
midbrain areas that modulate the release of dopamine including the VTA and 
substantia nigra pars compacta (Herkenham and Nauta, 1979; Ji and Shepard, 
2007; Matsumoto and Hikosaka, 2007).    
 Projections from the VTA are primarily to the ventromedial striatum 
including the nucleus accumbens shell and core as well as smaller projections to 
the prefrontal cortex (PFC), hippocampus, entorhinal cortex and lateral septal 
areas (Fields et al., 2007).  Furthermore, studies using retrograde tracers have 
shown that distinct groups of neurons originating in the VTA project to specific 
forebrain regions (Fallon et al., 1984; Margolis et al., 2006a).  Projections to the 
NAc contain the largest proportion of DA neurons, with 65-85% being DAergic, 
while the PFC projections are only 30-40% DAergic (Fallon et al., 1984; 
Swanson, 1982).  The remaining component of VTA afferents to the NAc and 
PFC arise from GABAergic neurons (Carr and Sesack, 2000).  Recently, 
evidence has shown that the VTA is not a homogeneous region and can be 
divided into three subregions, the anterior VTA, posterior VTA and the tail VTA.  
Additionally, evidence indicates that each region may project to distinct regions of 
the striatum and may also respond differently to drugs of abuse (Ikemoto, 2007; 
Shabat-Simon et al., 2008).  
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THE NUCLEUS ACCUMBENS 
  For decades, the nucleus accumbens has been a main focus of 
mesolimbic dopamine in studies of natural and drug reward (Gonzales et al., 
2004).  It is located in the ventromedial striatum and is primarily composed of 
GABAergic medium spiny neurons (~95 %) and to a lesser extent, cholinergic 
interneurons (1-2 %).  Two distinct regions of the nucleus accumbens have been 
described, the core and shell, based on differences in functions and anatomical 
connectivity (Heimer et al., 1991; Zahm, 1999).  Additionally, studies have shown 
that the response to extracellular dopamine release of these two regions differs.  
For example, it has been shown that the dopamine release induced by a food 
reward is rapidly habituated in the shell, but not the core (Bassareo et al., 2002).  
Another study showed differential NAc shell and core Fos immunolabeling of 
cholinergic interneurons after cocaine self-administration (Berlanga et al., 2003).  
These and other data suggest the possibility that the shell may act to modulate 
the initiation of drug seeking behavior by mediating the hedonic states associated 
with reward (Pecina and Berridge, 2000; Rodd-Henricks et al., 2002) while the 
core may modulate acquisition and maintenance of drug seeking (Ito et al., 
2004).   
 The extracellular dopamine concentration in the NAc is regulated by two 
main factors; (1) the rate of release of dopamine from DAergic neurons that 
originate in the VTA and (2) by dopamine uptake through dopamine transporters 
located in perisynaptic areas (Nirenberg et al., 1997).  DAergic neurons of the 
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VTA are known to be the main input source of extracellular DA in the NAc.  
Under normal conditions, the action potential (AP) firing rate of DAergic neurons 
is tonic with spike activity at 1-5 Hz (Grace and Bunney, 1984).  However, when 
an unexpected presentation of a primary reward or a reward-predicting stimulus 
occurs, the firing rate increases to 2-10 APs at 10-30 Hz (Pan et al., 2005; 
Schultz, 1998).   
DRUGS OF ABUSE 
 Drugs of abuse are varied in chemical structure and act on several 
different molecular targets to hijack the endogenous brain reward circuitry.  While 
drugs can have different physiological effects (i.e., sedative or stimulant) it is 
clear that they all act, at least acutely, on the mesolimbic dopamine pathway to 
increased dopamine in the NAc (Wise and Rompre, 1989).  The primary 
molecular targets for most drugs of abuse including nicotine, cocaine, 
amphetamines and opioids has been extensively studied and well defined 
(Gonzales et al., 2004).  Some drugs act on the primary, dopamine containing 
neurons, while others act on secondary neurons within the circuit.  For example, 
nicotine binds to and activates nicotinic acetylcholine receptors (nAChRs), ligand 
gated ion channels that modulate presynaptic dopamine release, while cocaine 
binds to and blocks the presynaptic dopamine transporter (Koob et al., 1998).  
Other drugs such as morphine and heroin increase dopamine release by acting 
at the circuit level.  These drugs bind G-protein coupled opioid receptors located 
on GABAergic interneurons and cause them to become hyperpolarized.  This 
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reduces the GABA input to the DAergic neurons, leading to a disinhibition of DA 
neurons, which results in an increase of DA release.  Thus, the effect of most 
drugs of abuse in the brain is the result of the molecular interactions between the 
drug and the primary molecular targets found on neurons that result in an 
increase of DA release in the NAc.  However, the molecular mechanisms of how 
ethanol alters the activity of mesolimbic dopamine system are not entirely clear. 
 
I.D. Alcohol’s action in the mesolimbic pathway 
 There are likely to be similarities and overlapping mechanisms in how the 
brain is affected by alcoholism compared to other drugs of abuse.  Although it is 
clear that most addictive drugs produce an increase in mesolimbic DA release, 
the precise mechanisms that lead to an increase in extracellular DA vary 
according to the molecular targets upon which each specific drug acts.  So 
understanding how alcohol produces the disease alcoholism requires knowledge 
of how ethanol affects particular molecular, cellular and system level functions.   
ACUTE EFFECTS OF ETHANOL ON DOPAMINERGIC NEURONS OF THE 
VTA 
 Several papers published in the late 1980s and early 1990s further 
implicated the role of the mesolimbic DA system in mediating the reinforcing 
properties of ethanol. In 1985, ethanol was first shown to cause a dose-
dependent increase in the spontaneous firing rate of DAergic neurons in vivo 
(Gessa et al., 1985).  This paper also showed that DAergic neurons of the VTA 
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were activated by lower doses of ethanol compared to the neighboring DAergic 
neurons in the substantia nigra.  This suggested that ethanol preferentially 
activated the DAergic neurons of VTA.  Soon after, it was shown that systemic 
administration of several drugs of abuse, including ethanol, stimulated DA 
transmission, resulting in increased dopamine levels in the NAc (Di Chiara and 
Imperato, 1988; Imperato and Di Chiara, 1986).  Later, additional studies found 
that rats will self-administer ethanol directly into the VTA (Gatto et al., 1994), and 
more specifically, the posterior VTA (Rodd et al., 2004).  Interestingly, studies 
also found that ethanol induced a dose-dependent increase in spontaneous firing 
of VTA DAergic neurons that were placed in media that blocked synaptic 
transmission or even in acutely dissociated DAergic neurons (Brodie et al., 1999; 
Brodie et al., 1990) suggesting that ethanol acts directly on these DAergic 
neurons.  Thus, the search for primary targets of ethanol has been a main focus 
of the alcohol research field.   
THE PROTEIN THEORY: ETHANOL’S PRIMARY TARGETS 
 Until the 1980s, it was believed that alcohol affected the central nervous 
system by acting on and perturbing membrane lipids of CNS neurons (Spanagel, 
2009).  Several lipid theories were proposed and these suggested that alcohol 
affected the membrane fluidity, disordering, volume occupation or expansion 
(Peoples et al., 1996).  This theory however, has fallen out of favor in recent 
years due to several restrictions of the hypothesis.  For example, to induce 
membrane disorder, extremely high concentrations of alcohol (>500 mg/dl blood 
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alcohol level (BAL)) that are close to the LD50 of ethanol in humans is necessary.  
Even at high physiological concentrations of ethanol (~300 mg/dl) that induce 
loss of consciousness, only 1 alcohol molecule would be present per ~200 lipid 
molecules (Peoples et al., 1996; Spanagel, 2009).  These and other observations 
led to an ideological switch in the 1970s to a theory of alcohol that suggested that 
alcohols bound directly to proteins, producing conformational changes that 
diminished or abolished their activity (Eyring et al., 1973). 
 Three general mechanisms of action were proposed as to how alcohols 
could interact with proteins such as ligand-gated ion channels (Peoples et al., 
1996).  Alcohols could interact with the ligand-binding site and act as agonists or 
competitive antagonists, they could act on modulatory sites of the receptor to 
change agonist binding or cause the opening of the channel to occur more or 
less frequently, or alcohols could act as a physical channel blocker by binding a 
site within the ion channel lumen (Peoples et al., 1996).  Therefore, determining 
which proteins are sensitive to ethanol and elucidating how ethanol affects the 
structure and function of those proteins to alter cellular physiology are of 
particular importance.  Additionally, the protein theory is favorable from a 
therapeutic standpoint because developing pharmacotheraputic drugs targeted 
for proteins tend to be more specific than drugs targeted to lipids. 
 Indeed, this theory was validated by the findings that physiological 
concentrations of ethanol, ranging from 30 to 100 mM, directly affect the function 
of several ligand-gated ion channels including glutamate, GABAA, glycine, 
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nAChR and 5-hydroxytryptamine 3 (serotonin) (5-HT3) receptors (Lovinger, 
1997).  Several studies have identified a role for alcohol action on glycine and 
GABAA chloride-sensitive ion channels, with the most common effect being an 
enhancement of receptor function (Mihic et al., 1997; Suzdak et al., 1986; Wick 
et al., 1998).  Similarly, alcohol has been shown to potentiate 5-HT3 receptors 
(Lovinger, 1999) and neuronal nAChR function (Narahashi et al., 1999), which 
will be discussed in more detail in the next section.  Interestingly, this potentiating 
effect of ethanol is similar in these receptor channels that are all part of the cys-
loop family.  This family shares similar features including a pentameric structure, 
four transmembrane (TM) domains per subunit, a membrane-spanning pore 
forming region in TM2, and a short loop defined by a disulfide bond in the amino 
terminal region (Lovinger, 1997).  Unlike the previously mentioned receptors, 
alcohol was shown to inhibit the ionotropic glutamate receptors including the 
AMPA, NMDA and kainate, but with varied mechanisms and effects (Dopico and 
Lovinger, 2009).   
 Several non-ligand-gated ion channels have also been implicated as 
primary targets of alcohol.  For example, alcohol inhibits L-type Ca2+ channels 
(Wang et al., 1994), opens G-protein-activated inwardly rectifying K+ channels 
(GIRKS) (Kobayashi et al., 1999), and modulates the steady-state activity of 
large-conductance calcium- and voltage-gated  potassium (BK) channels (Dopico 
et al., 1996).   
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 While these receptors and ion channels are the currently known primary 
targets of ethanol, the action of ethanol depends on several variables including 
the concentration of ethanol and subunit composition of the channel or receptor 
(Spanagel, 2009).  Additionally, the overall effect of how alcohol’s modulation of 
these proteins at the molecular level contributes to altered neuronal cell 
physiology, and eventually to changes in circuit level processing to mediate the 
rewarding properties of alcohol remains an open question.   
MOUSE MODELS OF ALCOHOLISM 
 The disease alcoholism is a very complex disorder that cannot easily be 
reproduced in its entirety.  Fortunately, several animal models exists that focus 
on specific aspects of human addictions including self-administration, reward, 
withdrawal and locomotor activation (Schlaepfer et al., 2008b).  Furthermore, the 
animal models used to represent the human aspects have strong face validity 
(Koob et al., 2009).  This means that the animal model seems to be a valid 
representation of what is supposed to be measured (i.e., the animal phenotype 
resembles a human trait).  It is useful to develop animal models defined by the 
symptoms that are specific for each stage of the addiction cycle including the 
binge-intoxication stage, the withdrawal-negative affect stage and the 
preoccupation-anticipation stage.  For the purpose of this thesis, I will focus on 
animal models of the binge-intoxication stage. 
 To create an accurate representation of alcohol addiction in an animal 
model, certain criteria have been proposed: 1) ethanol should be orally self-
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administered; 2) the amount of ethanol consumed should elevate blood ethanol 
concentration (BEC) to pharmacologically significant levels; 3) ethanol should be 
consumed for its pharmacological effects, rather than calories, taste or smell; 4) 
ethanol should be positively reinforcing; 5) chronic ethanol consumption should 
produce metabolic and functional tolerance; and 6) chronic ethanol consumption 
should produce signs of physical dependence (Cicero, 1980; Rhodes et al., 
2005).  In reality, it would be quite difficult to include all of these criteria into one 
model, but partial models do exist.    
 Preference drinking is one of the most widely used partial mouse models 
of alcoholism (Belknap et al., 1993; McClearn and Rodgers, 1959; Metten et al., 
1998).  In this assay, animals receive a bottle of plain water and a bottle of an 
ethanol solution in their home cage and consumption of each solution is 
measured over a 24hr period for several days to weeks to determine the animal’s 
preference for ethanol or water.  This assay led to the discovery of certain mouse 
lines that have genetically based preferences for ethanol.   
 For instance, the C57BL/6 strain of inbred mouse has an inherently high 
preference for ethanol, CBA/J mice have a moderate preference for alcohol and 
the DBA/2 strain will almost completely avoid ethanol (McClearn and Rodgers, 
1959; Rhodes et al., 2007).  Indeed, several studies have confirmed that C57BL 
genes are a strong predictor for high alcohol drinking by showing that other 
strains in the C57 lineage including C57/LJ, C57BR/cdJ, C58/J and C57BL/10J 
also show high ethanol preferences (Belknap et al., 1993; Rhodes et al., 2007; 
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Rodgers, 1966).  One proposed hypothesis for the difference in alcohol 
preference in C57BL/6J mice is that this strain contains fewer dopamine D2 
receptors in the hypothalamus and hippocampus compared to strains that avoid 
alcohol such as DBA/2J mice (Ng et al., 1994).  This same result has also been 
found in rats that are selectively bred for high alcohol preference compared to 
rats with low alcohol preference (McBride et al., 1997; Stefanini et al., 1992).  
Additionally, C57BL/6J mice treated with dopamine receptor agonists have 
decreased ethanol consumption (Ng and George, 1994), suggesting that reduced 
dopamine function may result in the high ethanol preference seen in C57BL/6J 
mice (Kamdar et al., 2007).   
 However, even when using high alcohol preferring mouse strains in 
preference drinking assays, mice will rarely reach BEC levels that produce 
measurable effects on behavior and physiology and the measured BECs also 
tend to fluctuate with drinking throughout the 24 hour period (Dole and Gentry, 
1984).  As a result, this would not be an appropriate assay to use to test the 
efficacy of pharmacotherapeutic drugs for reducing ethanol intake (Le et al., 
1994; Rhodes et al., 2005).   
 When the period of alcohol intake is limited in the two-bottle assay, from 
24 hours to a short period each day, several studies found that the rate of 
ethanol consumption and BEC is increased relative to continuous access 
(Linseman, 1987; Macdonall and Marcucella, 1979); however, the BECs 
achieved in the limited access assay remained low (~0.50 mg/ml).  Interestingly, 
25 
in a study of the temporal pattern of ethanol intake, it was shown that rats 
consumed ethanol in discrete bouts mostly during the dark phase of the light-
dark cycle (Gill et al., 1986). 
 Many labs have developed models of alcohol self-administration in which 
mice do reach pharmacologically significant levels of BEC.  One paradigm 
requires a 35-day ethanol training period, food restriction to 80 % of baseline 
weight, and periodic water deprivation for 22 hours followed by placement of food 
in the cage 1h prior to placement of the ethanol bottle to induce “high thirst 
motivation” (Middaugh et al., 1999).  While this assay results in mice reaching 
high ethanol intake (~8 g/kg) and BECs (~3.5 mg/ml), it does not have high face 
validity (Rhodes et al., 2005) because of the altered motivational state of the 
mice.  Variations on this assay include using a sucrose fading design where mice 
are initially exposed to high sucrose and low ethanol concentrations and over the 
course of several days the sucrose concentration decreases while the ethanol 
concentration increases (Samson, 1986; Tolliver et al., 1988).  In this assay, 
mice are trained to consume up to 3 g/kg ethanol and reach BECs averaging 2.5 
mg/ml (Ryabinin et al., 2003).  Similarly, water deprivation fading prior to ethanol 
placement results in behavioral intoxication in motor coordination tests (Cronise 
et al., 2005; Finn et al., 2005). 
 An additional model of alcoholism that has greater face validity is operant 
conditioning.  In this assay the mice learn to perform a behavior such as a nose 
poke or lever press in order to receive ethanol.  While this assay does produce 
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pharmacologically significant drinking in rodents, it requires a lengthy training 
period and much attention to individual animals (Rhodes et al., 2005) 
 In 2005, a new rodent model of alcoholism was introduced that does not 
require food or water restriction and produces pharmacologically significant 
drinking.  This model, now referred to as “Drinking-In-The-Dark” (DID), is a 
relatively simple, limited access procedure that allows for high-throughput 
screening of drugs that may act to alter ethanol consumption (Rhodes et al., 
2005).  The procedure works by taking advantage of the normal diurnal rhythm of 
consumatory behavior of mice (Freund, 1970; Goldstein and Kakihana, 1977).  
Mice eat and drink according to a sinusoidal curve and the peak time period of 
increased eating and drinking occurs within the first few hours into the dark cycle 
(Kurokawa et al., 2000).  Thus, the assay begins 2 hours after the lights are off 
when the water bottle is removed from the home cage and replaced with a single 
ethanol bottle that is left in place for 2 hours.  Ethanol intake is recorded and 
converted to grams ethanol per kilogram body weight of the mouse.  
 The DID assay has many benefits over the previously described methods.  
For instance, from the first day of presenting the ethanol bottle, mice will 
consume high concentrations of ethanol.  Interestingly, the concentration of 
ethanol (10 %, 20 %, or 30%) does not affect the quantity of ethanol consumed in 
g/kg, but does affect the volume consumed over the 2-hour period (Rhodes et al., 
2005).  This is important for screening drugs that may act to alter acute ethanol 
intake.  By eliminating the acclimation process of slowly increasing ethanol 
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concentrations over periods of weeks, any changes that would be induced by 
chronic ethanol consumption are also eliminated.  Then, when the assay is 
repeated for 2 or more days, mice will regularly consume ethanol to 
physiologically relevant concentrations of > 1.0 mg/ml BEC.  One pitfall of this 
assay is that it only works well with the high alcohol preferring strain of mice, 
C57BL/6J; however, this happens to be the genetic background strain used in 
our lab.  Thus, the DID procedure was adopted and modified for use in our lab.   
 
I.E. nAChRs: Structure, function and role in addiction 
 nAChRs are fast ionotropic receptors that are activated by ACh and 
nicotine (Albuquerque et al., 2009).  They belong to the superfamily of Cys-loop 
ligand-gated ion channels that include receptors for γ-amino butyric acid (GABAA 
and GABAC), glycine and 5-hydroxytryptamine (5-HT3) (Changeux and Edelstein, 
1998; Le Novere and Changeux, 1995).  These ligand-gated ion channels have 
similar structural and functional features.  All subunits in this family contain a pair 
of disulfide-bonded cysteines separated by 13 residues (Cys-loop) in their 
extracellular amino terminus (Karlin, 2002) (Fig. I-2A).  Nicotinic receptors are 
formed by an arrangement of 5 subunits around a central pore with an 
extracellular endogenous ligand-binding domain that is distinct from the channel 
pore (Albuquerque et al., 2009).   
 In vertebrate species, 17 nAChR subunits have been identified (α1-α10, 
β1-β4, γ, δ, and ε) all of which can be found in humans and other mammalian 
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species, except for α8 which has only been identified in avian species (Millar and 
Gotti, 2009).  Subunits are classified as either α-, by the presence of a Cys-Cys 
pair near the start of TM1, or non-α when the Cys pair is missing (Changeux and 
Edelstein, 1998; Le Novere and Changeux, 1995) (Fig. I-2A).  Within the family of 
nAChRs, one more classification must be made between the muscle-type 
nAChRs and neuronal-type nAChRs.  The distinction between these types of 
receptors was first discovered by performing binding assays using radiolabled 
nicotinic agonists.  Muscle-type nAChRs bind the snake venom αBungarotoxin 
(αBgtx) at nM affinity, while neuronal-type nAChRs bind other 3H-agonists with 
nM affinity but do not bind αBgtx (with the exception of α7 containing nAChRs) 
(Lukas and Bencherif, 1992).  Later, it was discovered that the subunit 
composition as well as the major sites of expression differs between muscle and 
neuronal nAChRs (Millar and Gotti, 2009).  The muscle nAChRs consist of the 
α1, β1, γ, δ, and ε subunits and can form functional receptors with only two 
subunit compositions, α1, β1, γ, δ in adult tissues or α1, β1, γ, ε in embryonic 
tissues (Mishina et al., 1986; Takai et al., 1985).  Muscle nAChRs mediate the 
transmission of nerve signals to skeletal muscle, which is critical for the operation 
of voluntary and involuntary muscle response (Lindstrom, 1997). Thus, 
dysfunction of these receptors results in neuromuscular disorders that affect 
muscle control such as Myasthenia Gravis (Lindstrom, 1997).   
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NEURONAL nAChRs: STRUCTURE 
 Neuronal nAChRs regulate processes including neurotransmitter release, 
and cell excitability (Gotti and Clementi, 2004; Role and Berg, 1996).  These 
receptors, as a part of the cholinergic system, have been implicated in 
modulating many physiological functions including anxiety, pain, arousal, and 
food intake (Changeux and Edelstein, 2001; Gotti and Clementi, 2004; Gotti et 
al., 1997).  Further, disruption of neuronal nAChR function and cholinergic 
transmission has been implicated in several CNS diseases including Alzheimer’s 
disease, Parkinson’s disease, drug addiction, and schizophrenia among others 
(Hogg et al., 2003; Lindstrom, 1997).   
Neuronal nAChRs, like all members of the cys-loop family of ligand-gated 
channels are formed by the arrangement of five subunits to create a central pore 
(Albuquerque et al., 2009).  The structure of neuronal nAChRs is homologous to 
muscle nAChRs (Karlin, 2002), for which the atomic structure has been 
determined from electron microscopy studies from the fish electric organ 
(Torpedo nAChRs) (Miyazawa et al., 2003; Unwin, 2005).  Each nAChR gene 
encodes a protein subunit consisting of a large amino-terminal extracellular 
domain composed of β-strands, four transmembrane α-helices segments (M1-
M4), a variable intracellular loop between M3 and M4, and an extracellular 
carboxy-terminus (Corringer et al., 2000) (Fig I-2A).  The extracellular N-terminus 
contains the ACh binding domain that forms a hydrophobic pocket located 
between adjacent subunits in an assembled receptor (Sine, 2002).  The M2 
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segment of all five subunits forms the conducting pore of the channel, and 
regions in the M2 intracellular loop contribute to cation selectivity and channel 
conductivity (Corringer et al., 2000).   
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Figure I-2.  Structure of nicotinic acetylcholine receptors.  A) The membrane topology of an 
individual nAChR subunit.  The N-terminal extracellular domain contains two cysteine pairs (red 
circles) near the beginning of TM1 which would designate this as an α subunit.  Also shown in red 
is the Cys-Cys loop, characteristic of all Cys-loop ligand-gated ion channel subunits.  B) Diagram 
of the pentameric subunit arrangement of an assembled heteromeric nAChR.  C) Subunit 
composition of two examples of homomeric nAChRs (left) and two heteromeric nAChRs (right).  
The yellow diamonds indicate the proposed location of the ACh binding site(s).  Figure modified 
with permission from (Improgo et al., 2010). 
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 Of the 17 total nAChR subunits, twelve have been identified as neuronal 
subunits and consist of nine α subunits (α2- α10) and three β subunits (β2-β4) 
(Le Novere and Changeux, 1995).  As previously mentioned, α subunits contain 
two adjacent cysteines at positions that are homologous to those present at the 
α1 muscle-type nAChR while the β subunits lack the cysteine pair (Changeux 
and Edelstein, 1998).  Five subunits combine to form two classes of receptors: 
homomeric receptors containing only α subunits (α7- α9) or heteromeric 
receptors that contain α and β subunits (α2- α6 and β2- β4) (Dani and Bertrand, 
2007) (Fig. I-2B, 2C).  The most commonly found subtypes in the brain are the 
low affinity α7 homomeric and high affinity α4β2* heteromeric nAChRs.  An 
asterisk in nAChR nomenclature (i.e., α4*, α4β2*) indicates that other nAChR 
subunits are also present and can be read as “α4 containing nAChRs”.  This 
subunit diversity contributes to nAChRs with distinct pharmacological and 
biophysical properties (Gotti et al., 2007; McGehee and Role, 1995).   
 Using heterologous expression systems, the subunit composition and 
resulting pharmacological and biophysical properties of functional nAChRs has 
begun to be elucidated.  When each nAChR subunit was expressed in Xenopus 
oocytes alone, the only functional homomeric receptors preferentially formed 
were those composed of α7, α8, or α9 nAChR subunits (Couturier et al., 1990; 
Gerzanich et al., 1994; Gotti et al., 1994).  Together, these homomeric nAChRs 
have high Ca2+ permeability, a rapid desensitization rate and are blocked by 
nanomolar concentrations of αBgtx and are therefore termed, αBgtx-nAChRs 
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(Gotti and Clementi, 2004).  Notably, α8 nAChRs have only been identified in the 
chick nervous system (Gotti et al., 1994) and while the α9 nAChR subunit can 
form homomeric nAChRs (Elgoyhen et al., 1994), studies show that it forms 
functional nAChRs much more efficiently when co-expressed with the α10 
subunit (Elgoyhen et al., 2001; Sgard et al., 2002).   
 α7-containing nAChRs are one of the most abundantly expressed 
subtypes in the brain and account for the majority of high affinity αBgtx binding 
(Gotti and Clementi, 2004).  In the hippocampus, α7 nAChRs presynaptically 
modulate glutamate and GABA release (MacDermott et al., 1999).  Additionally, 
in other perisynaptic areas α7 nAChRs regulate other inputs to neurons as well 
as activate downstream cell signaling pathways (Berg and Conroy, 2002; Shoop 
et al., 1999).  Recently, evidence from heterologous expression systems has 
indicated that α7 can also form functional heteromeric receptors when co-
assembled with β2 (Khiroug et al., 2002) and this finding was later confirmed by 
the discovery of similar α7-containing heteromeric nAChRs in rat brain (Liu et al., 
2009).  However, these α7-containing heteromeric nAChRs have distinct ion 
permeability and pharmacological properties compared to α7 homomeric 
nAChRs (Khiroug et al., 2002).  The remaining neuronal nAChR subunits (α2-α6 
and β2-β4) do not form functional nAChRs when expressed alone in Xenopus 
oocyte systems (Boulter et al., 1987; Luetje and Patrick, 1991) and are found to 
be contained within the cell and not expressed on the cell surface (Cooper et al., 
1999; Millar and Gotti, 2009). 
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 In addition to α7 homomeric receptors, nAChRs containing the α4 and β2 
subunits (i.e., α4β2* nAChRs) are the most abundant and widely distributed 
heteromeric receptors in the brain and contribute to the high affinity nicotine 
binding sites (Champtiaux and Changeux, 2002).  In heterologous expression 
systems, additional pair-wise combinations of functional nAChRs include α2β4, 
α3β2, α3β4, and α4β4 (Duvoisin et al., 1989; Papke et al., 1989).  The α5 and α6 
nAChR subunits are unable to form functional nAChRs unless co-expressed with 
additional α and β subunits to form triplet nAChRs.  For example, α5* nAChRs 
include α3α5β2, α3α5β4 and α4α5β2 and α6* nAChRs include α6β3β4, α3α6β4 
and α3α6β2 (Millar and Gotti, 2009).   
 Through the use of nAChR knock-out and knock-in mice, in situ 
hybridization and subtype-specific ligands and antibodies, much work has been 
done to elucidate the native nAChR subtypes present in nervous system.  As 
discussed previously, α7 homomeric and α4β2 heteromeric nAChRs are the 
most abundant subtypes in mammalian brain.  However, studies now indicate 
that approximately 20 % of all native α4β2 nAChRs also contain the α5 subunit 
(Brown et al., 2007).  And, in specific brain regions, additional nAChR subtypes 
have been found (Millar and Gotti, 2009).  For example, the α3β4 subtype is the 
most abundant nAChR in the autonomic ganglia and subsets of the medial 
habenula and interpeduncular nucleus (Millar and Gotti, 2009).  In the rodent 
mesostriatal pathways, 40 - 60 % of all α6* nAChRs are present as α4α6β2β3 
with the remaining subtype as α6β2β3 (Zoli et al., 2002) and each of these 
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subtypes have different affinities for the antagonist α-conotoxin MII (Salminen et 
al., 2007; Zoli et al., 2002). 
 This vast diversity of nAChR subunit expression allows for specialization 
of nAChR functions including receptor open times and single channel 
conductance as well as pharmacological properties such as agonist and 
antagonist binding affinities (McGehee and Role, 1995).  Additionally, the 
selective expression of nAChR subunits also allows for specific brain regions to 
be more or less affected by exposure to nicotine (Albuquerque et al., 2009).  For 
instance, DA neurons in the VTA express the α6 and β3 subunits in addition to 
α4 and β2 (Hendrickson et al., 2010) and this subtype (α4α6β2β3*) has been 
shown to have one of the highest affinities for nicotine (Salminen et al., 2007). 
 Unlike muscle-type nAChRs, neuronal nAChRs can have various receptor 
stoichiometries, which can affect agonist specificity and the function and 
regulation of the receptor (Nelson et al., 2003; Zwart and Vijverberg, 1998).  For 
example, α4β2 nAChRs can be formed by either two α and three β subunits 
((α4)2(β2)3) or three α and two β subunits ((α4)3(β2)2) (Moroni et al., 2006; 
Nelson et al., 2003; Zwart and Vijverberg, 1998).  Interestingly, while these α4β2 
nAChRs have similar high affinities for nicotine, the (α4)2(β2)3 subtype has been 
found to be most sensitive to upregulation by nicotine (Albuquerque et al., 2009), 
thus, adding another layer to the complexity of nAChR structure and function. 
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NEURONAL nAChRs: FUNCTION 
 Upon ligand binding, a conformational change of the receptor occurs, 
opening the channel within microseconds, allowing the passage of small 
monovalent (K+ and Na+) and divalent (Ca2+) cations through the pore, down their 
electrochemical gradient (Dani and Bertrand, 2007; Laviolette and van der Kooy, 
2004).  The ligand-binding site is a hydrophobic pocket at the interface between 
adjacent α subunits for homomeric nAChRs or between the α subunit and the 
‘back’ face of the neighboring β subunit for heteromeric nAChRs (Gotti and 
Clementi, 2004).  For all nAChRs, the ‘front’ side of the ligand-binding site is 
formed by the α subunit, where the Cys-Cys pair is required (Albuquerque et al., 
2009). 
 Neuronal nAChRs can exist in three conformational states and are 
regulated by exposure to agonist: closed at rest, when the receptor has low 
affinity for agonist and the channel is closed; the active state, when agonist 
occupies the ligand binding site and the channel is open allowing cations to flow 
down their electrochemical gradient; and the desensitized state, when the 
channel is closed and the receptor is not responsive to ligand (Albuquerque et 
al., 2009; Dani and Bertrand, 2007).  The wide distribution of nAChRs on cellular 
membranes results in several physiological outcomes, depending on the location 
of the receptor.   
 Interestingly, while nAChRs mediate fast, direct synaptic transmission at 
neuromuscular junctions and autonomic ganglia, there are very few examples of 
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fast nicotinic transmission in the mammalian brain (Dani and Bertrand, 2007).  
Instead, studies show that a significant proportion of nAChRs are located 
presynaptically (Role and Berg, 1996) where they facilitate Ca2+ dependent 
release of neurotransmitters (Wonnacott, 1997).  This may occur indirectly as a 
result of Na+ influx causing membrane depolarization and activation of voltage-
gated Ca2+ channels or directly through Ca2+ influx through the channel itself (α7 
nAChRs, see below) (Albuquerque et al., 2009).  Additionally, nAChRs are found 
on the somas of both GABAergic and DAergic neurons of the VTA (Wooltorton et 
al., 2003).  Activation of these somatodendritic nAChRs by nicotine mediates 
neuronal excitability (Pidoplichko et al., 1997) as well as modulates gene 
expression through the local increases of Ca2+ in the cytoplasm (Dajas-Bailador 
and Wonnacott, 2004).  For example, α7 homomeric nAChRs have a higher 
Ca2+:Na+ permeability ratio compared to other nAChRs (Albuquerque et al., 
2009).  Thus, activation of an α7 nAChR can affect several Ca2+ dependent 
second messenger systems (Suzuki et al., 2006). 
nAChRs MEDIATE NICOTINE ADDICTION 
 Several studies have shown that the mesolimbic DA pathway mediates 
nicotine addiction because DA antagonists or lesions of DA neurons of this 
pathway reduce nicotine self-administration (Corrigall and Coen, 1989; Corrigall 
et al., 1994; Corrigall et al., 1992; Di Chiara, 2000).  Nicotine from tobacco 
smoke rapidly crosses the blood brain barrier, binds and activates its molecular 
targets, nAChRs.  The activation of nAChRs located on DAergic neurons of the 
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VTA causes an increase in burst firing as well as overall firing rates (Dani and 
Bertrand, 2007) resulting in DA release in the NAc (Nisell et al., 1994).  This 
nicotine-induced increase of DA release in the NAc, and the resulting rewarding 
properties, are mediated by nAChRs because infusion of a nAChR antagonist 
into the VTA blocks the development of nicotine reward behaviors (Corrigall et 
al., 1994; Corrigall et al., 1992).  
 The subtype of nAChR found on the DAergic and GABAergic neurons of 
the VTA are predominantly the high affinity α4β2* nAChRs and after nicotine 
activates these receptors, they transition to a desensitized state (Dani and 
Bertrand, 2007; Pidoplichko et al., 1997).  At the same time, nicotine activates 
presynaptic α7 nAChRs located at the terminals of glutamate neurons, thus 
increasing glutamatergic transmission onto the DA neurons (Mansvelder and 
McGehee, 2000; Schilstrom et al., 2000).  The α7 nAChRs rapidly desensitize at 
high agonist concentrations; however, at the nicotine concentrations achieved 
through smoking, the receptors do not significantly desensitize (Wooltorton et al., 
2003).  Thus, the net effect of decreased GABAergic transmission and increased 
glutamatergic transmission results in excitation of the mesolimbic DA reward 
system (Mansvelder et al., 2002).   
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FIGURE I-3.  nAChR subtypes within the VTA & implications for nicotine addiction.  
Schematic diagram of the mesolimbic DA pathway, originating in the ventral tegmental area 
(yellow box) and projecting to the NAc (purple box).  DAergic projection neurons (blue) express 
the α3, α4, α5, α6, α7, β2 and β3 nAChR subunit genes (depicted inside the soma) and the 
known functional receptor subtypes found on this neuron include the α4β2*, α6β2*, and α7 
subtypes (depicted as a receptor on the cell membrane and pre-synaptic terminal).  GABAergic 
interneurons (pink) express the α3, α4, α5, α7, β2, and β4 nAChR subunit genes and have known 
functional nAChRs of α4β2* and α7 subtypes.  Cholinergic afferents from the PPTg/LDT synapse 
onto both cell types in the VTA.  Glutamatergic inputs from the prefrontal cortex also synapse in 
the VTA, and have functional α7 nAChRs on the pre-synaptic terminals.  Nicotine addiction, 
beginning on the right: (1) nicotine binds and activates the high affinity α4β2* nAChRs located on 
the DAergic neurons of the VTA, (2) causing DA release in the NAc.  (3) The high affinity nAChRs 
rapidly desensitize and stay in the desensitized state for a long period of time.  (4) Low affinity α7 
nAChRs are activated and desensitize; however, the α7 nAChRs are able to recover from 
desensitization very quickly, such that they are able to be activated again, increasing glutamate 
release in the VTA. 
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GENETICALLY MODIFIED nAChR MOUSE MODELS 
 Because of the large number of possible combinations of functional 
nAChRs present in the brain, traditional pharmacological approaches are difficult.   
Thus, genetically modified nAChR mouse models have been invaluable to 
determine the specific nAChR subtypes that contribute to nicotine addiction 
(Mineur and Picciotto, 2008).  Genetically modified nAChR mice, in combination 
with nAChR pharmacology and behavioral assays of nicotine addiction, are even 
more powerful tools. 
 The first genetically modified nAChR mouse was made by deleting a 
region of DNA that encodes the β2 subunit gene, Chrnb2, termed “β2 knock-out” 
and abbreviated as β2 KO (Picciotto et al., 1995).  Importantly, these mice 
develop and breed normally and have normal behaviors compared to WT mice 
(Picciotto et al., 1995).  However, the β2 KO appear to lack high affinity binding 
of α4β2 nAChR agonists, as well as have decreased nicotine-induced DA 
release in the striatum and an absence of nicotine self-administration (Grady et 
al., 2001; Mineur and Picciotto, 2008; Picciotto et al., 1998).  Thus, using the β2 
KO mouse, it was determined that β2* nAChRs were involved in the reinforcing 
properties of nicotine addiction (Picciotto et al., 1997).  The sufficiency of high-
affinity, α4β2* nAChRs in mediating the rewarding properties of nicotine was 
further validated with the Leu9′Ala α4 knock-in nAChR mouse model (Tapper et 
al., 2004) as well as targeted re-expression of the β2 subunit in β2 KO mice 
(Maskos et al., 2005).   
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 In addition to assessing the normal, drug-naive state of the mouse (i.e., 
development, breeding, behavior) and the ability to develop (or not to develop) 
nicotine-induced reward, it is also important to measure other reward behaviors 
to verify that the effects of the nAChR subunit knock-out are specific for nicotine 
addiction.  For example, β2 KO mice have an increased threshold for food 
reinforcement, an increased threshold for cocaine conditioned place preference, 
but maintained morphine self-administration to the VTA, among other tests 
(Mineur and Picciotto, 2008).  Since 1995, this knock-out approach has been 
repeated with the α7, α4, α3, β4, α5, α6, and β3 nAChR subunits (Champtiaux et 
al., 2002; Cui et al., 2003; Marubio et al., 1999; Orr-Urtreger et al., 1997; Ross et 
al., 2000; Salas et al., 2003; Wang et al., 2002; Xu et al., 1999a; Xu et al., 
1999b).   
 For the purposes of this thesis, only two additional nAChR mouse models 
will be described in detail.  The first mouse model is the α4 knock out mouse (α4 
KO) which does not express the gene encoding the α4 nAChR subunit, Chrna4, 
and therefore does not express functional α4* nAChRs (Ross et al., 2000).  The 
homozygous α4 KO mouse was created by removing a 750 bp fragment from the 
fifth exon of the Chrna4 gene (Ross et al., 2000).  This fragment contains DNA 
encoding the first hydrophobic transmembrane domain through the second 
intracytoplasmic loop.  Homozygous knockout mice are born in normally 
expected ratios, are capable of reproduction and have no physical abnormalities.  
Similar to the β2 KO, α4 KO mice do not show nicotine-induced DA release in the 
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striatum and are less sensitive to the locomotor depressant effects of nicotine 
(Marubio et al., 2003); however, α4 KO mice have higher baseline locomotor 
activity compared to controls (Ross et al., 2000). Importantly, there is no 
significant difference in the expression of other nAChR subunits such as α3, α5, 
or α6, indicating that deletion of the α4 gene does not induce compensatory 
changes in other nAChR subunit mRNAs or proteins (Marubio et al., 1999).  
However, it has been suggested that increased function of α6β2* nAChRs may 
be responsible for the differences seen in baseline locomotor activity of the α4 
KO mice (Mineur and Picciotto, 2008). 
 The second mouse model discussed here is the Leu9′Ala knock-in mouse 
(Leu9′Ala).  This mouse line contains a single Leucine to Alanine point mutation 
at the 9′ position of the transmembrane 2 pore-forming domain causing these 
receptors to be 50-fold more sensitive to nicotine and endogenous acetylcholine 
(Tapper et al., 2004).  This hypersensitive mutation allows for selective activation 
of α4* nAChRs with low doses of nicotine that have no effect in WT mice.  For 
example, mice with this mutation developed nicotine-induced locomotor 
sensitization and nicotine conditioned place preferences at very low doses of 
nicotine that have no effect in WT mice (Tapper et al., 2004).  Both lines (α4 KO 
and Leu9′Ala) have been back-crossed at least ten times to a C57BL/6J 
background to minimize variability between strains due to genetic background. 
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I.F. Ethanol-nicotine interactions 
ALCOHOL’S ACTION ON nAChRs 
 Research on alcohol modulation of neuronal nAChRs did not occur until 
the mid 1980s, when the development of patch clamp techniques allowed the 
study of ion channels and receptors (Narahashi et al., 1999).  Neuronal nAChRs 
were of particular interest because of their structural similarity to GABAA 
receptors, one of the known primary targets of ethanol, as well as their 
modulation of pre-synaptic neurotransmitter release (Schlaepfer et al., 2008b).  
Several model systems including PC12 cells (Nagata et al., 1996), recombinant 
nAChRs expressed in Xenopus oocytes (Cardoso et al., 1999; Forman and 
Zhou, 1999, 2000), cultured neurons (Aistrup et al., 1999; Marszalec et al., 1999; 
Zuo et al., 2001), and transfected cell lines (Zuo et al., 2002) have been used to 
study alcohol modulation of nAChRs.  However, the results of these studies are 
varied and depend on the receptor subunit composition, agonist concentration, 
ethanol concentration and experimental conditions (Dopico and Lovinger, 2009).   
 Although ethanol is known to target several ligand gated ion channels 
including GABA, glutamate and 5-HT, the concentration of ethanol required to 
modulate these channels (30 – 200 mM) is much higher than the concentration of 
alcohol in the blood that results in behavioral intoxication (10 – 50 mM) 
(Narahashi et al., 1999; Spanagel, 2009).  Interestingly, studies using PC12 cells 
showed that ethanol potently modulates nAChRs at low concentrations of ethanol 
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(100 µM – 10 mM), identifying nAChRs as potential primary targets of ethanol 
(Nagata et al., 1996).   
 In cultured rat cortical neurons, ACh-evoked currents insensitive to αBgtx 
(i.e., heteromeric nAChRs) were significantly enhanced by physiologically 
relevant concentrations of ethanol while nAChRs sensitive to αBgtx (i.e., α7 
homomeric nAChRs) were inhibited (Aistrup et al., 1999).  More specifically, in 
Xenopus oocytes, acute alcohol (75 mM) potentiates ACh-induced current of 
α2β4, α4β4, α2β2 and α4β2 nAChRs while lower concentrations of ethanol (20-
50 mM) inhibited nicotine-induced current of α7 nAChRs and all concentrations of 
ethanol tested had no effect on α3β2 or α3β4 nAChRs (Cardoso et al., 1999).  
Not surprisingly, concentrations of ethanol higher than 100 mM are less selective 
for specific nAChR subtypes and potentiate most nAChR receptors (Spanagel, 
2009).   
 Similar to other ligand gated ion channels, ethanol potentiation of nAChRs 
is hypothesized to be a result of the ethanol-induced stabilization of the open 
channel state of the receptor (Forman and Zhou, 1999; Wu et al., 1994; Zuo et 
al., 2004).  Additionally, it is possible that the ethanol-induced inhibitory effect 
seen with α7 nAChRs is due to the inherently fast desensitization rate of these 
receptors, implying that ethanol potentiation results in enhanced desensitization 
(Dopico and Lovinger, 2009).  Thus, these and other in vitro and in vivo studies, 
suggest that alcohol modulation of nAChRs, either by enhancing or inhibiting 
function, may contribute to the common co-abuse of nicotine and alcohol. 
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CO-ABUSE OF NICOTINE AND ALCOHOL 
 Alcohol and nicotine are two of the most widely used drugs, and are often 
abused together. Several reports from the 1980s and 1990s have estimated that 
80 % of alcohol-dependent people are also smokers (Bobo, 1992; Miller and 
Gold, 1998) and that smokers have an increased risk of developing alcohol use 
disorders (DiFranza and Guerrera, 1990; Grant et al., 2004).  Interestingly, while 
the smoking rates in the general population have dramatically decreased over 
the past two decades, smoking has remained high in alcoholic individuals 
(Meyerhoff et al., 2006), with current estimates still between 70-75 % (Bobo and 
Husten, 2000).  These high rates of co-abuse of nicotine and alcohol have led 
some researchers to define this population as ‘alcoholic smokers’ as compared 
to ‘smokers’ (Littleton et al., 2007).  In fact, this population has increased risk 
factors for cardiovascular and lung diseases (Benowitz, 2003) and for some 
forms of cancer (Sasco et al., 2004). The risks of cancer of the mouth, throat, or 
esophagus for the smoking drinker are more than the sum of the risks posed by 
these drugs individually (Room, 2004). 
GENETIC LINKS BETWEEN ALCOHOLISM AND nAChRs 
 Many hypotheses have been proposed as to the basis of the high rates of 
nicotine and alcohol co-abuse. For example, it is possible that alcohol use leads 
to nicotine use or vice versa (Tyndale, 2003) or that because alcohol and nicotine 
are legal and readily available, the likelihood of their co-use is increased (Funk et 
al., 2006).  However, there is much evidence that suggests that common genes 
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may influence the development of alcohol and nicotine abuse behaviors 
individually as well as contribute to both disorders in humans (Bierut et al., 2000; 
Madden and Heath, 2002; True et al., 1999).  Using twin studies, it was 
determined that identical twins are two times as likely to be dependent on alcohol 
and/or nicotine if the other twin is dependent, compared to fraternal twins (Heath 
et al., 1997).  Additionally, experimental studies using rodents have indicated a 
genetic linkage between the effects of alcohol and nicotine by selectively 
breeding mice and rats for different responses to alcohol.  Animals that were 
more sensitive to alcohol’s sedative effects (long sleep mice (LS), and high 
alcohol sensitivity rats (HAS)) were more sensitive to the locomotor effects of 
nicotine when compared to animals with low sensitivity to alcohol’s effects (short 
sleep mice (SS) and low alcohol sensitivity rats (LAS)) (De Fiebre et al., 1987; de 
Fiebre et al., 2002).   
 Recent genetic association studies have identified several nAChR subunit 
genes as common genetic targets associated with both nicotine and alcohol 
addiction.  The CHRNA5/A3/B4 nAChR gene cluster was identified as a genetic 
locus that influences the development and level of alcohol use and nicotine 
addiction in human populations (Joslyn et al., 2008; Schlaepfer et al., 2008a).  
Variation in CHRNA5, the gene encoding the α5 nAChR subunit, has been 
associated with a genetic risk for alcoholism (Wang et al., 2009) and the β2 
nAChR subunit, encoded by CHRNB2, has also been associated with the 
subjective responses to alcohol and nicotine (Ehringer et al., 2007).  Using 
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nAChR mouse models, a polymorphism in the α4 nAChR subunit gene has been 
shown to influence the initial sensitivity of the α4β2* nAChR to ethanol (Butt et 
al., 2003) as well as partially mediate the difference between the LS and SS 
mice, discussed above (Stitzel et al., 2001).  Similarly, CHRNA3, the gene 
encoding the α3 nAChR subunit, was expressed at a higher rate in the brains of 
mice that were less sensitive to ethanol-induced stimulation, thus identifying 
CHRNA3 as a candidate for modulating the acute locomotor stimulant response 
to ethanol (Kamens et al., 2009).  
 
I.G. Evidence for nAChR modulation of ethanol reward 
 One of the goals of alcohol research is to identify molecules that may play 
a significant role in ethanol’s euphoric effects that promote voluntary drinking and 
acute intoxication (Hendrickson et al., 2009).  Because of the strong evidence of 
the co-abuse of nicotine and ethanol, and the fact that both drugs act on the 
mesolimbic pathway, nAChRs have emerged as target molecules in at least 
partially mediating the reinforcing properties of alcohol (Soderpalm et al., 2000).  
Indeed, there is ample of evidence that ethanol can modulate nAChR function in 
vitro, through re-expression in Xenopus oocytes (Cardoso et al., 1999), in 
cultured PC12 cells (Nagata et al., 1996), and dissociated rat cortical neurons 
(Aistrup et al., 1999).  However, the effects of ethanol on nAChRs of these 
systems produces varied results and greatly depends on the receptor subunit 
composition, concentration of ethanol and other agonists used, presence or lack 
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of synaptic terminals from afferent regions and experimental conditions (Dopico 
and Lovinger, 2009).  Thus, an important question is: what is the effect of ethanol 
modulation of nAChRs in vivo?   
INITIAL STUDIES: A DOGMA IS SET 
 In the past two decades, much of the work characterizing the role of 
nAChRs in mediating the behavioral and neurochemical effects of ethanol in 
rodents came from the Soderpalm and Engel research group in Sweden, among 
others.  This group was the first to show that ethanol-induced activation of the 
mesolimbic DA system, as measured by extracellular DA release in the NAc, 
could be blocked with a systemic injection of the nAChR antagonist 
mecamylamine (Blomqvist et al., 1993).  This antagonizing effect was then 
localized to the VTA by a local perfusion of mecamylamine (Blomqvist et al., 
1997).  Next, using rats that were trained to voluntarily consume ethanol, it was 
shown that both systemic (Blomqvist et al., 1996) and local VTA infusion (Ericson 
et al., 1998) of mecamylamine decreased ethanol intake and preference in the 
high-alcohol preferring rats.  As a result, these early studies were key in 
developing a hypothesis that has persisted in the field; that at least a part of the 
rewarding effects of ethanol are mediated by nAChRs located in the VTA 
(Blomqvist et al., 1992; Chatterjee and Bartlett, 2010).   
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FIGURE I-4. Alcohol’s action in the mesolimbic DA pathway, a role for nAChRs.  Beginning 
on the right, then moving leftward, in purple: (1) Ethanol administration, via voluntary drinking or a 
direct infusion into the VTA, activates DAergic cell bodies by either (2) increasing the release of 
ACh into the VTA or (3) directly activating / modulating nAChRs, with the end result being (4) 
increased DA release in the NAc.  Evidence for nAChRs, beginning on the right, in red: (1) pre-
application of the nAChR antagonist mecamylamine, either by systemic injection or direct infusion 
to the VTA, (2) blocks the ethanol-induced DA release in the NAc as well as decreases ethanol 
self-administration in rats. 
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NICOTINE’S EFFECT ON ETHANOL SELF-ADMINISTRATION 
 Several labs have investigated the effect of nicotine treatment on alcohol 
self-administration, with varying results.  In one study, researchers gave sub-
chronic nicotine (0.35 mg/kg, daily) to a group of medium alcohol preferring rats 
and saw a marked increase in ethanol intake and preference (Blomqvist et al., 
1996).  This is similar to a previous study that found that alcohol consumption 
was increased in rats with nicotine pellets implanted subcutaneously (Potthoff et 
al., 1983).  Interestingly, two additional studies found that acute nicotine 
administration has the opposite effect and actually decreases ethanol drinking 
(Gauvin et al., 1993; Le et al., 2000).  The differences in the effects of acute and 
chronic nicotine treatment on ethanol self-administration may be attributed to the 
development of locomotor sensitization to chronic nicotine (Benwell and Balfour, 
1992), or, that rats develop tolerance to the initial depressant effect of nicotine 
(Stolerman et al., 1995). 
ETHANOL’S ACTION ON nAChRs: DIRECT OR INDIRECT? 
 While there is considerable evidence that ethanol directly acts on several 
ligand-gated ion channels (Grant, 1994), most studies of ethanol’s action on 
nAChRs has demonstrated that it is more likely a co-agonist, acting to potentiate 
the effects of acetylcholine (Larsson et al., 2002; Marszalec et al., 1999). 
However, it has remained unclear whether ethanol acts directly on nAChRs or 
indirectly through an enhancement of cholinergic transmission.  To elucidate this 
mechanism, one study measured extracellular concentrations of ACh in the VTA 
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of rats that voluntarily consumed ethanol and found that ACh levels were 
increased after ethanol consumption and shortly thereafter, DA concentrations 
were elevated in the NA as well (Larsson et al., 2005).  The cholinergic afferents 
to the VTA are predominantly from the pedunculopontine and the laterodorsal 
tegmental area (Oakman et al., 1995), brain regions that have also been 
implicated in mediating natural as well as drug-reward behavior (Yeomans et al., 
1993).   
LOCALIZING ETHANOL’S EFFECT: ANTERIOR VS. POSTERIOR VTA  
 Recent studies have indicated that the VTA is not a homogeneous region 
and can be divided into at least two distinct brain regions, the anterior and 
posterior VTA (aVTA and pVTA) (Ikemoto, 2007; Shabat-Simon et al., 2008).  
While both regions consist of predominantly two types of neurons, DAergic 
projection neurons and GABAergic interneurons, studies have found that 
neurons within the anterior and posterior VTA project to different regions of the 
striatum and respond differently to drugs of abuse (Ikemoto, 2007; Shabat-Simon 
et al., 2008; Zangen et al., 2006).  Furthermore, differential expression of nAChR 
subunits has been identified in both types of neurons (Champtiaux et al., 2003; 
Klink et al., 2001; Wooltorton et al., 2003) and regions within the VTA (Zhao-
Shea et al., 2011).  While there is a general consensus in the field that the VTA is 
critical for at least partially mediating the initial rewarding properties of drugs of 
abuse, there are conflicting reports of which region is more important.  For 
example, one study found that blocking nAChRs of the anterior, but not posterior 
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VTA, blocked NAc DA release when ethanol was directly infused to the NAc, 
implicating a role for the anterior VTA in a neuronal NAc-aVTA-NAc feedback 
loop (Ericson et al., 2008).   
 Despite this study, the evidence suggesting that the pVTA plays a critical 
role in modulating ethanol reward is much more compelling than for the aVTA.  
For instance, one study showed that alcohol-preferring rats will self-administer 
ethanol directly into the pVTA (Gatto et al., 1994).  Similarly, this result has been 
repeated, but instead showed that male and female non-alcohol preferring rats 
will also self-administer ethanol directly to the posterior, but not anterior VTA 
(Rodd et al., 2004; Rodd-Henricks et al., 2000).  Furthermore, this effect is 
attenuated with co-application of the DA D2 receptor agonist, quinpirole, 
indicating that the activation of pVTA DA neurons is involved in the process 
(Rodd et al., 2004).  Another more recent study showed that infusion of ethanol 
to pVTA is sufficient for increased DA release in the NAc (Ding et al., 2009).  
nAChR SUBTYPE SPECIFICITY: CURRENT APPROACHES 
 Recently, the scope of nAChR/ethanol reward research has changed from 
an examination of the role of nAChRs in ethanol reward to a more focused study 
of specific nAChR subtypes that mediate ethanol reward and therefore may be 
possible targets for the development of alcohol cessation therapies.  The most 
common approach used to determine the nAChR subtype associated with the 
behavioral effects of ethanol are to use a variety of nAChR antagonists that are 
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selective for one subtype of nAChR versus another (Chatterjee and Bartlett, 
2010).   
 The non-competitive nAChR antagonist mecamylamine has been shown 
to decrease ethanol intake in several mouse and rat models of ethanol intake 
and/or preference (Blomqvist et al., 1996; Dyr et al., 1999; Ericson et al., 1998; 
Farook et al., 2009; Kuzmin et al., 2009; Le et al., 2000; Nadal et al., 1998).  
However, because mecamylamine is non-selective for a particular subtype of 
nAChR, it does not further elucidate which nAChR is critical for the effect.  
 Antagonists that are nAChR selective include DHβE, selective for α4β2 
and MLA, selective for α7 nAChRs; however prior studies using these 
compounds have found no effect on ethanol consumption (Kuzmin et al., 2009; 
Le et al., 2000).  An additional compound, α-conotoxin MII, is an antagonist 
selective for α3β2*, β3* and/or α6* nAChRs.  This peptide, while potent and 
selective, does not cross the blood brain barrier, and must be locally 
administered via cannula or intracranial injection.  Interestingly, α-conotoxin MII, 
when infused into the VTA, was shown to significantly reduce ethanol-induced 
DA release in the NAc, reduce the locomotor stimulatory effect as well as reduce 
ethanol intake in both rats and mice (Jerlhag et al., 2006; Larsson et al., 2004) 
 Several studies have had success using the newly discovered compound 
varenicline, a high affinity α4β2* nAChR partial agonist that is FDA approved as 
a smoking cessation medication (Coe et al., 2005).  Varenicline selectively binds 
and partially activates the nAChRs that modulate nicotine intake (i.e., α4β2* 
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nAChRs) thus occupying or desensitizing the relevant receptors, precluding any 
further activation by nicotine .  Additionally, the selective activation of α4* 
nAChRs themselves may act to increase DA release in the NAc such that 
nicotine has no further enhancing effect.  Recently, studies have found that 
varenicline significantly reduced ethanol seeking and consumption in rats 
(Steensland et al., 2007), significantly reduced alcohol consumption in a group of 
heavy drinking smokers (McKee et al., 2009), and attenuated alcohol stimulated 
DA release in the NAc of rats (Ericson et al., 2009).  Although varenicline was 
designed as a potent high affinity partial agonist of α4β2* nAChRs (Coe et al., 
2005; Jorenby et al., 2006), it also acts as a low affinity, partial agonist of α3β2* 
and α6* nAChRs and a low affinity, full agonist of α7 and α3β4* nAChRs (Mihalak 
et al., 2006).  Thus, the nAChR subtypes that mediate varenicline’s effect on 
alcohol consumption and stimulated DA release in the NAc remain unknown.  
 Surprisingly, even though nAChRs have long been molecular targets of 
interest in mediating the rewarding properties of ethanol, and the α4 KO and β2 
KO mice have been available for over a decade, very few studies have used 
these mice to examine the role of nAChRs in ethanol consumption or other 
behavioral responses to ethanol.  To date, only one published study has reported 
baseline ethanol consumption in the β2 KO and α7 KO mice, and this was just 
last year.  This study found that female, but not male, α7 KO mice consumed less 
ethanol than WT mice and there was no difference in ethanol intake in β2 KO 
mice (Kamens et al., 2010).  Additionally, both β2 KO and α7 KO mice had 
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decreased ethanol intake after varenicline treatment, suggesting that varenicline 
does not act solely through α7 or β2* nAChRs (Kamens et al., 2010).  Incredibly, 
no published study, to our knowledge, has examined baseline ethanol 
consumption or the acute rewarding effects of ethanol in the α4 KO mouse line.  
This is even more baffling since two polymorphic forms of the α4 nAChR subunit 
gene were shown to be responsible for the differences in the behavioral 
sensitivity to ethanol and nicotine in mice almost 10 years ago (Butt et al., 2003; 
Dobelis et al., 2002; Stitzel et al., 2001).  
56 
Preface to Chapter II 
 
This chapter has been published separately in: 
 
Hendrickson LM, Zhao-Shea R, Tapper AR. (2009). Modulation of ethanol 
drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor 
agonists in C57BL/6J mice.  Psychopharmacology (Berl) Jul;204(4):563-72.
 
Author contributions: 
Hendrickson LM, Tapper AR designed experiments. 
Hendrickson LM performed experiments. 
Zhao-Shea R performed imaging of c-Fos immunostaining. 
Hendrickson LM, Tapper AR wrote the paper. 
 
 
 
 
 
 
57 
CHAPTER II 
Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic 
acetylcholine receptor agonists in C57BL/6J mice 
 
II.A. INTRODUCTION 
 Alcoholism is the third preventable cause of mortality in the world and few 
therapeutic treatments are available highlighting the importance of understanding 
the underlying molecular mechanisms of ethanol’s reinforcing properties (CDC, 
2004). Animal models of voluntary alcohol drinking provide a unique tool to study 
potential pharmacological means to reduce ethanol intake, but few of these 
models yield intoxicating blood alcohol levels. Recently a straight forward 
voluntary drinking paradigm has been established whereby high alcohol 
preferring C57BL/6J mice are exposed to 20 % ethanol for two or four hours 
during the dark cycle.  Termed “Drinking in the Dark” (DID), this novel assay 
reliably produces pharmacologically relevant blood ethanol concentrations even 
upon first exposure and has been utilized as a mouse model of “binge drinking” 
(Rhodes et al., 2005; Rhodes et al., 2007). 
 A major goal of alcohol addiction research is to identify molecules that 
may play a significant role in ethanol’s euphoric effects that could promote 
persistent voluntary drinking and acute intoxication. Achieving this goal has 
proven problematic due to ethanol’s properties to interact with a myriad of 
proteins expressed in the CNS (Harris, 1999). Neuronal nicotinic acetylcholine 
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receptors (nAChRs) have emerged as candidate molecules in at least partially 
mediating the reinforcing properties of alcohol (Soderpalm et al., 2000). Neuronal 
nAChRs are ligand-gated cation channels that are activated by the endogenous 
neurotransmitter, acetylcholine, as well as the addictive component of tobacco 
smoke, nicotine. Currently, 12 mammalian neuronal nicotinic acetylcholine 
receptor subunits have been identified (α2-10 and β2-4). The majority of high 
affinity nAChRs are heteromeric pentamers consisting of α and β subunits. Thus, 
multiple receptor subtypes with varying subunit compositions and 
electrophysiological properties exist (Jones et al., 1999; Laviolette and van der 
Kooy, 2004; Lindstrom et al., 1996). Indeed, many neuronal nAChR subtypes are 
expressed throughout the mesocorticolimbic reward pathways especially in the 
VTA in both DAergic neurons projecting to nucleus accumbens and in local 
GABAergic interneurons (Klink et al., 2001; Wooltorton et al., 2003). How does 
ethanol interact with these receptors? Interestingly, systemic ethanol has been 
shown to increase acetylcholine concentrations in the VTA, presumably, 
activating nAChRs in this area (Ericson et al., 2003). In addition, ethanol can 
directly modulate nAChR activity depending on the subtype of nicotinic receptor 
expressed (Forman and Zhou, 2000; Zhou et al., 2000; Zuo et al., 2002). 
Because a variety of subtypes exist in these nuclei, identification of the specific 
nicotinic receptor subtype(s) that may underlie ethanol reward is paramount. 
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 The nonspecific antagonist, mecamylamine, when injected systemically or 
locally within the VTA, blocks ethanol self administration in high ethanol 
preferring rats that have acquired robust ethanol drinking through increasing 
concentration of ethanol exposure over a two week period (Blomqvist et al., 
1996; Ericson et al., 1998). Using a similar paradigm in rats, studies have shown 
that DHβE and MLA, antagonists selective for α4β2 and homomeric α7 nAChRs, 
respectively, fail to block ethanol consumption (Le et al., 2000), and dopamine 
overflow in nucleus accumbens (Ericson et al., 2003; Larsson et al., 2002). On 
the other hand, it has been shown that the α3β2*, β3*, and α6* subunit specific 
antagonist, α-conotoxin MII, does inhibit ethanol consumption, activity, and 
dopamine release in nucleus accumbens (Jerlhag et al., 2006; Larsson et al., 
2004). More recently, varenicline, an α4β2 partial agonist clinically approved as a 
smoking cessation therapeutic (Coe et al., 2005; Gonzales et al., 2006; 
Steensland et al., 2007; Tonstad et al., 2006), was found to reduce both ethanol 
intake and seeking in rats (Steensland et al., 2007). To our knowledge, the role 
of nAChRs in acute ethanol intake in mice has not been examined. 
 The goal of the current study was to test the hypothesis that nAChR 
signaling is involved in acute alcohol intake (i.e. “binge drinking”) as measured 
using the DID assay in C57BL/6J mice. Toward this end, we exposed mice to a 
panel of nAChR antagonists and agonists prior to the presentation of ethanol and 
measured alcohol intake.  
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II.B. MATERIALS AND METHODS 
Animals.  Male C57BL/6J mice (Jackson Laboratory) used in the experiments 
were between 8-14 weeks of age and were housed 3-4 animals per cage up until 
the start of each experiment.  During acclimation, animals were kept on a 
standard 12 hour light/dark cycle with lights on at 7:00 AM and off at 7:00 PM.  
The animals were given food and water ad libitum, except when ethanol was 
substituted for water for 2 hours at night as described below.  All experiments 
were conducted in accordance with the guidelines for care and use of laboratory 
animals provided by the National Research Council (National Research Council, 
1996), as well as with an approved animal protocol from the Institutional Animal 
Care and Use Committee of the University of Massachusetts Medical School.   
 
Drugs and drinking solutions.  Ethanol solutions were prepared from 190 proof 
absolute anhydrous ethanol (95 % ethanol, 5 % water; Pharmco-Aaper brand, 
Brookfield, CT) diluted to 20 % ethanol (v/v) using tap water.  Sucrose (EMD) 
was dissolved in tap water to make a 10 % (w/v) concentration.  Mecamylamine 
hydrochloride, hexamethonium hydrochloride, MLA, DHβE, nicotine hydrogen 
bitartrate, and cytisine (all purchased from Sigma-Aldrich, St. Louis, MO), were 
dissolved in 0.9 % saline and were administered via intraperitoneal (i.p.) 
injections at the indicated doses.  Nicotine concentrations are reported as 
nicotine base.   
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Drinking in the dark (DID) procedure.  Animals were placed in experimental 
chambers for 1 week prior to the beginning of the DID sessions. The mice 
received a 15 ml graduated cylinder water bottle fitted with a one holed rubber 
stopper with a stainless steel double-ball-bearing sipper tube which was sealed 
with parafilm to prevent leakage. Our drinking assay is a modified 2-day version 
of a limited access drinking procedure first described in Rhodes et al., 2005. On 
the first night, two hours after the lights were turned off, half of the mice were 
given an i.p. injection of saline and the other half were i.p. injected with drug.   
Immediately after the injections, the water bottle was removed and replaced with 
a single bottle of 20 % ethanol and left in place for two hours.   On the second 
night, the injection groups were switched (i.e. mice that received saline on the 
first night received drug on the second; whereas mice that received drug on the 
first night received saline on the second) and again given a single 20 % ethanol 
bottle for two hours.  The amount of ethanol consumed was recorded 
immediately after each two hour session and converted to g/kg per each animal’s 
ethanol consumption and body weight.  For control experiments, mice received 
10 % sucrose for two hours instead of ethanol. 
 
Experimental Design.  Table 1 lists the experiment number, type, drug injected, 
and number of animals used.  For DID experiments, each mouse received two 
DID sessions with a low and high dose of the same drug, except in experiments 
1, 3, 4, 11 and 12 where the mice only received saline and one dose of drug.  
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Mice that received two doses of drug were given seven days of rest between 
two-day DID experiments, and tested again in the same two-day DID procedure.  
Lower doses were used in the initial two-day DID round followed by higher doses 
in the second DID round (see Table 1).   In experiments 14 and 15, the DID 
procedure was exactly the same as described above except that ethanol 
measurements were taken in 15 minute intervals throughout the two hour 
drinking session. 
 
Blood Ethanol Concentration.  For experiment 5 (blood ethanol concentration 
(BEC) measurements), prior to ethanol drinking, one group of mice was injected 
i.p. with saline and a separate group was i.p. injected with 1 mg/kg 
mecamylamine.  Trunk blood was obtained from the mice after completion of the 
two hour ethanol drinking assay.  Blood was collected in heparinized capillary 
tubes, centrifuged at 1500 X g for 5 minutes and blood analyzed using an alcohol 
oxidase-based assay.  Blood ethanol concentrations were measured on a GM7 
Micro-Stat Analyzer (Analox Instruments Ltd.).   
 
Immunohistochemistry.  Mice were i.p. injected with saline for three days prior to 
the start of the experiment to habituate them to handling and to reduce c-Fos 
activation due to stress.  Two groups of six mice were used.  Mice from the first 
group received two injections:  An i.p. injection of 3.0 mg/kg mecamylamine 
followed by a 2.0 g/kg ethanol injection, or a saline injection followed by a 2.0 
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g/kg ethanol injection, or a saline injection followed by a second saline injection.  
The time between the first and second injection was forty-five minutes and was 
estimated based on the delayed effect that mecamylamine had on drinking 
pattern (Fig. 4).   The second group of mice received an i.p. injection of 0.5 
mg/kg nicotine followed by a saline injection, or a 0.5 mg/kg nicotine injection 
followed by a 2.0 g/kg ethanol injection, or a saline injection followed by a second 
saline injection.  The time between injections was fifteen minutes based on 
nicotine’s more rapid effect on drinking pattern.   
Ninety minutes after the second injection, all mice were deeply 
anesthetized with sodium pentobarbital (200 mg/kg, i.p.) and perfused 
transcardially with 10 ml of 0.1 M phosphate-buffered saline (PBS) followed by 
10 ml of 4 % paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). 
Brains were removed and post-fixed for 2 h with the same fixative and 
cryoprotected in sodium phosphate buffer containing 30 % sucrose until brains 
sank. VTA serial coronal sections (20µm) were cut on a microtome (Leica CM 
3050S, Leica Microsystems Inc.) and collected into a 24-well tissue culture plate 
containing 1 X PBS. Slices containing VTA were collected between -2.92 mm 
and -4.04 mm from bregma.  After rinsing sections in PBS twice for 5 min., they 
were treated with 0.4 % Triton X-100 PBS (PBST) twice for 2 min. followed by 
incubation in 2 % BSA/PBS for 30 min. Sections were washed with PBS once 
and then incubated in a cocktail of primary antibodies for Tyrosine Hydroxylase 
(TH, mouse monoclonal, 1:250, Santa Cruz Biotechnology, Santa Cruz, CA, 
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USA) and c-Fos (rabbit polyclonal, 1:400, Santa Cruz) in 2 % BSA/PBS overnight 
at 4° C. The sections were then washed with PBS three times for 5 min followed 
by incubation in secondary fluorescent labeled antibodies (goat anti-rabbit Alexa 
Fluor® 488 and goat anti-mouse Alexa Fluor® 594, 1:300, Molecular Probes, 
Inc., Eugene, USA) at room temperature in dark for 30 min. After washing with 
PBS five times for 5 min/wash, sections were mounted on slides by using 
VECTASHIELD® Mounting Medium (Vector laboratories, Inc., Burlingame, CA). 
The number of positive neurons was counted under a fluorescence microscope 
(Zeiss, Carl Zeiss MicroImaging Inc., NY) at a magnification of 400X. The 
intensity of fluorescence was quantified by using a computer-associated image 
analyzer (Axiovision Rel. 4.6).  Neurons were counted as signal positive if 
intensities were at least two times higher than that of the average value of 
background (sections staining without primary antibodies).   
 
Data Analysis.  The effect of pre-injections of nicotinic agonists and antagonists 
on ethanol intake was compared to saline pre-injections using one of two 
statistical tests.  In experiments where one group of mice received one dose of 
drug, One-Way ANOVAs followed by Tukey post-hoc tests were used.  In 
experiments where one group of mice received two doses of drug, a Repeated 
measure ANOVA followed by Tukey post-hoc test was used.   Data were 
analyzed using Graphpad software (Graphpad Software, Inc.).  Student’s t tests 
were used to analyze immunohistochemistry data.  Results were considered 
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significant at p<0.05. All data are expressed as means ± standard errors of 
means (SEM).  
 
II.C. RESULTS 
Effects of mecamylamine on alcohol consumption in the DID assay. 
 To determine if mecamylamine can inhibit ethanol self-administration in 
the DID paradigm, mice were pre-injected, i.p. with 0.5, 1.0, or 3 mg/kg 
mecamylamine immediately prior to 20 % ethanol exposure.   Mecamylamine 
dose dependently reduced the volume of ethanol drinking (Fig. II-1A). Mice 
receiving a pre-injection of 1.0 or 3.0 mg/kg mecamylamine consumed 
significantly less ethanol compared to saline injected mice (Fig. II-1B, 1.30 +/- 
0.44 and 1.53 +/- 0.24 compared to 2.62 +/- 0.28 and 3.05 +/- 0.28 g/kg ethanol, 
respectively).  Repeated measure ANOVA indicated an overall significant 
difference between saline and mecamylamine pre-injection on ethanol intake 
(F3,18 = 9.33, p<0.001). Tukey Post-hoc analysis indicated a significant effect of 
mecamylamine with a pre-injection dose of 1.0 and 3.0 mg/kg compared to 
respective saline values.  The antagonist did not affect sucrose intake in mice at 
the tested doses of 1 or even as high as 6 mg/kg (Fig. II-1C, for 1 mg/kg F1,12 = 
0.54, p<0.05, for 6 mg/kg F1,10 = 3.23, p<0.05).  Pre-injection of the peripheral 
nAChR antagonist, hexamethonium, at a dose of either 1 or 3 mg/kg, also did not 
significantly reduce ethanol intake (F3, 21 = 0.20, p>0.05, data not shown). 
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 To determine if the effect of mecamylamine ultimately resulted in a lower 
blood ethanol concentration, we acquired blood samples immediately following 
the two hour DID assay in mice that received either a saline or 1 mg/kg 
mecamylamine pre-injection (Fig. II-1D).  Mice that received mecamylamine prior 
to their ethanol bottle exhibited significantly lower blood ethanol levels compared 
to mice that received a pre-injection of saline (Fig. II-1D, 13.5 +/- 3.9 mM 
compared to 25.8 +/- 2.8 mM ethanol, respectively F1,9 = 6.2, p<0.05).  
Effects of selective nAChR antagonists on ethanol consumption. 
 Pre-injection of a low (1 mg/kg) or high (3 mg/kg) dose of the nAChR 
competitive antagonist, DHβE, did not significantly affect ethanol intake in 
C57BL/6J mice compared to a pre-injection of saline. Repeated measure 
ANOVA yielded a non-significant effect of pretreatment:  F3,21 = 0.67, p>0.05 
(data not shown).  Similarly, pre-injection of a low (5 mg/kg) or high (10 mg/kg) 
dose of the α7 selective antagonist, MLA, did not significantly reduce ethanol 
intake (F3,18 = 0.56, p>0.05, data not shown). 
Effects of nAChR agonists on ethanol consumption in the DID assay. 
 To evaluate the effects of nAChR agonists on ethanol intake in the DID 
assay, we pre-injected C57BL/6J mice with nicotine immediately prior to 
presentation of the 20 % alcohol bottle.  Compared to a saline injection, both 
0.25 mg/kg and 0.5 mg/kg nicotine decreased the volume of ethanol drinking 
(Fig. II-2A).  Repeated-measure ANOVA indicated an overall effect of 
pretreatment on intake (F3,18 = 6.33, p<0.01, Fig. II-2B). Post-hoc comparisons 
67 
indicated that 0.5 mg/kg nicotine significantly reduced ethanol intake compared 
to saline (p<0.05, 2.42 +/- 0.32 compared to 3.76 +/- 0.36 g/kg ethanol).  Pre-
injection of either dose did not significantly reduce consumption of sucrose 
solution (Fig. II-2C, F3,21 = 0.24, p>0.05).  The β4* nAChR full agonist, and α4β2 
selective partial agonist, cytisine also dose dependently reduced the volume of 
ethanol drinking compared to a saline injection (Fig. II-3A).  There was a 
significant effect of 3 mg/kg cytisine on ethanol intake (F1,6 = 29.8, p<0.01, Fig. 
3B, 1.37 +/- 0.39 compared to 4.01 +/- 0.39 g/kg ethanol) but not with 1 mg/kg 
(F1,16 = 0.15, p>0.05).  Repeated measure ANOVA on the effect of pre-injection 
on sucrose drinking revealed a significant interaction (F3,21 = 9.63, p<0.01).  
However, post-hoc analysis revealed no significant difference between mice 
given 1 or 3 mg/kg cytisine compared to saline injected controls (Fig. II-3C, p > 
0.05, NS).     
Effects of mecamylamine and nicotine on ethanol drinking patterns. 
 To determine if mecamylamine, a nicotinic antagonist, and nicotine, an 
agonist could affect ethanol intake differently, we measured the pattern of alcohol 
drinking in mice pre-injected with each drug.  Ethanol intake was measured in 
fifteen minute intervals over the course of two hours.  Figure II-4A illustrates 
ethanol intake in two separate groups of mice that received either saline/nicotine 
or saline/mecamylamine pre-injections.  Data from each group were normalized 
to their average saline values per 15 minute interval so comparisons could be 
made between groups.  Pre-injection of 0.5 mg/kg nicotine decreased ethanol 
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intake during the first hour of drinking (Fig. II-4A).  Conversely, 3 mg/kg 
mecamylamine reduced ethanol intake predominantly during the second hour of 
the DID assay.  Figure II-4B illustrates average interval intake in the first hour 
compared to the second hour of the DID assay.  One Way ANOVA indicated a 
significant effect of nicotine on average interval intake in the first hour compared 
to saline (Fig. II-4B).  Actual values from the first hour are 0.502 g/kg/interval 
after saline injection compared to 0.159 g/kg/interval after nicotine (F 1,46 = 14.5, 
p<0.001).  Mecamylamine significantly inhibited ethanol intake in the second hour 
of the assay (0.688 g/kg/interval after saline compared to 0.33 mg/kg/interval 
after mecamylamine, F1,54 = 11.0, p<0.01). 
Effects of mecamylamine and nicotine on ethanol-induced VTA DAergic 
neuron c-Fos expression.    
 To gain mechanistic insight into how nicotinic antagonists and agonists 
may influence ethanol intake, we analyzed expression of the immediate early 
gene, c-Fos, as a measure of neuronal activation (Cole et al., 1989) in tyrosine 
hydroxylase (TH) positive neurons of the VTA via immunohistochemistry.  The 
number of c-Fos, TH double positive cells in VTA was counted in mice that 
received mecamylamine or nicotine prior to an i.p. injection of 2.0 g/kg ethanol 
(Fig. II-5).  A single ethanol exposure significantly increased the number of 
double positive cells in VTA compared to saline injection (Fig. II-5a, C, p<0.01, 
independent two-sample Student’s t test).  Pre-injection of 3 mg/kg 
mecamylamine 45 minutes prior to ethanol injection significantly reduced the 
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number of c-Fos/TH positive cells compared to a saline pre-injection (Fig. II-5c, 
p<0.05).   
To determine how nicotine may effect ethanol-induced c-Fos expression, 
we injected mice with 0.5 mg/kg nicotine, followed by either a saline or 2.0 g/kg 
ethanol injection.  In the absence of ethanol, nicotine significantly increased the 
number of VTA c-Fos/TH double positive neurons compared to saline injected 
animals (Fig. II-5b, d, p<0.01).  Ethanol exposure after the initial nicotine injection 
did not significantly increase or decrease the number of double positive neurons 
compared to nicotine alone (Fig. II-5d, p>0.05).           
 
II.D. DISCUSSION 
 Previously, the nonspecific nicotinic receptor antagonist, mecamylamine, 
has been shown to reduce ethanol intake in rats that have learned to drink 
ethanol through at least two week training with increasing concentration of free or 
limited access ethanol (Blomqvist et al. 1996; Le et al. 2000). In addition, 
mecamylamine has been reported to reduce the subjective euphoria of ethanol in 
humans (Blomqvist et al., 1996; Chi and de Wit, 2003; Le et al., 2000).  To our 
knowledge, this is the first report that nAChR blockade reduces ethanol 
consumption in mice during the DID paradigm, a model of binge drinking where 
C57BL/6J mice consume alcohol until intoxicated.  Mecamylamine dose-
dependently reduced alcohol intake and this also led to a significant reduction in 
blood-ethanol concentration suggesting that mecamylamine was not inhibiting 
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the metabolism of ethanol. In addition, sucrose intake was not reduced indicating 
specificity for alcohol consumption and not a general effect on reward signaling.   
Reduction of ethanol intake by mecamylamine was mediated by blockade of 
neuronal nAChRs expressed in the CNS because the non-specific nAChR 
antagonist, hexamethonium, did not significantly alter alcohol consumption. Prior 
studies indicate that mecamylamine delivered systemically or directly into the 
VTA blocks elevation of ethanol-mediated dopamine release in the nucleus 
accumbens (Blomqvist et al., 1993; Blomqvist et al., 1997). Thus, it is likely that 
mecamylamine is reducing ethanol intake via a similar mechanism in the DID 
assay.  Although there have been reports that high doses of mecamylamine can 
non-competitively inhibit NMDA receptors (Fu et al., 2008; O'Dell and 
Christensen, 1988), we observe a decrease in the volume of ethanol 
consumption at doses as low as 0.5 mg/kg suggesting that mecamylamine is 
acting via blockade of neuronal nAChRs.   
 Because of the vast array of nAChR subtypes expressed in the CNS, 
identifying the specific composition of receptors involved in ethanol reinforcement 
is a difficult, but important question.   High affinity α4β2* and low affinity α7 
nAChRs are two of the most abundant nicotinic receptors in the CNS and could 
represent potential candidates for at least partially mediating ethanol reward, 
α4β2 in particular since these receptors have been clearly implicated in nicotine 
dependence (Picciotto et al., 1998; Tapper et al., 2004).   However, the α4β2 
selective and α7 selective antagonists DHβE and MLA, respectively, both of 
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which readily cross the blood-brain barrier, failed to significantly reduce ethanol 
intake.  These data support prior studies that have shown little effect of these 
compounds on both operant responding, ethanol-mediated dopamine release in 
nucleus accumbens, and ethanol self-administration in rats (Le et al., 2000; 
Soderpalm et al., 2000).  The straightforward interpretation of these data would 
be that α4β2 and α7 nAChRs are not involved in alcohol self-administration.  
However, caution in this interpretation is warranted especially in regard to higher 
affinity heteromeric nicotinic receptors that could contain α4β2 in addition to a 
third or even fourth subunit that may render them relatively insensitive to DHβE 
(Salminen et al., 2004).     
 Interestingly, acute exposure to nicotine dose dependently reduced 
alcohol intake in the DID paradigm.  This is in opposition to at least one previous 
study that indicates that nicotine can enhance ethanol intake in rats in a 
restricted access drinking assay (Smith et al., 1999).   The most likely difference 
between studies is that our DID assay utilized mice from the C57BL/6J strain 
which are high alcohol preferring animals; whereas Smith et al.’s study utilized 
rats that needed to be given low doses of ethanol for weeks before voluntary 
drinking was established.  Throughout the adaptation period, where rats learned 
to drink increasing alcohol doses that produced robust blood ethanol 
concentrations, they were exposed to nicotine daily.  Thus, chronic nicotine 
enhanced ethanol consumption, while our study illustrates that acute nicotine in 
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naïve mice reduces ethanol intake.  It will be interesting to determine the effect of 
chronic nicotine exposure on consumption in the DID assay. 
 Our results indicate that cytisine can also reduce ethanol drinking.  While 
nicotine is a full agonist, cytisine is known to be a full agonist for β4* nAChRs and 
a partial α4β2 agonist (Mineur et al., 2007; Picciotto et al., 1995).  The α4β2 
selective partial agonist, varenicline is a derivative of cytisine and recently has 
been shown to inhibit alcohol intake and seeking in rats (Coe et al., 2005; 
Steensland et al., 2007).  Based on these observations, cytisine may also be a 
candidate compound for alcohol cessation.     
 Because of the complexity of nAChR subunit composition, as well as the 
robust expression patterns of nAChRs throughout the CNS, it is not so surprising 
that blocking nAChRs (i.e., with mecamylamine) and activating them with agonist 
can both reduce ethanol intake.  However, could both classes of compounds 
impact the same ethanol reward circuit to impact voluntary ethanol intake?  
Based on multiple studies indicating that nAChRs rapidly desensitize after a 
single nicotine exposure, often for prolonged periods of time (Mansvelder et al., 
2002; Pidoplichko et al., 1997), it is possible that an acute injection of nicotine or 
cytisine prior to ethanol exposure desensitizes the relevant nAChR subtype 
precluding activation of circuits involved in voluntary drinking.   Thus, blocking 
nAChRs with an antagonist or desensitizing nAChRs with pre-exposure to 
agonists would both reduce alcohol consumption.   
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 Alternatively, ethanol intake may be reduced by the nAChR agonists 
because the agonists themselves elevate nucleus accumbens dopamine release, 
thereby increasing dopamine signaling prior to ethanol drinking (Marubio et al., 
2003; Picciotto et al., 1998).  The dopamine reuptake blocker GBR 12909 has 
been shown to also reduce ethanol intake in the DID paradigm, presumably via a 
similar mechanism (Kamdar et al., 2007) but this compound was also shown to 
decrease sugar water intake.  Our results argue against a common reward 
pathway because nicotine and cytisine reduced ethanol intake without affecting 
sucrose drinking suggesting that nicotinic receptor activation is involved in 
alcohol/nicotine reward specifically.  
 Interestingly, mecamylamine and nicotine differentially modulate alcohol 
drinking patterns.  Mecamylamine reduced ethanol intake predominantly in the 
second hour of the DID assay; whereas nicotine reduced intake during the first 
hour, perhaps indicating independent mechanisms of action for each compound.  
Although drinking patterns may be explained by differences in the 
pharmacokinetics of each drug and how readily they cross the blood brain 
barrier.  Nicotine is known to permeate the brain on the order of seconds 
(Lockman et al., 2005), while mecamylamine likely has a longer latency to reach 
effective concentrations in the CNS (Young et al., 2001).    
 In summary our data indicate that nAChRs are involved in acute ethanol 
drinking until intoxication.  Identification of the specific nAChR subtypes involved 
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in this behavior should lead to novel therapeutic targets that could be used to 
prevent binge drinking.          
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Table II-1. DID experiments. 
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Figure II-1.  Mecamylamine dose dependently reduces ethanol DID.  A) Total ethanol drinking 
volume (mls ethanol solution) over the course of two hours starting two hours after lights off. 
Immediately prior to introduction of the ethanol solution into each individual cage, mice were 
injected i.p. with either 0 (saline), 0.5, 1.0, or 3.0, mg/kg mecamylamine.  One group of animals 
was used for the 0.5 mg/kg dose; whereas a second group of animals was used for the 1 and 3 
mg/kg doses (see methods).  B) Bar graph representation of total ethanol intake over the two 
hour DID assay (g/kg) for the three mecamylamine doses.  C) Total 10 % sucrose volume intake 
(mls) after an i.p. injection of 0 (saline), 1 or 6 mg/kg mecamylamine.  Mice had access to 10 % 
sucrose for two hours during the dark cycle starting two hours after lights out.  D)  Blood ethanol 
concentration (mM) in mice given an i.p. preinjection of saline (n = 5) or 1 mg/kg mecamylamine 
(n = 6) immediately prior to an alcohol bottle.  Blood was isolated immediately after the two hour 
drinking session.  Data presented as mean +/- SEM.  * p<0.05, *** p<0.001 compared to same 
group saline controls, One-Way or Repeated Measure ANOVA, Tukey post-hoc (see Methods 
and Results section for details).   
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Figure II-2.  Nicotine reduces ethanol DID.  A) The effect of a preinjection of nicotine on ethanol 
drinking volume is shown.  One group of mice were used for both drug concentrations (n = 7)  B) 
Ethanol intake (g/kg) from (A).  C) Average effect of a preinjection of nicotine on sucrose intake.   
Data are presented as mean +/- SEM.  * p<0.05, ** p<0.01 compared to same group saline 
controls, Repeated Measures ANOVA, Tukey post-hoc. 
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Figure II-3.  Cytisine reduces ethanol DID.  A) Total volume of ethanol intake after saline, 1, or 
3 mg/kg cytisine pre-injection.  Separate groups of animals were used for each dose.  B) Ethanol 
intake (g/kg) from (A).  Asterisk indicates significance compared to within group intake after a 
saline pre-injection.  C) Effect of saline, 1, or 3 mg/kg cytisine on sucrose intake.  * p<0.05 
compared to same group saline controls, One-Way ANOVA, Tukey post hoc. 
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Figure II-4.  Mecamylamine and nicotine differentially affect DID ethanol drinking pattern.  
A) Normalized drinking bouts in two separate groups of mice that received saline/3 mg/kg 
mecamylamine or saline/0.5 mg/kg nicotine.  Dotted line represents the normalized saline value 
for each group.  B) Average 15 minute bout during the first and second hour of the DID assay in 
the two groups of animals.  ** p<0.01, *** p<0.001 compared to same group saline controls, One-
Way ANOVA, Tukey post hoc.       
 
80 
 
 
 
Figure II-5.  Mecamylamine and nicotine exhibit distinct effects on ethanol-induced VTA 
DAergic neuron activation. A) Representative images depicting VTA slices from mice receiving 
two saline injections (left), saline followed by a 2.0 g/kg ethanol injection (middle), or 3.0 mg/kg 
mecamylamine followed by a 2.0 g/kg ethanol injection (right). Slices are fluorescently double-
labeled with anti-tyrosine hydroxylase (red) and anti-c-Fos (green). B) Representative images 
depicting VTA slices from mice receiving saline injections (left), 0.5 mg/kg nicotine followed by 
saline (middle), or 0.5 mg/kg nicotine followed by 2.0 g/kg ethanol (right). C) Average number of 
c-Fos positive, TH positive cells per slice from mice treated as in A. D) Average number of c-Fos 
positive, TH positive cells per slice from mice treated as in b. Baseline c-Fos positive, TH positive 
cells from saline-injected control mice were subtracted from each value. Cells were counted from 
23 to 33 VTA slices per mouse. Three mice per treatment were used for analysis. Asterisks 
directly above each bar indicate significance from saline-treated control mice. *p<0.05, **p<0.01 
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CHAPTER III 
Alpha4* nAChRs play a critical role in ethanol reward 
 
III.A. INTRODUCTION 
 Alcohol abuse is the third largest cause of preventable mortality in the 
world (CDC, 2004).  Similar to all drugs of abuse, ethanol activates the 
mesocorticolimbic dopamine reward pathway resulting in a release of dopamine 
(DA) in the nucleus accumbens (NAc) (Soderpalm et al., 2009).  While it is clear 
how many addictive drugs including nicotine and cocaine activate this pathway, it 
is unclear how ethanol modulates DA release.  Systemic ethanol has been 
shown to increase acetylcholine (ACh) concentrations in the ventral tegmental 
area (VTA), presumably activating nicotinic acetylcholine receptors (nAChRs) in 
this area (Ericson et al., 2003) and several studies in the past two decades have 
shown that ethanol-induced activation of the mesolimbic dopamine system may 
be modulated by nAChRs.  In rats, ethanol mediated DA elevation in NAc is 
inhibited by either direct infusion into the VTA or systemic administration of the 
non-competitive nicotinic receptor antagonist, mecamylamine (Blomqvist et al., 
1993; Blomqvist et al., 1996; Ericson et al., 2003) suggesting nAChRs 
specifically within the VTA are important for ethanol reinforcement.  Additionally, 
blocking VTA nAChRs decreases ethanol self-administration in high-ethanol-
preferring rats (Blomqvist et al., 1996).  Recently, using a restricted access 
ethanol-drinking paradigm termed ‘Drinking-in-the-dark’ (DID) as a model of 
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binge drinking, our lab has demonstrated that nAChRs are involved in acute 
voluntary ethanol drinking to intoxication in C57BL/6J mice.  However, as 
multiple nAChR subtypes exist throughout the VTA, an important goal of alcohol 
research is to identify which subtype(s) modulate ethanol reinforcement. 
 Neuronal nAChRs are ligand gated cation channels that are activated by 
the endogenous neurotransmitter, ACh, as well as the addictive component of 
tobacco smoke, nicotine.  Currently, 12 neuronal nAChR subunits have been 
identified (α2-10 and β2-4).  The majority of high affinity nAChRs are heteromeric 
pentamers consisting of α and β subunits.  Thus, multiple receptor subtypes with 
varying subunit compositions, and electrophysiological properties exist 
(Albuquerque et al., 2009).   
 Indeed, many neuronal nAChR subtypes are expressed throughout the 
VTA in both DAergic neurons projecting to striatum and in local GABAergic 
interneurons (Klink et al., 2001; Wooltorton et al., 2003).  How does ethanol 
interact with these receptors?  Interestingly, systemic ethanol has been shown to 
increase ACh concentrations in the VTA, presumably, activating nAChRs in this 
area (Ericson et al., 2003).  In addition, ethanol can directly modulate nAChR 
activity depending on the subtype of nicotinic receptor expressed (Forman and 
Zhou, 2000; Zhou et al., 2000; Zuo et al., 2002).  Because a variety of subtypes 
exist in these nuclei, an emerging goal of alcohol research is focused on 
identifying the nicotinic receptor subtype(s) that underlie ethanol reward.   
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 One of the highest affinity and widely expressed nAChR subtypes in the 
brain are those that contain the α4 subunit, termed α4* nAChRs (Grady et al., 
2007; Klink et al., 2001).  These receptors have been shown to be necessary and 
sufficient for nicotine addiction (Tapper et al., 2004) and interestingly nicotine 
dependence and alcoholism have very high rates of comorbidity (Bobo, 1992; 
Miller and Gold, 1998).  Additionally, to our knowledge, the role of α4* nAChRs 
has not been thoroughly investigated in mouse models of voluntary ethanol 
consumption or ethanol conditioned place preference.   
 
III.B. MATERIALS AND METHODS 
Animals.  Adult (8-10 week) male α4 KO mice and their wild-type (WT) litter-
mates, as well as heterozygous Leu9′Ala KI mice and their WT litter-mates, all 
bred on site, were used.   The genetic engineering of both α4 KO and Leu9′Ala 
mouse lines have been described previously (Ross et al., 2000; Tapper et al., 
2004).  Both lines have been back-crossed to a C57BL/6J background > nine 
generations.   For consumption experiments, mice were individually housed on a 
reversed 12 h light/ 12 h dark cycle (lights on 10 PM, off 10 AM) with ad libitum 
access to food and water (except during experiments as described below).  For 
all other experiments, mice were group housed in the colony room on a standard 
light/dark cycle with ad libitum access to food and water. All experiments were 
conducted in accordance with the guidelines for care and use of laboratory 
animals provided by the National Research Council(National Research Council, 
85 
 
1996), as well as with an approved animal protocol from the Institutional Animal 
Care and Use Committee of the University of Massachusetts Medical School.   
 
Drugs and drinking solutions.  Ethanol drinking solutions were prepared from 190 
proof absolute anhydrous ethanol (95 % ethanol, 5 % water; Pharmco-Aaper) 
diluted to 2 %, 5 %, 10 % or 20 % ethanol (v/v) using tap water.  Sucrose (EMD) 
was dissolved in tap water to make a 10 % (w/v) concentration.  Saccharin 
sodium salt hydrate (Sigma-Aldrich,) was dissolved in tap water to a final 
concentration of 10 mM.  Quinine was dissolved in tap water to a final 
concentration of 0.1 mM. 
 
Drinking in the dark (DID).  Ethanol consumption was measured using a DID 
procedure as previously described (Hendrickson et al., 2009).  Animals were 
singly housed in experimental chambers for 1 week prior to the beginning of the 
DID sessions. The mice received a 15-ml graduated cylinder water bottle fitted 
with a one-hole rubber stopper with a stainless steel double-ball-bearing sipper 
tube which was sealed with parafilm to prevent leakage.  In week one, for the first 
four nights, two hours after the lights were off, the water bottle was removed and 
replaced with a 2 % ethanol bottle, and mice were allowed to drink for two hours.  
This procedure was repeated the following weeks, with the concentrations 
increasing to 5 %, 10 % and 20 % on weeks 2, 3, and 4, respectively.  Therefore, 
each concentration of ethanol was seen for 4 consecutive nights, with 3 nights off 
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in between each ethanol concentration.  The amount of ethanol consumed was 
recorded immediately after each two-hour session and converted to g/kg per 
each animal’s ethanol consumption and body weight.  In a separate group of 
mice, saccharine, quinine and sucrose intake was measured, in a similar assay 
but mice only drank each solution for two nights.  
 
Ethanol metabolism.  Prior to an ethanol injection, blood was obtained from the 
tail vein (~30 uL each time point) to provide a zero point for each animal.  After a 
2 g/kg i.p. injection of ethanol, blood samples were taken at intervals of 30, 60, 
90, and 120 min.  Blood was collected in heparinized capillary tubes, centrifuged 
at 1500Xg for 5 minutes and blood analyzed using an alcohol oxidase-based 
assay.  Blood ethanol concentrations were measured on a GM7 Micro-Stat 
Analyzer (Analox Instruments Ltd.)  
 
Immunohistochemistry.  Adult (8-10 weeks), male, α4 KO mice and their WT 
litter-mates, as well as heterozygous Leu9′Ala KI mice and their WT litter-mates 
were  injected i.p. with saline for three days prior to the start of the experiment to 
habituate them to handling and to reduce c-Fos activation due to stress.  In the 
α4 KO and WT group, two groups of three mice from each genotype were used 
in each of the following conditions: an i.p. injection of saline or an i.p. injection of 
2.0 g/kg ethanol.  In the Leu9′Ala and WT group, three groups of three mice were 
used per genotype in each of the following conditions: an i.p. injection of saline, 
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0.5 g/kg ethanol or 2.0 g/kg ethanol.  Ninety minutes after the injection, mice 
were deeply anesthetized with sodium pentobarbital (200 mg/kg, i.p.) and 
perfused transcardially with 10 ml of 0.1 M phosphate-buffered saline (PBS) 
followed by 10 ml of 4 % paraformaldehyde in 0.1 M sodium phosphate buffer 
(pH 7.4). Brains were removed and post-fixed for 2 h with the same fixative and 
cryoprotected in sodium phosphate buffer containing 30 % sucrose until brains 
sank. VTA serial coronal sections (20 µm) were cut on a microtome (Leica 
Microsystems, Inc.) and collected into a 24-well tissue culture plate containing 1 
X PBS. Slices containing VTA were collected between -2.8 mm and -4.04 mm 
from bregma.  After rinsing sections in PBS twice for 5 min, they were treated 
with 0.2 % Triton X-100 PBS (PBST) for 5 min followed by incubation in 2 % 
BSA/PBS for 30 min. Sections were washed with PBS once and then incubated 
in a cocktail of primary antibodies for tyrosine hydroxylase (TH, mouse 
monoclonal, 1:250 dilution, Santa Cruz Biotechnology) and c-Fos (rabbit 
polyclonal, 1:400 dilution, Santa Cruz Biotechnology) in 2 % BSA/PBS overnight 
at 4°C. The sections were then washed with PBS three times for 5 min followed 
by incubation in secondary fluorescent labeled antibodies (goat anti- rabbit Alexa 
Fluor® 488 and goat anti-mouse Alexa Fluor® 594, 1:300 dilutions, Molecular 
Probes, Inc.) at room temperature in the dark for 30 min. After washing with PBS 
5 times for 5 min/wash, sections were mounted on slides using VECTASHIELD® 
Mounting Medium (Vector Laboratories, Inc.). The number of positive neurons 
was counted under a fluorescence microscope (Carl Zeiss MicroImaging, Inc.) at 
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a magnification of 400X. The intensity of fluorescence was quantified using a 
computer-associated image analyzer (Axiovision Release 4.6).  Neurons were 
counted as signal-positive if intensities were at least 2 times higher than that of 
the average value of background (sections stained without primary antibodies).  
Image analysis was performed by an individual blind to drug treatment. 
 
Conditioned Place Preference (CPP).  The conditioning and testing apparatus 
(Med Associates) used contains two white chambers (6.6” x 5.0”) with a door 
separating the two sides.  The floors of the chambers are interchangeable; one a 
‘ROD’ floor and the other a ‘MESH’ floor.  The apparatus is placed inside a sound 
attenuation chamber equipped with a fan and corner mounted lights.  Infrared 
photo beams record the movement and activity of the mouse in each chamber 
and data was collected by MED-PC software.  The CPP experiment consists of 
one habituation session, eight training sessions and one testing session.  On the 
habituation day, one side of the chamber has the ROD floor and the other side 
has the MESH floor.  The mice are allowed free access to both sides of the 
chamber for 30 min and the time spent on each floor during the 30 min session is 
recorded.  For training, mice are assigned to an ethanol (+) and saline (-) floor 
combination: ROD+ and MESH- or MESH+ and ROD-.  In the first training 
session, mice are injected with saline and placed in the chamber with both sides 
containing the saline-paired floor (i.e. for the ROD+ group, the mice are injected 
with saline and placed on mesh floors).  The mice are allowed free access to 
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both sides for 5 min.  The following day, mice are injected with ethanol (α4 KO 
and WT receive 2 g/kg while Leu9′Ala and WT receive 0.5 g/kg) and placed in 
the chamber for 5 min with both sides containing the ethanol-paired floors (i.e. for 
the ROD+ group, the mice are injected with ethanol and placed on rod floors).  
Daily training session alternate between the ethanol-paired and saline-paired 
floors for eight sessions such that the mice experience the ethanol-paired floor 
on the ninth day.  On the test day, mice are placed in the chamber with one side 
ROD floors and one side MESH floors for 30 min and the time spent on each 
floor is recorded.  A difference score is calculated by time spent on the ethanol-
paired floor on the Test Day - Habituation Day such that a positive number 
indicates that more time was spent on the ethanol-paired floor after training. 
 
Data Analysis.  Data were analyzed using One-way or Two-way ANOVAs with 
genotype and treatment as variables followed by Bonferroni post hoc tests. Data 
were analyzed using Graphpad software (Graphpad Software, Inc.).  Results 
were considered significant at p<0.05. All data are expressed as means ± 
standard errors of means (SEM). 
 
III.C. RESULTS 
α4 KO mice consume less ethanol than WT mice 
 To determine if α4* nAChRs modulate voluntary ethanol consumption, we 
measured baseline ethanol intake in α4 KO and WT mice using the DID assay at 
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4 different concentrations of ethanol (2 %, 5 %, 10 %, and 20 % ethanol, Fig. III-
1A).  Two-way ANOVA revealed a significant main effect of treatment (F3,60 = 
103.6, p<0.0001), genotype (F1,60 = 36.25, p<0.0001) and a significant treatment 
x genotype interaction (F3,60 = 11.37, p<0.0001). The post hoc test indicates that 
α4 KO mice drank significantly less 10 % and 20 % ethanol compared to WT 
mice (Fig. III-1A, p<0.001 for both concentrations, consumption of 2 % and 5 % 
was not statistically different). 
 Because ethanol has both taste and caloric value, we measured intake of 
one tastant solution, quinine, and one caloric solution, sucrose, in α4 KO and WT 
mice (Fig. III-2A).  We found no significant difference in intake between the two 
genotypes for any of the solutions tested.  Furthermore, there is no difference in 
the metabolism of an i.p. injection of 2 g/kg ethanol in α4 KO and WT mice (Fig. 
III-2C). 
Voluntary ethanol consumption in Leu9′Ala mice does not differ from WT 
 We measured voluntary 2 %, 5 %, 10 %, and 20 % ethanol intake in 
Leu9′Ala mice and their WT littermates using the same assay described above 
(Fig. III-1B).  Surprisingly, we saw no significant differences between ethanol 
consumption of Leu9′Ala and WT mice in any concentration tested.  Additionally, 
there were no differences in quinine or sucrose intake or ethanol metabolism 
between Leu9′Ala and WT mice (Fig. III-2B, 2C). 
Ethanol activates dopaminergic neurons of posterior VTA by an α4* nAChR 
dependent mechanism 
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 Previously, using c-Fos as a marker for neuronal activation and tyrosine 
hydroxylase (TH) as a marker for dopaminergic (DAergic) neurons, we have 
shown that ethanol activates DAergic neurons of the posterior VTA and that 
these activated neurons express higher levels of the α4, α6 and β3 nAChR 
subunit mRNA (Hendrickson et al., 2010).  To determine if α4* nAChRs are 
necessary for this activation, we injected α4 KO and WT mice with 2 g/kg ethanol 
and examined the VTA for c-Fos expression within TH-immunopositive neurons 
90 min later (Fig. III-3).  Two-way ANOVA indicated that ethanol had no effect on 
c-Fos expression of TH neurons of the anterior VTA in either genotype (Fig. III-
3C).  However, in the posterior VTA, there was a significant main effect of 
genotype (F1,8 = 8.15, p<0.05), treatment (F1,8 = 12.28, p<0.01) and a significant 
genotype x treatment interaction (F1,8 = 13.25, p<0.01).  Bonferroni post-test 
indicates that WT mice injected with 2 g/kg ethanol had significantly higher 
expression of c-Fos compared to α4 KO mice injected with 2 g/kg ethanol (Fig. 
III-3C, p<0.01).  One-way ANOVAs also indicated that WT mice treated with 2 
g/kg ethanol had significantly increased c-Fos expression compared to a saline 
injection (Fig. III-3A, 3C, p<0.05) in the posterior VTA whereas the same dose of 
ethanol had no effect in α4 KO mice (Fig. III-3B, 3C, p> 0.05). 
 Because of the lack of ethanol induced c-Fos expression in α4KO mice, 
we sought to determine if α4* nAChRs are sufficient for ethanol activation of 
DAergic neurons.  We injected hypersensitive Leu9′Ala and WT mice with two 
concentrations of ethanol, the rewarding dose of 2 g/kg and a sub-threshold dose 
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of 0.5 g/kg and analyzed their brains for c-Fos expression in TH-immunopositive 
neurons.  In the anterior VTA, there was no significant expression of c-Fos in 
either genotype, after both doses of ethanol (Fig. III-4E).  In the posterior VTA, 
Two-Way ANOVA revealed a significant main effect of treatment (F2,14 = 22.01, 
p<0.001), genotype (F1,14 = 11.65, p<0.01) and a significant treatment x genotype 
interaction (F2,14 = 8.97, p<0.01).  A Bonferroni post-test indicates that Leu9′Ala 
mice treated with 0.5 g/kg had significantly increased c-Fos expression 
compared to WT mice (Fig. III-4B, 4E, p<0.0001).  Additionally, one-way 
ANOVAs revealed that Leu9′Ala mice treated with 0.5 g/kg and 2 g/kg ethanol 
had significantly increased c-Fos expression compared to a saline injection 
(p<0.01 for both doses) and WT mice treated with 2 g/kg had significantly 
increased c-Fos expression compared to both saline and 0.5 g/kg treated WT 
mice (p<0.001 for both, Fig. III-4E).    
α4* nAChRs are critical for ethanol reward 
 Since α4 KO mice drink less ethanol than WT mice and are resistant to 
ethanol activation of DAergic neurons of the posterior VTA, we hypothesized that 
they would also be resistant to ethanol reward.  To assess ethanol reward, we 
measured ethanol conditioned place preference (CPP) in α4 KO and WT mice 
using the known rewarding dose of ethanol, 2 g/kg (Fig. III-5A).  There was a 
significant main effect of treatment (F1,22 = 20.27, p<0.001) but not genotype and 
there was no interaction between the two.  Bonferroni post-test indicates that 
after training, WT mice spent significantly more time on the ethanol-paired floor 
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compared to the saline paired floor (Fig. III-5A, p<0.001) while the time spent on 
the ethanol or saline paired floors did not significantly differ for α4 KO mice after 
training (p>0.05).  These data suggest that α4* nAChRs are necessary for 
ethanol induced CPP, and thus of ethanol reward. 
 Based on the c-Fos experiments above, we hypothesized that Leu9′Ala 
mice may have a lower threshold for ethanol reward.  To test this, we used the 
CPP assay, but lowered the dose of ethanol to 0.5 g/kg, the same dose that 
significantly increased DAergic neuron activation in the posterior VTA of Leu9′Ala 
mice, but had no effect in WT mice (Fig. III-4A, 4B, 4E).  Two-way ANOVA 
indicated a significant main effect of treatment (F1,26 = 9.92, p<0.01) but not of 
genotype and there was no significant interaction between the two.  Bonferroni 
post-test revealed a significant difference between the time spent in the 0.5 g/kg 
ethanol and saline paired chambers of Leu9′Ala mice, but not of WT mice (Fig. 
III-5B, p<0.05).   
 
III.D. DISCUSSION 
 Since a variety of nAChR subtypes are expressed in the mesolimbic 
reward circuitry (Wooltorton et al., 2003), an emerging goal of alcohol research is 
focused on identifying the nicotinic receptor subtype(s) that may underlie ethanol 
reward.  Attempts have been made to identify possible nAChR subtypes that may 
be involved, however, most studies to date have used pharmacological 
approaches and have had mixed results.  For example, the nonspecific 
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antagonist, mecamylamine, when injected systemically or locally within the VTA, 
blocks ethanol self-administration and locomotor stimulation (i.e., sensitization) in 
rats (Blomqvist et al., 1992; Ericson et al., 1998) as well as reduced voluntary 
ethanol intake in mice (Hendrickson et al., 2009).  Both methyllycaconitine citrate 
(MLA) and dihydro-β-erythroidine (DHβE), α7 and β2* nAChR specific 
antagonists, respectively, failed to block ethanol consumption in rats (Le et al., 
2000) and mice (Hendrickson et al., 2009) or ethanol-induced dopamine overflow 
in the NAc (Ericson et al., 2003; Larsson et al., 2002). 
 Here, we used two complementary genetically modified nAChR mouse 
models to investigate the role of α4* nAChRs in ethanol reward.  Utilizing a 
voluntary ethanol drinking assay, we have identified α4* nAChRs as being 
necessary for voluntary ethanol intake.  In the absence of α4* nAChRs, mice 
consume significantly less 10 % and 20 % ethanol compared to their WT 
littermates.  Importantly, α4 KO mice consume the same amount of sucrose and 
quinine as WT mice indicating that the difference in ethanol intake was specific 
for the drug and not a more general effect on caloric/taste reward or drinking 
volume.   
 Surprisingly, ethanol consumption did not significantly differ between 
Leu9′Ala and WT littermate mice at any concentration of ethanol tested.  
However, the current number of mice used in the assay remains low and the 
large error bars warrant further investigation, especially that of 10 % and 20 % 
ethanol. 
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 We hypothesized that α4* nAChRs are necessary for ethanol-induced 
activation of the mesolimbic dopamine pathway.  The lack of these receptors in 
the α4 KO mice would result in less ethanol consumption than in WT mice, as we 
saw.  In addition, our data measuring c-Fos induction in ventral midbrain, as a 
marker for neuronal activation, supports this hypothesis.  Similar to previous 
studies, an acute injection of the rewarding dose of ethanol, 2 g/kg, activated 
tyrosine hydroxylase (TH) positive neurons of the posterior VTA of WT mice; 
whereas this same dose in α4 KO mice resulted in no activation.  Next, we 
showed that the sub-reward threshold dose of 0.5 g/kg ethanol significantly 
activated the posterior VTA of the hypersensitive Leu9′Ala mice, but had no 
effect in WT mice.  Taken together, our data suggest that activation of α4* 
nAChRs mediate ethanol-induced activation of the posterior VTA, a key region of 
the mesolimbic dopamine reward pathway. 
 Additionally, the rewarding properties of ethanol were absent in α4 KO 
mice as measured by the place preference assay.  This result is consistent with 
previous work indicating that ethanol place preference is expressed through a 
VTA dependent mechanism (Bechtholt and Cunningham, 2005) and that DAergic 
neuron activity is sufficient for CPP (Tsai et al., 2009).  Our CPP results are less 
likely to be affected by differences in learning between WT and α4 KO mice 
because, in the passive avoidance paradigm, both genotypes learned to avoid 
the dark chamber after it was paired with a 2 mA shock (data not shown).  
Furthermore, the hypersensitive Leu9′Ala mice conditioned a place preference to 
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an extremely low dose of ethanol, 0.5 g/kg, suggesting that activation of α4* 
nAChRs modulates ethanol induced reward.   
While nAChRs are known to play a primary role in nicotine dependence, to 
our knowledge, this is the first study firmly implicating α4* nAChRs in modulating 
the reinforcing effects of alcohol.  Our data indicate that expression of α4* 
nAChRs is necessary for voluntary consumption of 10 % and 20 % ethanol, 
ethanol-induced activation of the posterior VTA and ethanol reward.   
Additionally, our results highlight the importance of α4* nAChRs as possible 
targets for alcohol cessation therapeutics.  
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Figure III-1. Voluntary ethanol intake in a 2h limited access assay in α4 KO and Leu9′Ala 
nAChR mouse models.  A) Ethanol intake in g/kg (± SEM) of α4 KO mice was not significantly 
different from WT litter-mate mice at lower concentrations of ethanol (2 % and 5 %) but was 
significantly lower than WT mice at higher concentrations of ethanol (10 % and 20 %) (n = 
8/genotype).  B) Leu9′Ala mice consumed similar amounts of ethanol at all concentrations tested 
compared to WT litter-mate mice (n = 4-8/genotype). ***p<0.001   
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Figure III-2. α4 KO and Leu9′Ala mice have no differences in taste, caloric or metabolic 
controls.  A) WT, α4 KO and Leu9′Ala mice consume similar volumes (mls ± SEM) over a two 
hour period of the bitter solution quinine, as well as the sweet, caloric solution, sucrose (n = 8-
19/genotype/solution).  B) WT, α4 KO and Leu9′Ala have similar peak blood ethanol 
concentration (in mM) and ethanol metabolism after challenge with 2 g/kg i.p. injection of ethanol 
(n = 4/genotype). 
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Figure III-3. Ethanol induced c-Fos activation in TH positive neurons is dependent on α4* 
nAChRs.  Representative photomicrographs illustrating midbrain sections of the posterior VTA 
from A) WT mice and B) α4 KO mice injected with 2 g/kg ethanol.  Sections are immunolabeled 
for TH (red) and c-Fos (green).  White boxes delineate slice regions that are magnified in the 
adjacent photomicrographs.  Scale bar = 100 µm.  C) Number of TH (+) c-Fos (+) neurons per 
slice taken from mice given an i.p. injection of 2 g/kg ethanol.  48 slices/treatment/mouse were 
analyzed, n = 3 mice/treatment. One-way ANOVA and Bonferroni post-test comparing saline to 
ethanol treatment in WT mice was used, ^p<0.05.  Two-way ANOVA and Bonferroni post-test 
comparing treatments in WT and α4 KO mice was also used, **p<0.01.  
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Figure III-4. 
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Figure III-4.  α4* nAChRs are sufficient for ethanol induced activation of DAergic neurons.  
Representative photomicrographs illustrating midbrain sections of the posterior VTA from A) WT 
mice and B) Leu9′Ala mice injected with 0.5 g/kg ethanol as well as C) WT mice and D) Leu9′Ala 
mice injected with 2 g/kg ethanol.  Sections are immunolabeled for TH (red) and c-Fos (green).  
White boxes delineate slice regions that are magnified in the adjacent photomicrographs. White 
arrowheads point to neurons that are TH (+) c-Fos (+).  Scale bar = 100 µm.  E) Number of TH 
(+) c-Fos (+) neurons per slice taken from mice given an i.p. injection of 0.5 g/kg or 2 g/kg 
ethanol.  48 slices/treatment/mouse were analyzed, n = 3 mice/treatment. One-way ANOVA and 
Bonferroni post-test comparing saline to ethanol treatments in WT mice or Leu9′Ala mice was 
used, ^^^p<0.001 for WT mice, ##p<0.01 for Leu9′Ala mice.  Two-way ANOVA and Bonferroni 
post-test comparing treatments in WT and α4 KO mice was also used, ***p<0.001. 
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Figure III-5.  α4* nAChRs are critical for ethanol reward.  A) After 4 training sessions with 2 
g/kg ethanol, WT mice spent significantly more time on the ethanol-paired floor compared to the 
saline-paired floor.  Difference score (in seconds) calculated as the difference in time spent on 
each floor on the test day compared to the habituation day.  In the α4 KO mice, the time spent on 
the ethanol-paired floor did not differ from the time spent on the saline-paired floor (n = 
8/genotype).  B) After 4 training sessions with the low dose of ethanol, 0.5 g/kg, Leu9’Ala mice 
spent significantly more time on the ethanol paired floor compared to the saline paired floor while 
there was no significant difference in the WT mice (n = 8/genotype).  Two-way ANOVA and 
Bonferroni post-test comparing treatments in WT and α4 KO or WT and Leu9’Ala mice was used, 
*p<0.05, ***p<0.001.  
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CHAPTER IV 
 
Activation of α4* nAChRs is necessary and sufficient for varenicline-induced 
reduction of alcohol consumption. 
 
IV.A. INTRODUCTION  
 Complications from alcoholism are responsible for up to 1.8 million deaths 
per year making it the third largest cause of preventable mortality in the world 
(W.H.O., 2004).  Despite large costs to society, very few therapeutics that 
successfully aid in curbing alcohol consumption are available, highlighting the 
need to identify new molecular targets and treatments for alcoholism.  Recently, 
varenicline, a neuronal nicotinic acetylcholine receptor (nAChR) partial agonist, 
currently FDA approved as a smoking cessation aid (Coe et al., 2005; Jorenby et 
al., 2006), was shown to reduce drinking in alcohol preferring rats (Steensland et 
al., 2007) and in a group of heavy-drinking smokers (McKee et al., 2009), 
suggesting that nAChRs may represent novel therapeutic targets for reducing 
alcohol consumption. 
 Ethanol is reinforcing, at least in part, by its propensity to activate 
dopaminergic (DAergic) neurons within the ventral tegmental area (VTA) (Brodie 
and Appel, 1998; Brodie et al., 1999), a key region of the mesocorticolimbic DA 
system, resulting in DA release in the nucleus accumbens (NAc), a phenomenon 
widely associated with drug reinforcement (Soderpalm et al., 2009).  Several 
nAChR subunit genes are expressed throughout the mesocorticolimbic DA 
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system particularly in DAergic neurons of the VTA. Neuronal nAChRs are ligand-
gated, pentameric cation channels normally activated by the endogenous 
neurotransmitter, acetylcholine (ACh). Twelve mammalian genes encoding 
neuronal nAChR subunits have been identified (α2-α10, β2-β4) which form either 
hetero- or homomeric receptors yielding a vast array of nAChR subtypes with 
distinct pharmacological and biophysical properties (Albuquerque et al., 2009). 
Although ethanol is not a direct agonist of nAChRs, alcohol increases ACh 
release into the VTA (Ericson et al., 2003) and potentiates the response of high 
affinity nAChR subtypes to ACh (Zuo et al., 2002).  Mecamylamine, a non-
selective nAChR antagonist, either directly infused into the VTA or delivered 
systemically, decreases ethanol mediated DA release in the NAc (Blomqvist et 
al., 1997; Larsson et al., 2002) and also decreases self-administration in rodents 
(Ericson et al., 1998; Hendrickson et al., 2009).  Thus, nAChR activation 
modulates alcohol consumption and reinforcement. 
 While varenicline was designed as a selective α4β2* nAChR partial 
agonist (Coe et al., 2005; Jorenby et al., 2006), it is also a partial agonist at 
α3β2* and α6* nAChR subtypes, and a full agonist at α3β4* and α7 nAChR 
subtypes (Mihalak et al., 2006).  Varenicline has also been shown to reduce 
alcohol consumption in knockout (KO) mice lacking expression of either α7 or 
β2* nAChRs (Kamens et al., 2010). Thus, the nAChR subtype(s) that varenicline 
targets to reduce alcohol consumption is unknown.  The goal of the present study 
was to localize and identify nAChR subtypes expressed in the VTA that may be 
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involved in the response to alcohol and to determine if they play a role in the 
molecular mechanism by which varenicline reduces alcohol consumption.  
 
IV.B MATERIALS AND METHODS 
Animals.  Adult (8-10 week), male C57BL/6J mice bred in house were used for 
immunohistochemistry, gene expression, and brain infusion experiments (n = 
46).  For consumption experiments, adult, male α4 knock-out (α4 KO) mice and 
their wild type (WT) litter mates (n = 45), as well as heterozygous Leu9′Ala 
knock-in mice and their WT litter mates (n = 42), all bred on site, were used.   
The genetic engineering of both α4 KO and Leu9′Ala mouse lines have been 
described previously (Ross et al., 2000; Tapper et al., 2004).  Both lines have 
been back-crossed to a C57BL/6J background for at least nine generations.   
C57BL/6J mice were group housed four mice/cage and given food and water ad 
libitum. For consumption experiments, mice were individually housed on a 
reversed 12 h light/dark cycle (lights on 10 PM, off 10 AM) with ad libitum access 
to food and water (except during experiments as described below).  All 
experiments were conducted in accordance with the guidelines for care and use 
of laboratory animals provided by the National Research Council (National 
Research Council, 1996), as well as with an approved animal protocol from the 
Institutional Animal Care and Use Committee of the University of Massachusetts 
Medical School.   
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Drugs and drinking solutions.  Ethanol drinking solutions were prepared from 190 
proof absolute anhydrous ethanol (Pharmco-Aaper) diluted to 2 % or 20 % 
ethanol (v/v) using tap water.  Sucrose was dissolved in tap water to make a 10 
% (w/v) concentration.  Varenicline tartrate, a gift from Pfizer, and ethanol were 
dissolved in 0.9 % saline and administered via intraperitoneal (i.p.) injection at 
the indicated doses.  For infusion of drug into the brain, varenicline was dissolved 
in artificial cerebrospinal fluid (aCSF containing, in mM: 126 NaCl, 2.5 KCl, 2 
CaCl
2
, 1 MgCl
2
, 1.25 NaH
2
PO
4
, 26 NaHCO
3
, 25 D-glucose).  For 
immunohistochemistry and behavioral experiments, varenicline doses were 
chosen based on previous studies of varenicline effects on nicotine self-
administration and DA turnover in addition to predicted therapeutic 
concentrations achieved in smokers’ brains (O'Connor et al., 2010; Rollema et 
al., 2010). Varenicline concentrations are reported as freebase.   
 
Immunohistochemistry.  Adult (8-10 weeks), male, C57BL/6J mice were injected 
i.p. with saline for three days prior to the start of the experiment to habituate them 
to handling and to reduce c-Fos activation due to stress.  Four groups of three 
mice were used in each of the following conditions: an i.p. injection of saline 
followed by an i.p. injection of saline, an i.p. injection of saline, followed by a 2.0 
g/kg ethanol injection, an i.p. injection of 0.3 mg/kg varenicline followed by a 
saline injection, and 0.3 mg/kg varenicline i.p. injection followed by a 2.0 g/kg 
ethanol injection.  The time between the first and second injections was 15 min.  
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Ninety minutes after the second injection, all mice were deeply anesthetized with 
sodium pentobarbital (200 mg/kg, i.p.) and perfused transcardially with 10 ml of 
0.1 M phosphate-buffered saline (PBS) followed by 10 ml of 4 % 
paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4). Brains were 
removed and post-fixed for 2 h with the same fixative and cryoprotected in 
sodium phosphate buffer containing 30 % sucrose until brains sank. VTA serial 
coronal sections (20 µm) were cut on a microtome (Leica Microsystems Inc.) and 
collected into a 24-well tissue culture plate containing 1 X PBS. Slices containing 
VTA were collected between -2.8 mm and -4.04 mm from bregma.  After rinsing 
sections in PBS twice for 5 min, they were treated with 0.2 % Triton X-100 PBS 
(PBST) for 5 min followed by incubation in 2 % BSA/PBS for 30 min. Sections 
were washed with PBS once and then incubated in a cocktail of primary 
antibodies for tyrosine hydroxylase (TH mouse monoclonal, 1:250 dilution, Santa 
Cruz Biotechnology) and c-Fos (rabbit polyclonal, 1:400 dilution, Santa Cruz 
Biotechnology) in 2 % BSA/PBS overnight at 4°C. The sections were then 
washed with PBS three times for 5 min followed by incubation in secondary 
fluorescent labeled antibodies (goat anti-rabbit Alexa Fluor® 488 and goat anti-
mouse Alexa Fluor® 594, 1:300 dilutions, Molecular Probes, Inc.) at room 
temperature in the dark for 30 min. After washing with PBS 5 times for 5 
min/wash, sections were mounted on slides using VECTASHIELD® Mounting 
Medium (Vector Laboratories, Inc.). The number of positive neurons was counted 
under a fluorescence microscope (Carl Zeiss MicroImaging Inc.) at a 
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magnification of 400X. The intensity of fluorescence was quantified using a 
computer-associated image analyzer (Axiovision Rel. 4.6).  Neurons were 
counted as signal-positive if intensities were at least 2 times higher than that of 
the average value of background (sections stained without primary antibodies).  
Image analysis was performed by an individual blind to drug treatment.   
 
Laser Capture Microdissection (LCM). Adult, male C57BL/6J mice were i.p. 
injected with saline for three days prior to the start of the experiment to habituate 
them to handling and to reduce c-Fos activation due to stress.  On the 
experiment day, mice were i.p. injected with 2.0 g/kg ethanol and decapitated 90 
min later.  The brain was removed, snap-frozen in dry ice-cooled 2-methylbutane 
(-60° C) and stored at -80° C.  Coronal serial sections (10 µm) of the VTA were 
cut using a cryostat (Leica Microsystems Inc.) and mounted on pre-cleaned glass 
slides (Fisher Scientific).  The sections were immediately placed in a slide box on 
dry ice until completion of sectioning followed by storage at -80°C.  A quick 
immunofluorescence double-staining protocol for TH and c-Fos was used to 
identify TH and c-Fos immunopositive neurons. First, frozen sections were 
allowed to thaw for 30 seconds then immediately fixed in cold acetone for 4 min. 
Slides were then washed in PBS, incubated with a cocktail of primary antibodies 
for mouse anti-TH and rabbit anti-c-Fos (Santa Cruz Biotechnology, Inc., 1:50 
dilutions) for 10 min, washed in PBS once followed by incubation in secondary 
fluorescent-labeled antibodies (Molecular Probes, Inc., a cocktail of goat anti-
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mouse Alex Fluor 594® and goat anti-rabbit Alex Fluor 488®, 1:100 dilution) for 
10 min. The slides were washed in PBS once, then subsequently dehydrated in a 
graded ethanol series (for 30 s each in 70 % ethanol, 95 % ethanol, 100 % 
ethanol, and once for 5 min in xylene). Slides were allowed to dry for 5 min.  All 
antibodies were diluted in DEPC-treated PBS containing 2 % BSA and 0.2 % 
Triton X-100. All ethanol solutions and xylene were prepared fresh to preserve 
RNA integrity.  
 The VeritasTM Microdissection System Model 704 (Arcturus Bioscience, 
Inc.) was used for LCM. Approximately  800 to 1400 TH-immunopositive neurons 
(including separate pools of c-Fos-immunopositive and c-Fos-immunonegative) 
were cut from the VTA in each animal. Five to seven different mice were used 
per treatment. Neurons were captured on CapSure® Macro LCM caps (Arcturus 
Bioscience, Inc.) for mRNA isolation.  
 
Real-time PCR. Total RNA was extracted from individual replicate samples using 
a Micro Scale RNA Isolation Kit (Ambion, Inc.). RNA samples extracted from 
DAergic neurons were reverse-transcribed into cDNA using TaqMan® Gene 
Expression Cells-to-CT™ Kit (Ambion, Inc.). PCR reactions were set up in 10-µl 
reaction volumes using TaqMan Gene Expression Assays (ABI, Inc.). GAPDH 
was used as an internal control gene to normalize gene expression levels. PCR 
was performed using an ABI PRISM 7500 Sequence Detection System. Negative 
controls with no reverse transcriptase were performed for all Taqman Assays. All 
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reactions were performed in triplicate. Relative amplicon quantification was 
calculated as the difference between Ct values of GAPDH and that of the gene of 
interest. Relative gene expression differences between c-Fos immunopositive 
neurons and c-Fos immunonegative neurons were calculated using the 2-∆∆Ct 
method.  
 
Drinking in the Dark (DID).  Ethanol consumption was measured using a similar 
Drinking in the Dark (DID) procedure as previously described (Hendrickson et al., 
2009). Animals were singly housed in experimental chambers for 1 week prior to 
the beginning of the DID sessions. The mice received a 15-ml graduated water 
bottle fitted with a one-hole rubber stopper with a stainless steel double-ball-
bearing sipper tube which was sealed with Parafilm to prevent leakage. For the 
first three nights, two hours after the lights were off, mice were i.p. injected with 
saline immediately before their water bottle was replaced with the ethanol bottle 
(2 % or 20 %), and allowed to drink for two hours.  This procedure was used to 
acclimatize the mice to the experimental conditions and allow them to reach a 
baseline of ethanol intake prior to drug administration. On the fourth night, the 
mice received their first dose of drug just prior to placement of the ethanol bottle.  
The amount of ethanol consumed was recorded after each two-hour session and 
converted to g/kg per each animal’s ethanol consumption and body weight.  The 
mice were given 2 days of rest (no injections or ethanol) and then began the 
saline injection/ethanol consumption assay for two to three days or until a stable 
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ethanol intake was reached.  Once the baseline returned, a second, higher dose 
of drug was administered prior to the ethanol bottle being placed in the cage.  In 
this design, all mice in one group drink a single concentration of ethanol 
throughout the experiment, but receive two doses of drug, 4-5 days apart, with 
the lower concentration of drug first.  The baseline value immediately prior to the 
first drug exposure is shown in all figures. There was no significant difference in 
baseline ethanol intake between doses in any of the experiments (data not 
shown).  For control experiments, mice received 10 % sucrose for two hours 
instead of ethanol. 
 
Cannula surgeries.  C57BL/6J mice were anesthetized with a mixture of 
ketamine (100 mg/kg) and xylazine (10 mg/kg) (VEDCO). The surgical area was 
shaved and disinfected.  Mice were placed in a stereotaxic frame (Stoelting Co) 
with mouse adaptor and a small incision was cut in the scalp to expose the skull.  
Using bregma and lambda as landmarks, the skull was leveled in the coronal and 
sagittal planes.  For cannula placement, holes were drilled in the skull at the 
anteroposterior (AP, in reference to bregma) and mediolateral (ML) coordinates 
that correspond to either the anterior VTA (-2.6 mm AP, ± 0.5 mm ML) or 
posterior VTA (-3.4 mm AP, ± 0.5 mm ML) based on “The Mouse Brain in 
Stereotaxic Coordinates” (Paxinos and Franklin, 2000). Stainless steel unilateral 
guide cannula (-4.0 mm dorsal ventral, + 0.5 mm ML, Plastics One) with dummy 
cannula in place, were inserted into the brain and secured to the skull with 
113 
 
cerebond (Plastics One).  Mice were allowed to recover for at least 3 days before 
behavioral testing.  
 
Intra-VTA infusions and DID. Two hours after the lights were turned off, mice 
were anesthetized with 2 % Isoflurane via a nose cone adaptor at a flow rate of 
800 ml/L.  Once anesthetized, an infusion cannula designed to reach -4.5 mm 
below the skull was inserted into the guide cannula and vehicle, 10 pmol, 100 
pmol, or 1000 pmol varenicline was infused at a rate of 1 µl/min for 45 s and a 
total volume of 0.75 µl.  Immediately after infusion, mice were placed back into 
their home cages and monitored until awake, ~45 s.  During this time, the home 
cage water bottle was removed and replaced with a bottle containing 20 % 
ethanol, which was left in place for 2 hours as previously described for the DID 
experiments.  Before the drug exposure day, mice were infused with vehicle daily 
until a stable baseline of ethanol intake was reached.  After completion of 
behavioral experiments, mice were culled and brains were removed and frozen 
on dry ice.  Coronal sections (20 µm) were cut with a cryostat (Leica 
Microsystems Inc.).  Sections were mounted and stained with neutral red (Sigma) 
to visualize cannula placement.  A total of 6 mice were excluded from analysis 
due to incorrect cannula placement.         
 
Data Analysis.  Data were analyzed using Two-Way ANOVA with drug treatment and 
either genotype or brain region as variables as indicated followed by Bonferroni post 
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hoc tests. Data were analyzed using Graphpad software (Graphpad Software, Inc.).   
Paired t-tests were used to analyze fold expression of qRT-PCR data.  Results were 
considered significant at p<0.05. All data are expressed as means ± standard errors of 
means (SEM).  
 
IV.C. RESULTS 
Varenicline and alcohol activate DAergic neurons within the posterior VTA 
 Recent evidence suggests that the VTA is not a homogeneous brain 
structure but is divided into distinct subregions (Ikemoto, 2007; Shabat-Simon et 
al., 2008).  Thus, using c-Fos expression as a marker of neuronal activation and 
TH as a marker of DAergic neurons of the VTA, we examined the activating 
effects of varenicline and ethanol alone and in combination throughout the VTA.  
The VTA was divided into two distinct regions, anterior and posterior, using 
known neuroanatomical landmarks and stereotaxic coordinates based on 
Paxinos and Franklin (Paxinos and Franklin, 2000) and previous publications 
(Shabat-Simon et al., 2008). C57BL/6J mice were injected i.p. with drug(s) and 
their brains were examined for c-Fos expression within TH-immunopositive 
neurons 90 min later.  Overall, there was a significant main effect of brain region 
(F1,20 = 166.5, p<0.001), treatment (F3,20 = 49.21, p<0.001), and a significant 
brain region ×  treatment interaction (F3,20 = 28.25, p<0.001).  Mice treated with 
0.3 mg/kg varenicline followed by a saline injection exhibited an increase in the 
number of TH and c-Fos double immunopositive neurons, which were restricted 
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to the posterior VTA (Fig. IV-1A, 1B).  Mice i.p. injected with saline, followed by 2 
g/kg ethanol also displayed a dramatic increase in the number of TH/c-Fos 
double-immunopositive neurons within the posterior but not anterior VTA (IV-Fig. 
1A, 1B).  Finally, mice i.p. injected with 0.3 mg/kg varenicline followed by 2.0 g/kg 
ethanol also exhibited a significant increase in the number of TH/ c-Fos double-
immunopositive neurons restricted to the posterior VTA (Fig. IV-1A, 1B).  
Bonferroni post tests revealed that each treatment condition was significantly 
different from control injections (saline/saline) within the posterior VTA (Fig. IV-
1B, p<0.001).  There were no significant effects of treatment on the number of 
TH/c-Fos double-immunopositive neurons within the anterior VTA when 
compared to saline injection.  These results are consistent with the finding that 
the VTA can indeed be divided into distinct regions and that ethanol and 
varenicline predominantly activate DAergic neurons within the posterior VTA.   
Differential expression of nAChR subunits in alcohol-activated posterior 
VTA neurons. 
 To gain insight into potential nicotinic receptor subunits that may be 
involved in alcohol activation of posterior VTA DAergic neurons, we challenged 
C57BL/6J mice with 2.0 g/kg ethanol and used LCM and qRT-PCR to analyze 
nicotinic receptor gene expression in activated, TH-, c-Fos-immunopositive 
neurons compared to non-activated, TH-immunopositive, c-Fos-immunonegative 
neurons.  mRNA from the two groups of neurons, (Fig. IV-2A) only within the 
posterior VTA was isolated and reverse transcribed. Neuronal nAChR subunit 
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gene expression was then analyzed using qRT-PCR.  In TH-, c-Fos-
immunopositive neurons, the order of expression for nicotinic receptor subunit 
genes, from highest to lowest expression, was:  α4 > α6 > β3 > β2 > α7 > α3 > 
α5. For TH-immunopositive, c-Fos-immunonegative neurons, the order of 
expression was: α4 > β3 > β2 > α6 > α7 > α3 > α5 (Table IV-1).  A paired t-test 
showed significantly higher levels of expression of the α4 (t = 2.24, df = 4, 
p<0.05), α6 (t = 4.06, df = 3, p<0.05), and β3 (t = 4.28, df = 4, p<0.01) nAChR 
subunit genes as well as c-Fos (t = 2.69, df = 3, p<0.05) in the c-Fos-
immunopositive neurons compared to c-Fos-immunonegative neurons (Fig. IV-
2B, Table IV-1).  These results indicate specific nAChR subtypes (α4α6β3*) may 
be important for modulating alcohol activation of posterior VTA DAergic neurons.  
Role of α4* nAChRs in varenicline-induced reduction of alcohol 
consumption 
 Because (1) the specific role of α4* nAChR in alcohol consumption has 
not been described and (2) α4 gene expression was higher in DAergic neurons 
activated by ethanol within posterior VTA, we tested the hypothesis that 
varenicline may reduce alcohol consumption via these receptors.  First, we 
examined the effects of 0.1 mg/kg and 0.3 mg/kg varenicline on 2 % alcohol 
intake in mice that do not express α4* nAChRs (α4 KO), and their WT litter mates 
(Fig. IV-3A).  There was a significant main effect of treatment (F2,45 = 8.0, 
p<0.001) but not genotype and there was no significant interaction between 
these two factors.  Both doses of varenicline significantly decreased 2 % ethanol 
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consumption in WT mice compared to saline (p<0.01 for both doses), but did not 
reduce consumption in α4 KO mice (Fig. IV-3A).  This experiment was repeated 
in a separate group of animals with the same doses of varenicline, but using a 
higher concentration of alcohol, 20 %.  Two-way ANOVA revealed a significant 
main effect of treatment (F2,64 = 5.31, p<0.01), genotype (F1,64 = 12.11, p<0.001), 
and a significant treatment ×  genotype interaction (F2,64 = 3.19, p<0.05).  
Whereas WT and α4 KO mice consumed similar baseline quantities of 2 % 
alcohol, baseline 20 % alcohol consumption after saline injection was 
significantly less in α4 KO mice compared to WT (p<0.01, Fig. IV-3B).  
Varenicline significantly decreased 20 % ethanol consumption in WT animals 
(Fig. IV-3B) and post hoc tests indicated that alcohol consumption after each 
varenicline dose was significantly lower compared to consumption after saline 
injection (p<0.01 for both doses).  In α4 KO mice, alcohol consumption after 
either varenicline dose was not significantly different compared to consumption 
after saline.  Thus, these data suggest that expression of α4* nAChRs is 
necessary for varenicline-induced reduction of ethanol consumption. 
 To determine whether activation of α4* nAChRs by varenicline was 
sufficient to decrease ethanol intake, we analyzed the effect of low doses of drug 
on alcohol consumption in mice expressing a single point mutation, Leu9′Ala, 
that renders α4* nAChRs hypersensitive to agonist (Tapper et al., 2004).  
Leu9′Ala and WT littermate mice were challenged with i.p. injections of 0.0125 
mg/kg and 0.05 mg/kg varenicline prior to receiving a 2 % ethanol bottle.  There 
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was a significant main effect of treatment (F2,55 = 6.86, p<0.01) and genotype 
(F1,55 = 6.14, p<0.05) and a significant treatment ×  genotype interaction (F2,55 = 
3.74, p<0.05). Surprisingly, both low doses of varenicline significantly decreased 
2 % ethanol intake in Leu9′Ala (0.0125 mg/kg and 0.05 mg/kg compared to 
saline, p<0.01 and p<0.001, respectively) but not WT mice (Fig. IV-3C).  
However, higher doses (0.1 mg/kg and 0.3 mg/kg) of varenicline did significantly 
reduce consumption in WT mice (Fig. IV-3C, D, p<0.05, and p<0.01 comparing 
0.1 mg/kg and 0.3 mg/kg varenicline to saline, respectively).  Similar results were 
obtained when this experiment was repeated and the concentration of alcohol 
was increased to 20 %. There was a main effect of treatment (F2,40 = 6.73, 
p<0.01) and genotype (F1,40 = 22.65) but no significant interaction.  Varenicline 
significantly decreased ethanol consumption in Leu9′Ala but not WT mice when 
challenged with low doses of the drug, and each dose of varenicline was 
significantly different compared to a saline injection (Fig. IV-3D, p<0.01 for both 
doses). Together, these data suggest that selective activation of α4* nAChRs by 
varenicline is sufficient for reduction of alcohol consumption.  Importantly, 
varenicline did not significantly reduce 10 % sucrose consumption in any of the 
genotypes, indicating that the effect of varenicline was specific for alcohol intake 
(Fig. IV-3E).   
Varenicline infusion into the anterior and posterior VTA 
 To determine if varenicline reduction of alcohol consumption was 
mediated by drug action in the posterior VTA, we selectively infused the drug into 
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either the anterior or posterior VTA of C57BL/6J mice and measured alcohol 
consumption.  Guide cannula were implanted into either brain region (see 
Methods) and vehicle, 10, 100, or 1000 pmol varenicline was infused into the 
VTA prior to presentation of a 20 % alcohol bottle.  Figures IV-4A and IV-4B 
depict the location of the guide cannula within each mouse brain from the two 
groups of animals.  Two-way ANOVA revealed a significant main effect of 
treatment (F3,47 = 3.13, p<0.05) and brain region (F1,45 = 4.88, p<0.05) and a 
significant treatment × brain region interaction (F3,47 = 4.39, p<0.01).  When 
infused into the anterior VTA, varenicline did not significantly reduce alcohol 
consumption compared to vehicle infusion (Fig. IV-4C).  However, 10, 100, and 
1000 pmol varenicline, when infused into the posterior VTA, significantly reduced 
alcohol consumption (Fig. IV-4D, p<0.01, p<0.05, and p<0.01 respectively).  
These data indicate that infusion of varenicline into the posterior VTA is sufficient 
to reduce alcohol consumption.  
 
IV.D. DISCUSSION 
 Because alcohol is one of the most commonly abused psychoactive drugs 
in the world resulting in significant health consequences, it is critical to identify 
novel therapies and molecular targets to treat alcoholism.  The nAChR partial 
agonist varenicline is an FDA approved smoking cessation aid that may hold 
promise as a treatment for alcoholism (Coe et al., 2005; Gonzales et al., 2006).  
For example, varenicline reduces alcohol consumption and seeking in rats 
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(Steensland et al., 2007) and also significantly reduces alcohol consumption in 
heavy drinking smokers (McKee et al., 2009).  Although much is known about 
how varenicline may reduce nicotine dependence, much less is known regarding 
the brain regions and nAChR subtypes that varenicline may target to reduce 
alcohol consumption.   
Varenicline-induced activation of the posterior VTA reduces alcohol 
consumption. 
Our data indicate that varenicline and ethanol interact in the VTA.  Indeed, 
much emphasis has been placed on the VTA because of its central importance in 
the mesocorticolimbic reward pathway (Funk et al., 2006).  Alcohol activates 
DAergic neurons within this region, ultimately increasing DA release in the NAc 
driving dependence (Brodie and Appel, 1998; Brodie et al., 1999; Mansvelder et 
al., 2002; Pidoplichko et al., 1997).  Mounting evidence indicates that the VTA is 
not a homogeneous brain region; rather it can be anatomically and functionally 
divided into at least two brain regions, the anterior and posterior VTA (Ikemoto, 
2007; Shabat-Simon et al., 2008).  Although both regions of the VTA contain 
predominantly two subtypes of neurons, DAergic projection neurons and local 
GABAergic interneurons, studies have shown that neurons within the anterior 
and posterior VTA project to distinct regions of striatum and also may respond 
differently to drugs of abuse (Ikemoto, 2007; Shabat-Simon et al., 2008; Zangen 
et al., 2006).  The predominant VTA subregion that is critical for alcohol’s action 
in the VTA is unclear.  Previous studies indicate that the anterior VTA is an 
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important modulator of alcohol intake (Ericson et al., 2008; Moore and Boehm, 
2009) while others find a role for the posterior VTA (Linsenbardt and Boehm, 
2009).  Additionally, local infusion of ethanol into the anterior VTA does not 
increase NAc DA output (Ericson et al., 2003; Lof et al., 2007a) while local 
infusion of ethanol to the posterior VTA is sufficient for increased DA release in 
the NAc (Ding et al., 2009). Our data are in line with previous work highlighting 
the importance of the posterior VTA in alcohol-mediated activation of DAergic 
neurons.  Injection of 2.0 g/kg alcohol, a dose that conditions a place preference 
in C57BL/6J mice (i.e., a rewarding dose) (Cunningham et al., 2003) activated 
DAergic neurons predominantly in the posterior VTA.  Varenicline also activated 
DAergic neurons selectively in this region and infusion of varenicline directly into 
the posterior, but not anterior, VTA reduced alcohol consumption, suggesting that 
the posterior VTA, specifically, could be a neuroanatomical substrate where both 
drugs interact. Thus, our data support previous studies indicating that rats will 
self-administer nicotine or ethanol directly into the posterior, but not anterior, VTA 
(Ikemoto et al., 2006; Rodd et al., 2004; Rodd-Henricks et al., 2000).   
 Activation of DAergic neurons by alcohol at least partially mediates the 
rewarding properties of the drug.   Interestingly, varenicline also activates these 
neurons and this reduces alcohol consumption.  Although the precise mechanism 
of this effect is unknown, one possibility is that activation of DAergic neurons by 
varenicline precludes further activation by alcohol.  At the molecular level 
varenicline may serve to occupy or desensitize nAChRs necessary for alcohol 
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activation of DAergic neurons thereby reducing DA release in the NAc and 
decreasing consumption. Supporting this idea, varenicline has been shown to 
reduce alcohol stimulated NAc DA release in rats (Ericson et al., 2009). This 
would also be consistent with the mechanism by which varenicline is thought to 
reduce nicotine reinforcement (Rollema et al., 2007a).      
The role of nAChRs in alcohol consumption.  
 Reduction of alcohol consumption by varenicline indicates that nAChRs 
may play a critical role in the reinforcing properties of ethanol.  Several studies 
have utilized various nicotinic agonists and antagonists to implicate nAChR 
activation as potentially important for alcohol consumption.  The non-specific 
nAChR antagonist, mecamylamine, either delivered systemically or selectively 
into the VTA, reduces alcohol intake and blocks alcohol-mediated DA release in 
NAc (Blomqvist et al., 1993; Blomqvist et al., 1997; Blomqvist et al., 1996; 
Hendrickson et al., 2009).  However, specific nicotinic receptor subtypes involved 
in alcohol consumption are unclear. Previous studies have demonstrated that the 
selective α4β2* nAChR competitive antagonist, DHβE, fails to modulate alcohol 
consumption suggesting that this subtype may not be involved in the response to 
alcohol (Hendrickson et al., 2009; Le et al., 2000).  The α7 selective antagonist, 
methyllycaconitine, also does not reduce alcohol intake (Hendrickson et al., 
2009). To gain insight into nAChR subtypes that may influence alcohol 
consumption, and be targeted by varenicline, we compared nAChR subunit gene 
expression between posterior VTA DAergic neurons that were activated by 
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alcohol and posterior VTA DAergic neurons not activated by alcohol.  We found 
that DAergic neurons that were activated by alcohol express higher levels of α4, 
α6, and β3 nAChR subunit transcripts.  Although this difference in mRNA 
expression does not necessarily translate into protein and/or assembled receptor 
expression, these data suggest that α4α6β3* nAChRs may be involved in alcohol 
consumption.  Our results are consistent with previous studies indicating that the 
α6/β3* nAChR selective antagonist α-conotoxin MII, when infused into the VTA, 
can reduce alcohol consumption and block alcohol-mediated DA release in NAc 
(Jerlhag et al., 2006; Larsson et al., 2004; Lof et al., 2007b).   Importantly, a 
significant portion of α6β3* nAChRs also contain the α4 subunit and these 
receptors represent one of the highest affinity nAChRs identified in the brain thus 
far (Salminen et al., 2007; Salminen et al., 2004).  
Activation of α4* nAChRs are critical for varenicline-induced reduction of 
alcohol consumption. 
The role of α4* nAChRs in varenicline reduction of alcohol consumption 
has not been examined previously.  We used two complementary genetic nAChR 
mouse models, one lacking the gene encoding the α4 subunit, CHRNA4 (α4 KO) 
(Ross et al., 2000) and another that has a single point mutation, Leu9′Ala, within 
the endogenous CHRNA4 exon 5 resulting in α4* nAChRs that are 
hypersensitive to agonist (Leu9′Ala) (Fonck et al., 2005; Tapper et al., 2004).  
Varenicline reduced consumption of both a low and high dose of alcohol in WT 
mice but did not significantly reduce consumption in α4 KO mice indicating that 
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expression of α4* nAChRs is necessary for the effects of the drug.   In contrast to 
the effects of varenicline in the KO animals, low doses of varenicline that had 
little effect on consumption in WT mice dramatically reduced ethanol intake in 
Leu9′Ala mice suggesting that activation of α4* nAChRs is also sufficient for 
varenicline effects on alcohol consumption. Importantly, varenicline did not 
reduce sucrose intake indicating that the effects the drug were specific for 
alcohol consumption and did not dampen general reward signaling.  Because 
varenicline may also target α7 as well as other nAChR subtypes in addition to 
α4β2* nAChRs, the mechanism by which varenicline reduces alcohol 
consumption is an open question (Mihalak et al., 2006; Papke et al., 2010).  A 
recent study demonstrated that varenicline reduced ethanol consumption in mice 
lacking either α7 or β2* nAChRs similar to WT (Kamens et al., 2010) indicating 
that expression of these receptors is not necessary for varenicline’s effects.  As 
discussed above, our data suggest that α4α6β3* nAChRs mediate varenicline’s 
effects on alcohol consumption, although it is expected that this subtype should 
also contain the β2 subunit (Grady et al., 2007).   Thus, varenicline reduction of 
ethanol intake in β2 KO mice may occur because of compensatory mechanisms 
in nAChR expression or subunit composition.  Alternatively, we cannot rule out 
the possibility that higher doses of varenicline than used in our study may reduce 
alcohol consumption by a non-α4* nAChR dependent mechanism.  However, we 
expect that the doses we used would result in concentrations of varenicline more 
selective for  high affinity nAChRs.  For example, 0.1 mg/kg varenicline is 
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predicted to yield a brain concentration of 38 nM (Rollema et al., 2009).  This 
concentration is predicted to be within the range experienced by smokers taking 
therapeutic doses of varenicline (Rollema et al., 2010).  Similar doses also 
reduce nicotine self-administration in rats without impacting food reinforcement 
unlike higher doses (O'Connor et al., 2010).  In addition, this range of varenicline 
dose also increases DA turnover in rat NAc (Rollema et al., 2010) consistent with 
our data illustrating that 0.3 mg/kg varenicline activates DAergic neurons.  
 Taken together, our results demonstrate that ethanol and varenicline 
selectively activate DAergic neurons within the posterior VTA and that activation 
of α4* nAChRs is necessary and sufficient for varenicline-induced reduction of 
ethanol consumption. Our data combined with recent clinical studies indicate that 
varenicline could potentially be a therapeutic candidate for the treatment of 
alcoholism.  
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Table IV-1.  Quantitative gene expression of nAChR subunit genes in pVTA DAergic neurons either activated or not activated by 2.0 g/kg 
ethanol (TH(+)/c-Fos(+) or TH(+)/c-Fos(-), respectively).  Values represent the negative change in threshold cycle (-DCt) compared to 
GAPDH.   
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Figure IV-1. Varenicline activates DAergic neurons within the posterior VTA.  A) 
Representative images of coronal sections from the anterior (left) and posterior (right) VTA.  
Sections were isolated from C57BL/6J mice injected with saline, 0.3 mg/kg varenicline, 2 g/kg 
ethanol, or both drugs.  Sections were immunolabeled to detect TH expression (red, left columns) 
and c-Fos expression (green, middle columns).  Merged images are represented in the right 
column.  White arrowheads mark c-Fos positive TH neurons.  B) Quantification of the number of 
TH-, c-Fos immunopositive (TH(+), c-Fos(+)) neurons within each region of the VTA after each 
drug treatment (34-51 slices analyzed per region, n = 3 mice/treatment).  * p<0.05, *** p<0.001. 
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Figure IV-2.  Differential nAChR subunit gene expression in alcohol-activated versus non-
activated DAergic neurons.  A) Immunofluorescence image of coronal midbrain slice from 
C57BL/6J mice challenged with 2.0 g/kg ethanol.  Sections were immunolabeled to detect TH 
(red) expression to visualize DAergic neurons and c-Fos (green) expression to identify neurons 
activated by ethanol.  Arrows point to two different cells, one, a TH immunopositive c-Fos 
immunonegative neuron (TH(+), c-Fos(-)) and the other a TH-, c-Fos immunopositive neuron 
(TH(+), c-Fos (+)).  B) Fold change of nAChR subunit gene expression, as measured by qRT-
PCR, in TH-, c-Fos immunopositive (left) neurons compared to TH immunopositive, c-Fos 
immunonegative neurons (right).  Three mice per treatment group were used.  Neurons were 
captured via LCM. TH-, c-Fos immunopositive neurons n = 2,298 and TH immunopositive, c-Fos 
immunonegative n = 3,645.  * p<0.05, ** p<0.01, paired T-test.  
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Figure IV-3.  Alcohol intake after varenicline treatment in α4 KO, Leu9′Ala and WT mice.  A) 
2 % ethanol intake in WT and α4 KO mice after saline or varenicline treatment (n = 8-9 / 
genotype).  B) 20 % ethanol intake in WT and α4 KO mice after saline or varenicline treatment (n 
= 10-12 / genotype).  C) Effect of saline and varenicline on 2 % ethanol intake in WT and 
Leu9′Ala  (n = 10-11 / genotype).  D) Effect of saline and varenicline on 20 % ethanol intake in 
Leu9′Ala and Leu9′Ala WT mice (n = 6-9 / genotype).  E) Effect of varenicline treatment on 10 % 
sucrose intake (n = 5-11 / genotype) in WT, α4 KO, and Leu9′Ala mice.  * p<0.05, ** p<0.01, ^ 
p<0.01 (α4 KO compared to WT after saline injection) 
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Figure IV-4. Alcohol intake after varenicline infusion into anterior or posterior VTA.  A)  
Left, representative neutral red stained coronal brain slice from a mouse with a guide cannula 
placed just dorsal to the anterior VTA (dotted box).  Right, schematic diagram of anterior VTA -
3.08 mm from bregma (adapted from (Paxinos and Franklin, 2000)).  X’s represent guide cannula 
placements within the anterior VTA.  B) Left, representative neutral red stained coronal brain slice 
from a mouse with a guide cannula placed just dorsal to the posterior VTA (dotted box).  Right, 
schematic diagram of posterior VTA at bregma -3.52.  X’s represent guide cannula placements 
within the posterior VTA.  C) 20 % ethanol intake after infusion of aCSF, 10 pmol, or 100 pmol 
varenicline in either the anterior or posterior VTA (n = 9-10 / brain region).  * p<0.05, ** p<0.01, 
Bonferroni post-test. 
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CHAPTER V 
Nicotinic acetylcholine receptors containing the α4 subunit are critical for 
nicotine-induced reduction of acute voluntary ethanol consumption. 
 
V.A. INTRODUCTION 
 Similar to all drugs of abuse, ethanol administration causes an increase of 
dopamine (DA) release in the nucleus accumbens (NAc).  This increase in DA 
release is thought to underlie the rewarding or reinforcing properties of the drug 
(Soderpalm et al., 2009).  Although ethanol has been found to modulate several 
receptors and ion channels, emerging evidence indicates that nicotinic 
acetylcholine receptors (nAChRs) may play a role in ethanol-induced accumbal 
DA release and ethanol reinforcement (Soderpalm et al., 2000).  Pre-application 
of mecamylamine, a nAChR antagonist, either by direct infusion into the ventral 
tegmental area (VTA) or an intraperitoneal (i.p.) injection, decreases ethanol-
induced DA release in the NAc (Blomqvist et al., 1997; Larsson et al., 2002) as 
well as decreases ethanol self-administration in rats (Ericson et al., 1998) and 
ethanol voluntary intake in mice (Hendrickson et al., 2009).  Thus, nAChRs are 
now a focus of intense investigations as molecular targets for not only nicotine 
addiction, but alcoholism as well. 
 For example, the nAChR partial agonist varenicline is an FDA approved 
smoking cessation aid that has also shown promise to reduce ethanol 
consumption in several rodent models and one clinical model (Hendrickson et al., 
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2010; Kamens et al., 2010; McKee et al., 2009; Steensland et al., 2007).  The 
molecular mechanism by which varenicline acts to decrease nicotine intake is 
well understood, while on the other hand, until recently, its role in decreasing 
ethanol intake was not entirely clear due to the vast array of nAChR subtypes it 
may act upon.   
 Neuronal nAChRs are pentameric, ligand-gated cation channels that are 
activated by the endogenous neurotransmitter acetylcholine (ACh) as well as 
exogenous agonists such as nicotine.  To date, twelve mammalian neuronal 
nAChR subunits have been identified (α2-α10, β2 -β4), which can combine to 
form either hetero- or homomeric receptors, producing multiple functional 
subtypes of receptors, each with distinct pharmacological and biophysical 
properties (Albuquerque et al., 2009). 
 Given the large number of nAChR subtypes with which varenicline may 
interact (Mihalak et al., 2006), we sought to identify which nAChR subtype 
underlies varenicline’s effect on ethanol intake.  Because varenicline was 
designed to be a partial agonist of nAChRs containing α4 and β2 subunits 
(designated as α4β2*) (Coe et al., 2005; Jorenby et al., 2006) we examined the 
effect of the drug on ethanol intake in α4 KO and α4 hypersensitive mice.  We 
found that activation of α4* nAChRs was necessary and sufficient for varenicline-
induced reduction of voluntary ethanol intake in a limited access ethanol-drinking 
assay (Hendrickson et al., 2010).  Here, we extend our previous findings and 
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present further evidence for the activation of α4* nAChRs in modulating the 
rewarding effects of ethanol. 
 
V.B. MATERIALS AND METHODS 
Animals.  Adult (8-10 week) male α4 knock-out (α4 KO) mice and their wild type 
(WT) litter mates, as well as heterozygous Leu9′Ala knock-in mice and their WT 
litter mates, all bred on site, were used.  The genetic engineering of both α4 KO 
and Leu9′Ala mouse lines have been described previously (Ross et al., 2000; 
Tapper et al., 2004).  Both lines have been back-crossed to a C57BL/6J 
background > nine generations.  Mice were individually housed on a reversed 12 
h light/dark cycle (lights on 10 PM, off 10 AM) with ad libitum access to food and 
water (except during experiments as described below).  All experiments were 
conducted in accordance with the guidelines for care and use of laboratory 
animals provided by the National Research Council (National Research Council, 
1996), as well as with an approved animal protocol from the Institutional Animal 
Care and Use Committee of the University of Massachusetts Medical School.   
 
Drugs and drinking solutions.  Ethanol drinking solutions were prepared from 190 
proof absolute anhydrous ethanol (Pharmco-Aaper) diluted to 20 % ethanol (v/v) 
using tap water.  Nicotine hydrogen bitartrate (Sigma-Aldrich), was dissolved in 
0.9 % saline and was administered via intraperitoneal (i.p.) injections at the 
indicated doses.  Nicotine concentrations are reported as nicotine base.   
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Drinking in the dark (DID).  Ethanol consumption was measured using a DID 
procedure as previously described (Hendrickson et al., 2010).  Animals were 
singly housed in experimental chambers for 1 week prior to the beginning of the 
DID sessions.  The mice received a 15-ml graduated cylinder water bottle fitted 
with a one-hole rubber stopper with a stainless steel double-ball-bearing sipper 
tube, which was sealed with Parafilm to prevent leakage.  For the first three 
nights, two hours after the lights were off, mice were i.p. injected with saline 
immediately before their water bottle was replaced with the 20 % ethanol bottle, 
and allowed to drink for two hours.  This procedure was used to acclimatize the 
mice to the experimental conditions and allow them to reach a baseline of 
ethanol intake prior to drug administration.  On the fourth night, the mice received 
their first dose of drug immediately before placement of the ethanol bottle.  The 
amount of ethanol consumed was recorded immediately after each two-hour 
session and converted to g/kg per each animal’s ethanol consumption and body 
weight.  The mice were given 2 days of rest (no injections or ethanol) and then 
began the saline injection/ethanol consumption assay for two to three days until a 
stable ethanol intake was reached.  Once the baseline returned, a second, higher 
dose of drug was administered prior to the ethanol bottle being placed in the 
cage.  In this design, all mice in one group drink a single concentration of ethanol 
throughout the experiment, but receive two doses of drug, 4-5 days apart, with 
the lower concentration of drug first. 
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Data Analysis.  The effect of nicotine on ethanol intake was compared to ethanol intake 
after a saline injection from the previous day using a Two-way ANOVA followed by 
Bonferroni post hoc tests. Data were analyzed using Graphpad software (Graphpad 
Software, Inc.).  Results were considered significant at p<0.05. All data are expressed 
as means ± standard errors of means (SEM).  
 
V.C. RESULTS 
α4* nAChRs are necessary for nicotine-induced reduction of ethanol 
consumption. 
 To examine the role of α4* nAChRs in baseline ethanol intake and after a 
pre-injection of nicotine, we used α4 KO and WT mice in the Drinking in the Dark 
(DID) assay (Rhodes et al., 2005) (Fig. V-1).  Two-way ANOVA revealed that 
there was a significant main effect of treatment (F2,72 = 7.77, p<0.001) but not 
genotype and a significant treatment x genotype interaction (F2,72 = 4.57, 
p<0.05).  Similar to our previously published observations (Hendrickson et al., 
2009), we again saw that nicotine dose dependently decreased voluntary ethanol 
intake in WT mice at doses of 0.25 mg/kg and 0.5 mg/kg nicotine compared to a 
saline injection (p<0.05, p<0.001, respectively).  In the α4 KO mice, neither dose 
of nicotine had any significant effect on ethanol intake, indicating that α4* 
nAChRs are necessary for the nicotine-induced effect on ethanol drinking.  In 
addition to nicotine having no effect in decreasing ethanol intake in the α4 KO 
mice, there was also a significant reduction in baseline ethanol consumption after 
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a saline injection when compared to WT mice (Fig. V-1, p<0.001) suggesting that 
α4* nAChRs may also be involved in generalized ethanol consumption. 
Activation of α4* nAChRs is sufficient for nicotine-induced reduction of 
ethanol consumption. 
 To determine if activation of α4* nAChRs was sufficient for nicotine-
induced reduction of ethanol consumption, we used the hypersensitive Leu9′Ala 
mice in the 20 % ethanol DID assay (Fig. V-2).  In this experiment however, the 
concentration of nicotine was lowered such that the dose used would have no 
effect on WT nAChRs, but would selectively activate mutant Leu9′Ala α4* 
nAChRs (Tapper et al., 2004).  Two-way ANOVA showed a significant main 
effect of genotype (F1,28 = 4.56, p<0.05) but not treatment and there was no 
significant interaction between these two factors.  A low dose of nicotine (0.05 
mg/kg) significantly decreased ethanol intake in Leu9′Ala mice, but had no effect 
on WT mice (Fig. V-2, p<0.05).  These data indicate that selective activation of 
α4* nAChRs is sufficient for nicotine-induced reduction of ethanol consumption. 
 
V.D. DISCUSSION 
 It is widely accepted that α4β2* nAChRs are critical for mediating the 
rewarding properties of nicotine and nicotine addiction (Picciotto et al., 1998; 
Tapper et al., 2004).  It is also known that nicotine and alcohol are often co-
abused and that 70–75 % of alcoholics are also dependent on nicotine (Bobo 
and Husten, 2000; Room, 2004), suggesting a functional interaction between 
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these drugs.  Varenicline, acting as a partial agonist of α4β2* nAChRs, is a 
successful smoking cessation aid and has also been shown to attenuate acute 
ethanol-induced DA release as well as reduce ethanol craving in smokers 
(Ericson et al., 2009; McKee et al., 2009). 
 Previously, several labs including our own have shown that varenicline 
can decrease ethanol intake in several rodent models (Hendrickson et al., 2010; 
Kamens et al., 2010; Steensland et al., 2007).  Because of the pharmacological 
promiscuity of varenicline (Mihalak et al., 2006), we sought to identify the nAChR 
subtype responsible for varenicline-induced reduction of alcohol consumption.  
While most of the previous studies primarily used pharmacology alone, our study 
combined pharmacology with genetically modified nAChR knock-out and knock-
in mice.  We showed that both varenicline and ethanol can activate DAergic 
neurons of the posterior VTA and that these activated neurons express higher 
levels of the α4, α6 and β3 nAChR subunit gene transcripts.  Additionally, we 
showed that nAChRs containing the α4 subunit, and possibly the α4α6β2β3 
subtype, are critical for varenicline’s effect on drinking (Hendrickson et al., 2010). 
 It is likely that the mechanism of action underlying varenicline’s ability to 
decrease ethanol intake is similar to how it is thought to decrease nicotine use.  
That is, acting as a partial agonist, varenicline selectively binds and partially 
activates the nAChRs that modulate ethanol intake (i.e., α4* nAChRs) thus 
occupying or desensitizing the relevant receptors, precluding any further 
activation by ethanol.  Additionally, the selective activation of α4* nAChRs 
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themselves may act to increase DA release in the NAc such that ethanol has no 
further enhancing effect.   
 In line with this idea, here we show that the nAChR full agonist nicotine 
also decreases ethanol consumption in an α4* nAChR-dependent mechanism.  
Nicotine reduced ethanol consumption in WT mice but had no effect in α4 KO 
mice implying that expression of α4* nAChRs is necessary for nicotine-induced 
reduction of ethanol consumption.  In contrast, low doses of nicotine that have no 
effect in WT mice significantly reduced ethanol intake in the Leu9′Ala 
hypersensitive mice indicating that the selective activation of α4* nAChRs is 
sufficient for the effect on alcohol consumption. 
 One common argument against a role for α4β2* nAChRs in alcohol 
consumption is that the selective competitive antagonist, dihydro-β-erythroidine 
(DHβE), fails to reduce ethanol intake in both rats and mice at several different 
concentrations (Hendrickson et al., 2009; Le et al., 2000).  However, caution 
should be used in interpreting these data for several reasons.  First, the ability of 
DHβE to block α4β2* nAChRs depends on the stoichiometry of the target 
receptor population (Moroni et al., 2006; Salminen et al., 2004), which is 
unknown in vivo.  And second, the subunit composition of nAChRs involved in 
alcohol reward, while likely containing α4 and β2 subunits, has not been fully 
elucidated.  For example, higher affinity α4β2* heteromeric nicotinic receptors 
that contain additional α or β subunits may be insensitive to DHβE (Salminen et 
al., 2004). 
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 Taken together, our results show that the selective activation of α 4* 
nAChRs is necessary and sufficient to reduce acute ethanol consumption.  This 
result also further supports the hypothesis that selective agonists or partial 
agonists of α 4* nAChRs may be valuable therapeutics for the treatment of 
alcoholism.  
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Figure V-1.  Alcohol intake after nicotine treatment in α4 KO and WT mice.  A pre-injection of 
nicotine (0.25 mg/kg and 0.5 mg/kg) dose dependently decreased 20 % ethanol intake in WT 
mice compared to a saline injection, but had no effect on α 4 KO mice (n = 9–18/genotype).  
Additionally, α4 KO mice consumed significantly less 20 % ethanol compared to WT mice after a 
saline injection.  *p<0.05, **p<0.01, ***p<0.001.  
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Figure V-2.  Alcohol intake in Leu9′Ala and WT mice after nicotine pre-treatment.  Low 
doses of nicotine (0.0125 mg/kg and 0.05 mg/kg) did not significantly decrease 20 % ethanol 
intake in WT mice compared to a saline injection.  Low dose nicotine (0.05 mg/kg) did 
significantly decrease 20 % ethanol intake in the hypersensitive Leu9′Ala mice compared to a 
saline injection (n = 5-12 /genotype).  *p<0.05. 
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CHAPTER VI: 
 
DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The neurobiological mechanisms underlying alcohol consumption and the 
development of alcohol addiction encompasses a broad set of questions with the 
most basic being, why do people drink? (Morikawa and Morrisett, 2010).  The 
effects of ethanol in the brain are varied and depend on the rate and amount of 
ethanol consumed.  Ethanol consumption produces a wide array of intoxicated 
states that alter behavioral and cognitive functions including euphoria, impaired 
memory, sedation, slurred speech, impaired balance and in severe cases, coma 
or death.  Despite (or possibly because of) these symptoms, alcohol use 
progresses in some people to the point of alcoholism, and withdrawal from 
chronic ethanol consumption produces a “negative affective state” resulting in 
dysphoria, anhedonia, and depression, which may persist for a prolonged period 
of time (Koob, 2009; Trevisan et al., 1998).  Thus, some would answer the 
proposed question by stating that, “We drink because we like the state of being 
drunk and we keep drinking because we want to avoid the affective symptoms of 
withdrawal” (Morikawa and Morrisett, 2010).   
 Alcoholism is the result of several interactions between a number of neural 
mechanisms that modulate the rewarding effects of ethanol, the acute sensitivity 
to ethanol, the tolerance to and dependence on ethanol and the desire to 
continue to consume ethanol (Lovinger and Crabbe, 2005).  Thus, one way to 
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elucidate the molecular mechanisms that modulate alcoholism is to break the 
disease into distinct stages that can be modeled and manipulated in the 
laboratory setting.  This approach, in combination with genetic mouse models 
and pharmacology, has allowed for the careful examination of the initial stage of 
alcoholism, the binge/intoxication stage.   
 While it is clear that most drugs of abuse act to increase extracellular 
dopamine levels in the NAc (Wise and Rompre, 1989), the molecular 
mechanisms mediating this process vary depending on the molecular target each 
drug acts on (Gonzales et al., 2004).  The molecular targets that mediate the 
rewarding properties of most drugs of abuse including cocaine, amphetamine, 
heroin and nicotine have been well established for some time; however, the 
molecular mechanisms by which ethanol acts to mediate reward have not been 
fully elucidated (Gonzales et al., 2004).  In this thesis, I have examined the role 
of nAChRs, known molecular targets for nicotine addiction, in mediating the initial 
rewarding properties of alcohol addiction.  Using a mouse model of voluntary 
ethanol consumption, in combination with nAChR pharmacology, I have provided 
further evidence for the role of nAChRs in mediating the initial rewarding 
properties of ethanol (Chapter II).  I have also shown, for the first time, that a 
specific nAChR subtype, those that contain the α4 subunit, mediate voluntary 
ethanol consumption and reward (Chapter III) and also that α4* nAChRs are 
potential molecular targets for the development of alcohol use disorder 
treatments (Chapter IV and V). 
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VI.A. nAChRs IN ETHANOL REWARD: ARE THEY INHERENTLY CRITICAL? 
 Considerable evidence over the past two decades has implicated nAChRs 
as common molecular targets for the interactions of ethanol and nicotine in the 
brain.  In 2005, a paper was published describing a new ethanol self-
administration paradigm in which mice reliably drink to pharmacologically 
significant BECs without lengthy training periods, or water or food restriction, 
called Drinking–In-The-Dark (DID) (Rhodes et al., 2005).  In this assay, WT mice 
consume ~ 4 g/kg ethanol in a 2 hour period which increases BEC > 1.0 mg/ml 
(Rhodes et al., 2005), and has been shown to produce behavioral intoxication as 
measured by impairment in rotarod and balance beam tests (Rhodes et al., 
2007).  For example, we found that the BEC of male WT mice after a 2h drinking 
session was 25 mM (Fig. II-1 D) which is equivalent to 1.15 mg/ml.  This high 
level of ethanol intake that occurs over a relatively short period of time is within 
the range of the recently proposed definition of human binge drinking (Courtney 
and Polich, 2009; Lowery et al., 2010).  Using this assay, we found that ethanol 
intake was significantly and dose dependently attenuated in WT mice after an i.p. 
injection of the nAChR antagonist mecamylamine (Fig. II-1. B).  While this was 
not the first study to show that mecamylamine can reduce ethanol intake in 
rodents, previous reports used ethanol consumption assays in which the rodents 
consumed ethanol for at least 2 weeks prior to treatment (Blomqvist et al., 1996; 
Le et al., 2000).  Prior studies indicate that mecamylamine delivered systemically 
146 
 
or directly into the VTA attenuates ethanol-induced dopamine release in the NAc 
(Blomqvist et al., 1993; Blomqvist et al., 1997) and mecamylamine has also been 
reported to reduce the subjective euphoria of ethanol in humans (Chi and de Wit, 
2003).  Thus, it is likely that mecamylamine reduces voluntary ethanol 
consumption via a similar mechanism in the DID assay.  Additionally, while some 
reports indicate that high doses of mecamylamine can non-competitively inhibit 
NMDA receptors, we saw a significant decrease in the amount of ethanol 
consumed at doses as low as 0.5 g/kg suggesting that mecamylamine is acting 
to reduce ethanol intake via blockade of nAChRs.  As an additional control, we 
tested the nAChR antagonist hexamethonium, which does not cross the blood 
brain barrier, and found that peripheral nAChRs did not affect voluntary ethanol 
consumption.  Therefore, this was the first report, to our knowledge, to show that 
blocking nAChRs in the CNS reduced acute ethanol intake in a model of 
voluntary ethanol consumption.   
 Interestingly, we also found that the nAChR full agonist nicotine and the 
selective, partial agonist cytisine both dose dependently decreased acute ethanol 
consumption in the DID assay (Fig. II-2 and II-3).  This result seemed to be in 
opposition to one previous study that found that nicotine can enhance ethanol 
intake in rats (Smith et al., 1999).  However one important difference between the 
two studies, among others, was the mode of nicotine administration, chronic in 
the Smith et al. study and acute in ours.  An obvious question then became, how 
can both blocking nAChRs with mecamylamine and activating them with nicotine 
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and cytisine decrease ethanol consumption?  We hypothesized that the two 
actions (blocking and activating) result in the same overall net effect.  That is, 
while mecamylamine blocks the nAChR to prevent activation, an acute single 
exposure of nicotine or cytisine will initially activate nAChRs which then become 
desensitized, often for prolonged periods of time (Mansvelder et al., 2002; 
Pidoplichko et al., 1997).  Thus, nAChR desensitization would prevent any further 
activation of the relevant nAChRs by ethanol.  This was further supported by our 
data showing that 1) mecamylamine blocks the ethanol-induced c-Fos activity of 
DA neurons in the VTA (Fig. II-5. C) and 2) nicotine activates DA neurons of the 
VTA to the same extent as nicotine pre-treatment followed by ethanol (Fig. II-5.  
D).   
 Taken together, these data suggest that nAChRs are inherently critical for 
voluntary ethanol consumption as well as ethanol-induced activation of the 
mesolimbic DA pathway.  Furthermore, these data indicate that nicotine and 
ethanol may activate similar pathways in the VTA, or possibly act on the same 
nAChR subtype.  One intriguing follow up to our initial findings would be to 
determine the effects of chronic nicotine exposure on daily ethanol consumption 
in WT mice using the DID assay (similar to Smith et al., 1999). 
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VI.B. SUBTYPE SPECIFICITY: A ROLE FOR α4* nAChRs IN ETHANOL 
REWARD 
 Because of the vast array of nAChR subtypes expressed within the VTA, 
an important goal of alcohol research is identifying which of these subtypes most 
directly modulates ethanol reinforcement.  Using pharmacology, we investigated 
the role of two of the most abundant nAChR subtypes found in the brain, the low 
affinity α7 and high affinity α4β2 nAChRs in mediating voluntary ethanol 
consumption (Chapter II).  We found that the nAChR antagonists DHβE, 
selective for α4β2 nAChRs and MLA, selective for α7 nAChRs, failed to 
significantly reduce ethanol intake in WT mice in the DID assay.  Previous 
studies have shown that similar doses of DHβE as used in our study (1 mg/kg - 
3.2 mg/kg) are able to block the locomotor activating and discriminative stimulus 
effect of nicotine in rats (Stolerman et al., 1997) as well as attenuate nicotine 
self-administration (Corrigall et al., 1994).  Thus, because of the evidence for 
α4β2* nAChRs modulating nicotine addiction (Picciotto et al., 1998; Tapper et al., 
2004) and the high co-abuse of nicotine and ethanol (Falk et al., 2006), we were 
surprised that DHβE had no effect on the ethanol intake of WT mice in our assay.  
However, this result is consistent with previous findings in the field that DHβE 
also has little effect on operant ethanol responding, ethanol-mediated DA release 
in the NAc and ethanol self-administration in rats (Le et al., 2000; Soderpalm et 
al., 2000).  Importantly, one caveat to these DHβE studies is the finding that 
higher affinity nAChRs that contain the α4β2 subunits in addition to a third or 
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fourth subunit are relatively insensitive to DHβE (Salminen et al., 2004).  
Therefore, it would be interesting to see if a pre-injection of DHβE could block the 
nicotine-induced reduction of ethanol consumption in WT mice.  If the nAChR 
subtype responsible for modulating nicotine-induced reduction of ethanol intake 
contains subunits in addition to α4β2, then I would expect that a pre-injection of 
DHβE would have no effect.  
 One of the most widely expressed, high affinity nAChR subtypes in the 
mammalian brain are α4* nAChRs, which have been demonstrated to be critical 
for behaviors associated with nicotine dependence including reward, 
sensitization and tolerance (Tapper et al., 2004).  Therefore, we were interested 
to see if α4* nAChRs are also critical for ethanol reward.  Until recently, studies 
had only utilized pharmacology to address this question, mostly in high alcohol 
preferring rats or WT mice.  Due to the diversity of nAChR subtypes in the brain, 
and the limited pharmacological compounds selective for specific nAChRs (such 
as DHβE as discussed above), we took a genetic approach to test our 
hypothesis.   
 Using mice that lack expression of the α4 subunit, α4 KO, and a line of 
mice that have α4* nAChRs that are hypersensitive to agonist, Leu9′Ala, we 
tested the necessity of α4* nAChRs in voluntary ethanol consumption, ethanol-
induced activity of DAergic neurons in the VTA, and ethanol conditioned place 
preference (Chapter III).  We found that α4 KO mice consumed significantly less 
10 % and 20 % ethanol compared to WT mice in the DID assay.  Therefore, 
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these data suggest that while WT mice voluntarily consume ethanol to the point 
of intoxication, mice lacking expression of the high affinity α4* nAChRs drink 
significantly less, presumably because ethanol is not rewarding to these mice.  
Importantly, WT and α4 KO mice consumed similar amounts of quinine and 
sucrose, indicating that the two genotypes have similar aversion to bitter tasting 
solutions and that the WT mice were not consuming the ethanol for caloric value 
(Fig. III-2A).  Furthermore, α4 KO and WT mice had similar peak BEC after a 2 
g/kg i.p. injection of ethanol and similar rates of ethanol clearance, indicating that 
there were no differences in the metabolism of ethanol between the groups (Fig. 
III-2B).   
 The finding that α4 KO mice voluntarily consume less ethanol compared to 
WT mice has been repeated in our lab by multiple researchers, over several 
years, in at least three generations of mice, and is therefore quite robust.  
Although the result that α4 KO mice consume less ethanol than WT mice is 
intriguing on its own, it does not necessarily mean that ethanol is not rewarding 
to them.  Recent studies indicate that ethanol may indirectly activate nAChRs 
and, in turn, DAergic neurons, by increasing acetylcholine concentrations in 
ventral midbrain (Ericson et al., 2003).  Using c-Fos as a measure of gross 
neuronal activation (Cole et al., 1989), and to further elucidate the circuitry 
involved in mediating the rewarding properties of ethanol, we analyzed the VTA 
of α4 KO and WT mice for ethanol-induced activation of the immediate early 
gene, c-Fos.  In WT mice, at the rewarding dose of ethanol (2 g/kg, see below), 
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the DAergic neurons of the posterior VTA were significantly activated whereas 
this same dose of ethanol produced no activation in the VTA of α4 KO mice (Fig. 
III-3).  Since ethanol did not induce c-Fos expression in α4 KO mice, our data 
strongly suggest that α4* nAChRs are necessary for activation of the mesolimbic 
pathway by alcohol. 
 Because c-Fos induction by ethanol occurred in a part of the DAergic 
mesolimbic reward pathway, this prompted us to directly compare the rewarding 
effects of ethanol in WT and α4 KO mice.  Using the conditioned place 
preference assay, previous studies have shown that 2 g/kg ethanol is the 
rewarding dose in many mouse strains, including C57BL/6J (Boyce-Rustay and 
Holmes, 2006; Cunningham et al., 2006).  This assay is used as an alternative to 
classic drug self-administration paradigms and is considered a direct measure of 
drug reward (Bardo and Bevins, 2000).  Using this paradigm, 2 g/kg ethanol 
conditioned a place preference to the chamber containing the ethanol-paired 
floor in WT mice but not in the α4 KO mice (Fig. III-5A).  These results are 
consistent with previous work indicating that ethanol place preference is 
expressed through a VTA dependent mechanism (Bechtholt and Cunningham, 
2005).  Taken together, our data indicate that expression of α4* nAChRs is 
necessary for voluntary ethanol intake, ethanol-induced activation of the 
mesolimbic DA pathway, and ethanol reward.   
  The hypersensitive Leu9’Ala nAChR mouse serves as a nice complement 
to the α4 KO mouse, because it allows for ethanol reward to be analyzed in 
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response to the selective activation of α4* nAChRs.  While we saw no significant 
difference in baseline ethanol intake in these mice, this is a result that has not 
been as consistent as the α4 KO result, as evidenced by the larger error bars in 
this group (Fig. III-1B).  We have seen in the past, and a trend in the current 
example, that the Leu9’Ala mice also consume less ethanol than WT mice.  We 
hypothesized that these mice consume less ethanol for the opposite reason as 
the α4 KO mice; i.e., that the Leu9’Ala mice experience ethanol reward at a lower 
threshold compared to WT mice, similar to results with nicotine (Tapper et al., 
2004).  This result was perplexing for some time, that is, until we analyzed the 
brains of Leu9’Ala mice and saw that very low doses of ethanol (0.5 g/kg), that 
have no effect in WT mice, significantly activated the DAergic neurons of the 
posterior VTA (Fig. III-4).  Our hypothesis was confirmed when the same low 
dose of ethanol conditioned a place preference in the hypersensitive Leu9’Ala 
mice, but not WT mice (Fig. III-5B).  Thus, these data suggest that ethanol 
mediated activation of α4* nAChRs is critical for ethanol reward. 
 While analyzing brains of WT or Leu9’Ala mice that had been injected with 
ethanol and immunolabeled for TH and c-Fos, our lab discovered that nicotine 
(Zhao-Shea et al., 2011) and ethanol (Figs. III-3, III-4) both activate DAergic 
neurons almost exclusively within the posterior VTA.  We hypothesized that 
those neurons activated by ethanol differentially expressed nAChR subunit 
genes that were important for mediating ethanol reward.  To gain insight into 
nAChR subtypes that may influence alcohol consumption, we compared nAChR 
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subunit gene expression between posterior VTA DAergic neurons that were 
activated by alcohol and posterior VTA DAergic neurons not activated by alcohol.  
Interestingly, we found that DAergic neurons that were activated by alcohol 
express higher levels of α4, α6, and β3 nAChR subunit transcripts (Table IV-1; 
Fig IV-2B).  These data suggest that α4α6β3* nAChRs may be involved in 
alcohol consumption.  Our results are consistent with previous studies indicating 
that the α6/β3* nAChR selective antagonist α -conotoxin MII, when infused into 
the VTA, can reduce alcohol consumption and block alcohol-mediated DA 
release in NAc (Jerlhag et al., 2006; Lof et al., 2007b).   Importantly, a significant 
portion of α6β3* nAChRs also contain the α4 subunit and these receptors 
represent one of the highest affinity nAChRs identified in the brain thus far 
(Salminen et al., 2007; Salminen et al., 2004).  Notably, the α4α6β2β3 subtype is 
insensitive to DHβE (Salminen et al., 2004).  Thus, this experiment provides 
insight to the discrepancy regarding the DHβE results, as discussed previously. 
 
VI.C. α4* nAChRs AS MOLECULAR TARGETS FOR ALCOHOL CESSATION 
 Currently, only three medications are approved for the treatment of alcohol 
use disorders and these medications have only proven useful for 20 % -30 % of 
patients who use them.  Although a large body of evidence exists implicating 
nAChRs as potential targets for mediating ethanol reward, the lack of nAChR- 
selective as well as nAChR-subtype selective ligands has slowed progress in this 
field (Chatterjee and Bartlett, 2010).  Additionally, once a ligand is discovered, 
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there are many obstacles in the road to developing new targets for ethanol 
cessation from the bench to the clinic, a process that can take up to 15 years or 
more (Chatterjee and Bartlett, 2010).   
 However, drugs already on the market for treating nicotine addiction can 
go directly into clinical research trials to fast track the development of novel 
medications for the treatment of alcoholism.  Thus, recent studies have found 
that the smoking cessation drug varenicline, an α4β2* partial agonist clinically 
approved as a smoking cessation therapeutic (Coe et al., 2005; Gonzales et al., 
2006; Steensland et al., 2007; Tonstad et al., 2006), can reduce both ethanol 
intake and seeking in rats (Steensland et al., 2007).  However, while varenicline 
was designed to be a partial agonist of α4β2* nAChRs, the precise nAChR 
subtype that varenicline acts on to modulate ethanol consumption was unknown.  
 In our study, we found that varenicline reduced consumption of both a low 
and high dose of alcohol in WT mice but did not significantly reduce consumption 
in α4 KO mice, indicating that α4* nAChRs are necessary for the effects of the 
drug (Fig. IV-3A, B).  In addition, low doses of varenicline that had little effect on 
consumption in WT mice dramatically reduced ethanol intake in Leu9’Ala mice 
suggesting that activation of α4* nAChRs are also sufficient for varenicline effects 
on alcohol consumption (Fig. IV-3C, D). Importantly, varenicline did not reduce 
sucrose intake indicating that the effects of the drug were specific for alcohol 
consumption and did not dampen general reward signaling (Fig. IV-3D).   
 Because higher doses of varenicline than used in our study may also 
155 
 
target α7 as well as other nAChR subtypes, in addition to α4β2* nAChRs, the 
mechanism by which varenicline reduces alcohol consumption is an open 
question (Mihalak et al., 2006; Papke et al.).  A recent study demonstrated that 
varenicline reduced ethanol consumption in mice lacking either α7 or β2* 
nAChRs similar to WT (Kamens et al., 2010) indicating that expression of these 
receptors is not necessary for varenicline’s effects.  As discussed above, our 
data suggest that α4α6β3* nAChRs may mediate varenicline’s effects on alcohol 
consumption, although it is expected that this subtype should also contain the β2 
subunit (Grady et al., 2007). Thus, varenicline reduction of ethanol intake in β2 
KO mice may occur because of compensatory mechanisms in nAChR 
expression or subunit composition.   
 Interestingly, varenicline, similar to nicotine and ethanol, also activated 
DAergic neurons selectively in the posterior VTA (Fig. IV-1).  Furthermore, an 
infusion of varenicline directly into the posterior, but not anterior, VTA reduced 
alcohol consumption (Fig. IV-4).  This suggests that the posterior VTA, 
specifically, could be a neuroanatomical substrate where both drugs interact.  
Thus, using the α4 KO and Leu9’Ala mouse models, we were the first to show 
that varenicline-induced reduction of ethanol consumption in mice is dependent 
on the activation of α4* nAChRs and that the posterior VTA is a site of action for 
mediating its effect.   
 Indeed, both the nicotine and alcohol addiction fields have now focused on 
not only selective-nAChR antagonists, but on selective partial agonists as well.  
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Partial agonists are thought to assist in smoking cessation by binding to and 
partially activating the specific nAChRs that mediate nicotine addiction (Rollema 
et al., 2007b).  The partial agonist activity at these receptors would cause a 
moderate, sustained release of DA in the NAc, which would counteract the low 
DA levels experienced during withdrawal and help to relieve craving.  
Furthermore, by binding the high affinity nAChRs, the partial agonist then acts as 
an antagonist by preventing nicotine from binding and fully activating the 
receptor, thus removing the enhanced DA transmission in the NAc experienced 
while smoking, essentially removing the reward experienced by smoking 
(Rollema et al., 2007b).  A similar mechanism is expected to be occurring in the 
brains of alcohol-addicted individuals as well as those who are dependent on 
both drugs (Crunelle et al., 2010).   
 Additionally, our follow up study (Chapter V) provides further evidence for 
a role of α4* nAChRs in mediating both nicotine and ethanol reward.  Similar to 
our previous study (Chapter II), we found that nicotine decreased ethanol intake 
in WT mice in the DID assay; however this same dose of nicotine had no effect in 
the α4 KO mice (Fig. V-1).  Furthermore, low doses of nicotine, that had no effect 
in WT mice, significantly reduced ethanol intake in the hypersensitive Leu9’Ala 
mice (Fig. V-2).  Taken together, these studies imply that a combination 
approach, of both activating and blocking nAChRs will be an optimal strategy for 
reduction of the rewarding behaviors and craving symptoms of alcohol addiction. 
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VI.D. EVIDENCE FOR ADDITIONAL nAChR SUBTYPES IN ETHANOL 
REWARD 
 Since a variety of nAChR subtypes are expressed in the mesolimbic 
reward circuitry (Wooltorton et al., 2003), an emerging goal of alcohol research is 
focused on identifying the nicotinic receptor subtype(s) that may underlie ethanol 
reinforcement.  In an effort to tease out individual nAChR subunits in ethanol-
related behaviors, most work has utilized pharmacology.   For example, both 
MLA and DHβE, an α7 and β2* nAChR specific antagonist, respectively, fail to 
block ethanol-induced locomotion (Larsson et al., 2002), reduce ethanol 
consumption (Le et al., 2000), or block ethanol-induced dopamine overflow in 
nucleus accumbens (Ericson et al., 2003; Larsson et al., 2002).  However, the 
α3β2*, β3*, and α6* subunit specific antagonist, α-conotoxin MII, does inhibit 
these behaviors (Larsson et al., 2004).  These data suggest that α7 and β2* 
nAChRs, the two most common CNS nicotinic receptors, may not have a critical 
role in ethanol-mediated striatal dopamine release.   However, a recent study 
found that varenicline, a partial agonist of α4β2* nAChRs, can reduce both 
ethanol intake and seeking in rats (Steensland et al., 2007).  While the 
varenicline data and α-conotoxin MII data are seemingly at odds, there is 
evidence that varenicline is not purely an α4β2* nAChR partial agonist, but can 
also activate α6* nAChRs, as well as other subtypes (Mihalak et al., 2006).   
 Interestingly, our result, that DAergic neurons activated by ethanol have 
higher gene expression of the α4, α6, and β3 subunits correlates nicely with 
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studies that found that blocking the α6β3* nAChR subtype with the peptide 
antagonist α -conotoxin MII decreases alcohol consumption and blocks alcohol-
mediated DA release in the NAc (Jerlhag et al., 2006; Larsson et al., 2004; Lof et 
al., 2007b).  Furthermore, the α6 subunit is very specifically expressed in the 
catecholaminergic system (Le Novere et al., 1996), making it an attractive target.  
While our data support the idea that α4* nAChRs are critical for ethanol 
reinforcement, recent data indicates that 1) over half of α-conotoxin MII-sensitive 
receptors contain the α4 subunit and 2) these receptors are most sensitive to 
acetylcholine-induced striatal dopamine release (Grady et al., 2007; Salminen et 
al., 2007).  Therefore, it is likely that α4α6β3* mediate activation of the 
mesolimbic pathway by ethanol.  Thus, it would certainly be interesting to 
investigate the role of α6* nAChRs in baseline ethanol consumption as well as 
ethanol conditioned place preference, preferably by use of the α6 KO mouse as 
opposed to pharmacology alone (Champtiaux et al., 2003; Champtiaux et al., 
2002; Pons et al., 2008).   
 Recently, human genetic association studies have implicated the genes 
encoding the α5 (CHRNA5), α3 (CHRNA3) and β4 (CHRNB4) nAChR subunits 
as playing a critical role in the development of nicotine and alcohol dependence 
(Joslyn et al., 2008; Saccone et al., 2009; Wang et al., 2009).  Additionally, one 
study showed that a new compound that is a partial agonist of α3β4* nAChRs, 
CP-601932, selectively decreased ethanol but not sucrose consumption and 
operant self-administration after long-term exposure to the drug (Chatterjee et al., 
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2011).  However, this compound is also a low-efficacy α4β2* nAChR partial 
agonist, so conclusions from this study are unclear.  Thus, because of the limited 
pharmacological compounds that cross the blood brain barrier and are also 
selective for α3β4* nAChRs, it is difficult to determine the role of these nAChR 
subtypes.  Therefore, more careful genetic and pharmacological experiments are 
necessary to determine the role of α3β4* nAChRs in ethanol reward.   
 In line with the genetic association studies, a recent study found that α5* 
nAChRs within the medial habenula (MHb) - interpeduncular nucleus (IPN) 
pathway are necessary to inhibit the motivational signal that controls nicotine 
intake (Fowler et al., 2011).  In the absence of α5* nAChRs within the MHb, mice 
had similar levels of nicotine reward, but had significantly increased nicotine 
intake (Fowler et al., 2011).  Although α5 nAChR subunit expression is low in the 
VTA, it is quite high in the habenulo-interpeduncular pathway (Marks et al., 
1992), which is known to regulate the avoidance of noxious substances 
(Donovick et al., 1970).  Interestingly, the lateral habenula (LHb) provides 
inhibitory control to the DAergic neurons of the VTA, is also activated by aversive 
stimuli, and is thought to be the source of negative motivational signals in the 
brain (Matsumoto and Hikosaka, 2007).  Although the nAChR subunit 
composition of the LHb remains unclear, it would be interesting to test α5 null 
mutant mice in our ethanol DID assay to see if they have escalated ethanol 
intake similar to the nicotine studies and in ethanol place preference to see if 
they have altered ethanol reward.   
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VI.E. FUTURE DIRECTIONS 
 In this thesis, a combination of behavioral assays, pharmacology and 
genetically modified nAChR mouse models have been used to ask a series of 
questions; are nAChRs inherently critical for ethanol reward?  If so, which 
subtype of nAChR is necessary for the rewarding properties of alcohol?  And are 
they sufficient for ethanol reward?   
 Using pharmacology, we found that blocking or activating nAChRs in WT 
mice decreases voluntary ethanol intake.  Using α4 KO and α4 Leu9’Ala KI mice, 
we determined that activation of α4* nAChRs are critical for ethanol reward, as 
well as necessary and sufficient for varenicline- and nicotine-induced reduction of 
ethanol consumption.  Despite the work discussed in this thesis, two main 
questions remain: 1) exactly which nAChR subtype modulates ethanol 
consumption and reward and 2) which brain region(s) are necessary and 
sufficient.   
 In continuation of Chapter III, the next immediate steps to take will be to 
further elucidate the specific nAChR subtypes responsible for the modulation of 
ethanol activation of the VTA.  The first step should try to block ethanol-induced 
c-Fos activation of the posterior VTA by pre-infusions of the α6β3* nAChR 
antagonist, α -conotoxin MII directly to the posterior VTA in WT and Leu9’Ala 
mice.  In WT mice, if α-conotoxin MII attenuates c-Fos expression induced by the 
rewarding dose of ethaonol (2 g/kg), then one can conclude that α6β3* nAChRs 
modulate ethanol activation of DAergic VTA neurons.  However, in the Leu9’Ala 
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mice, if α-conotoxin MII blocks activation of a low dose of ethanol (0.5 g/kg), one 
can conclude that the nAChR subtype responsible contains α4 in addition to α6 
and β3 nAChR subuits. 
 Next, to further illuminate the nAChR subtypes that modulate ethanol 
reward, one could try to block ethanol conditioned place preference by infusing α-
conotoxin MII to the posterior VTA via cannula implants just prior to the ethanol 
training sessions.  This would first be done in WT mice to see if blockade of 
α6β3* nAChRs has an effect on ethanol reward, then in combination with the 
Leu9’Ala mice. 
 In addition to the continuation of experiments using the α4 KO and 
Leu9’Ala KI mice, our lab has begun to investigate ethanol reward in the α6 KO 
mice.  The first steps will be to characterize voluntary ethanol intake using the 
DID assay, then to analyze the posterior VTA for ethanol-induced c-Fos 
expression and finally to see if α6* nAChRs are necessary for ethanol reward 
using the place preference assay.  The α6 KO mice will also be crossed to the 
Leu9’Ala and α4 KO mouse lines for further investigation.   
 To address the second question, one important next step would be to 
identify the brain region that mediates ethanol reward.  While the evidence is 
quite strong that the posterior VTA is a critical region, further techniques and 
experiments are necessary to verify this.  There are several recently developed 
strategies to re-express, with regional specificity, nAChR subunits on KO 
backgrounds.  Localized re-expression of functional nAChRs in the posterior VTA 
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that rescue the behaviors absent in the α4 KO mice, would be sufficient to denote 
a role for the posterior VTA in ethanol reward. 
163 
 
APPENDIX 1. 
 
This chapter has been published separately in: 
 
Identification of a BK channel auxiliary protein controlling molecular and 
behavioral tolerance to alcohol. Martin GE, Hendrickson LM, Penta KL, Friesen 
RM, Pietrzykowski AZ, Tapper AR*, Treistman SN*.  Proc Natl Acad Sci U S A. 
2008 Nov 11;105(45):17543-8. Epub 2008 Nov 3.  * Authors contributed equally  
 
Author Contributions: 
Linzy Hendrickson, Gilles Martin, Andrew Tapper designed experiments 
Gilles Martin, Andrew Tapper, Linzy, Hendrickson, Krista, Penta, Ryan, Friesen, 
Andrzej, Pietrzykowski, Andrew Tapper performed experiments 
Gilles Martin, Andrew Tapper, Steven Treistman wrote the paper  
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Concentration (BEC) assays, but not including activity monitoring.  Specifically, I 
oversaw and assisted Krista Penta in the creation of Figures A1-4D, 5A, 5B and 
provided data for Figures A1-5C, 5D. 
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A1.A. INTRODUCTION  
Alcohol abuse is the third largest cause of preventable mortality in the 
world.  Tolerance, described as the gradual loss of drug effectiveness over time, 
is a hallmark of abused drugs.  This phenomenon is particularly important in the 
response to acute alcohol because the degree of tolerance exhibited by a naïve 
subject can predict the likelihood to develop alcohol abuse (Chrostek and 
Szmitkowski, 1998; Erwin et al., 1980; Fillmore et al., 2005; Heath et al., 1999).  
Thus, identifying the mechanistic and molecular underpinnings of tolerance is 
essential for understanding the pathophysiology of alcoholism, as well as 
determining potential therapeutic targets for alcohol abuse.  The neurobiology of 
tolerance is thought to involve several types of adaptation, ranging from 
alteration in membrane lipid composition (Yuan et al., 2008) to neuroadaptative 
changes in target proteins (Crews et al., 1996; Woodward et al., 2006).   
In recent years, large conductance calcium- and voltage-gated potassium 
(BK) channels have emerged as one of the key targets of ethanol action, yet their 
role in the physiological and behavioral response to alcohol are unknown.  
Invertebrate studies suggest that BK channels may be important for the 
development of tolerance to ethanol (Cowmeadow et al., 2005; Davies et al., 
2003).  In mammals, BK channels exist as a complex formed by the association 
of the pore-forming α subunit with the auxiliary β subunit.  The α subunit is 
encoded by only one gene (slo) with several splice variants (STREX, P27, 
insertless, etc.), whereas the β subunit is the product of four distinct genes (β1-
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β4).  BK α subunits, unlike β, form functional BK channels (Coetzee et al., 1999; 
Kaczorowski et al., 1996; Vergara et al., 1998).  BK α subunit expression is 
robust and widespread throughout the brain, with particularly high levels in the 
neo-, olfactory and hippocampal cortices, striatum, habenula and cerebellum 
(Brenner et al., 2000; Chang et al., 1997; Gribkoff et al., 2001; Kaczorowski et 
al., 1996).  Other prominent sites for BK α are thalamus and amygdala, and to a 
lesser degree, the brain stem, and spinal cord (Chang et al., 1997).  In contrast, 
the β4 subunit, although highly expressed, appears to be restricted to specific 
brain regions like the lateral hypothalamus, the purkinje layer and the striatum 
(Brenner et al., 2000; Chang et al., 1997).  Whereas β1 expression is found at 
low levels in brain, β2 and β3 do not appear to be expressed in the central 
nervous system (Uebele et al., 2000; Wallner et al., 1999).  In previous work, we 
showed that low EtOH concentrations (10 – 50 mM) potentiated BK channel 
open probability in a number of brain regions (hypothalamo-hypophyseal axis 
and nucleus accumbens) (Dopico et al., 1996; Martin et al., 2004; Pietrzykowski 
et al., 2004).  Recently, we also reported that EtOH effects depend on BK 
channel subunit composition in ventral striatum.  We found that αβ4 BK channels 
were potentiated by EtOH, whereas αβ1 channels were not (Martin et al., 2004).  
In the present study, we tested the hypothesis that BK subunit composition can 
control the degree and duration of ethanol sensitivity and, because of robust 
expression in striatum, a brain region implicated in addiction, we predicted that 
differences in BK subunit expression can translate into altered ethanol-induced 
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behaviors.  We focused on the β4 subunit because of our previous work that 
indicates it is widely expressed in ventral striatum and co-assembles with BK α to 
form functional, ethanol sensitive channels in the soma of MSNs.  
A1.B. RESULTS  
We transfected HEK-293 cells with α alone or in combination with β4, 
and recorded BK single channel activity in cell-attached patch clamp mode for 
20 sec every minute for up to 20 min.  50 mM EtOH, a concentration known to 
strongly influence channel activity (Martin et al., 2004), increased αβ4 BK 
channel open probability (Fig. A1-1A; middle trace EtOH 3 min) compared to 
control (Fig. A1-1A; top trace Control).  This effect persisted up to 8 min after 
the start of EtOH exposure (Fig. A1-1A bottom trace).  The lack of tolerance 
was not voltage-dependent because we observed a similar phenomenon when 
large (+150 mV) depolarizing voltage steps evoked outward BK currents on 3 
additional patches (data not shown).  In five patches (two from HEK cells and 
three from freshly isolated neurons), we found that BK channel activity 
remained potentiated (about 3.4 fold) for up to 14 min (the longest tested) after 
the beginning of EtOH perfusion compared to control values (data not shown).  
A ceiling effect that would distort the magnitude of EtOH’s effects is very 
unlikely as we systematically set BK channel NPo to low values before exposing 
cells to the drug.  Furthermore, even in presence of EtOH, BK channels typically 
spent only a small fraction of their total open time in the second (Fig. A1-1A; O2 
middle trace) or third open states (Fig. A1-1C; O3 middle trace), indicating that 
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EtOH had not maxed out BK channel activity.  In control experiments, we 
measured BK channel activity for up to 15 minutes in the absence of ethanol 
and found no change in baseline (data not shown).  On average (n = 8), 50 mM 
EtOH increased BK channel activity by about 2.5 fold (Fig. A1-1B).   
We examined the effects of 50 mM EtOH on BK channels consisting of 
only α subunits.  We found that EtOH effects on both inward (Fig. A1-1C) and 
outward (data not shown) currents were similar.  Thus, under these conditions, 
50 mM EtOH also boosted channel activity compared to control.  In contrast to its 
effect on αβ4 BK channels, EtOH potentiation disappeared minutes after the 
beginning of alcohol exposure, demonstrating acute tolerance of the response 
(Fig. A1-1C lower trace EtOH 7 min).  When averaged over 8 patches, EtOH 
initially increased α BK channel activity by about 3 fold (Fig. A1-1D, light shaded 
box), before returning to control levels (Fig. A1-1D; darker shaded box).  To 
evaluate whether EtOH potentiation was voltage dependent, we tested EtOH’s 
effect on both α and αβ4 BK activity by recording macroscopic currents in whole 
cell mode at multiple potentials.  Plotting current amplitude (normalized to Imax, 
typically observed around +150 mV) vs. voltage revealed that EtOH increases 
both α and αβ4 BK current amplitude over a range of potentials (data not shown), 
indicated it was not voltage-dependent.   
From previous work, we know that the BK β4 subunit is coexpressed with 
the α subunit in rat ventral striatum MSNs (Martin et al., 2004), and that these 
channels are dose-dependently potentiated by EtOH.  RT-PCR amplification of 
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β4 mRNA confirms that this subunit is robustly expressed in mouse striatum 
along with much lower levels of the β1 subunit (Fig. A1-2A).  Therefore, we 
hypothesized that MSNs from WT mice should functionally express αβ4 BK 
channels and that they should be potentiated by EtOH, mirroring αβ4 BK activity 
in heterologous expression studies.  Indeed, the WT BK channel response to 50 
mM EtOH was very similar to that observed with αβ4 BK channels in HEK293 
cells: EtOH potentiated BK channel activity (Fig. A1-2B, middle trace and Fig. 
A1-2C, light shaded box) and this was sustained throughout the recording 
session (Fig. A1-2B, bottom trace and Fig. A1-2C, darker shaded box).  To 
determine if this persistent EtOH mediated channel potentiation was dependent 
on β4 expression, we recorded from BK channels in MSNs isolated from mice 
that do not express KCNMb4, the gene encoding the β4 subunit (β4 KO) 
(Gribkoff et al., 2001).  Interestingly, MSNs from KO mice exhibited BK channel 
activity that was potentiated by EtOH but rapidly returned to control levels (Fig. 
A1-2D and A1-2E, 4/5 neurons), indicating that, in the absence of β4, acute 
tolerance develops.  This effect mirrored what we found when BK α subunit alone 
was expressed in HEK293 cells (Fig. A1-1D and A1-1E).   
To better understand the physiological role of BK β4 subunit expression 
on neuronal excitability, we evoked APs in WT and β4 KO mice using whole cell 
patch clamp recordings in striatal slice, and freshly isolated MSNs.  Similar to 
previous reports from hippocampal neurons (Brenner et al., 2005), the number of 
APs evoked by current injection was increased in β4 KO MSNs compared to WT 
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(Fig. A1-3A).  Since BKs contribute to determining MSNs AP patterning in WT 
mice, we tested the idea that EtOH-mediated modulation of BK channels should 
alter the excitability of these neurons, and that this effect should show little 
tolerance.  In contrast, in KO mice where most BK channels are presumably 
composed of α subunits only, we expected to see a transient effect of EtOH on 
AP patterning.  In WT mice, 50 mM EtOH markedly decreased the number of 
APs 2 min after EtOH perfusion (Fig. A1-3B; middle trace, left panel) and this 
effect persisted 8 min after the start of EtOH application, indicating a lack of 
tolerance.  In β4 KO MSNs, the number of APs was also reduced 2 minutes after 
EtOH perfusion.  However, unlike WT responses, significant tolerance developed 
to EtOH induced suppression of excitability within the 8 minute EtOH exposure 
(Fig. A1-3B, middle panel, bottom trace).  In freshly isolated MSNs from KO mice 
(n = 3, Fig. A1-3B; right panel), EtOH similarly transiently reduced the number of 
APs, mirroring results obtained in slices.  This latter experiment demonstrates 
that EtOH effects on MSN spike patterning are intrinsic to these neurons.  On 
average, 2 min after EtOH exposure, the number of evoked APs in β4 KO MSNs 
decreased by 60% of control compared to 40 % for neurons from WT mice (Fig. 
A1-3C).  While the number of APs in KO mice was almost back to control level 
after 8 min exposure, it was smaller in WT mice compared to the 2 min time point 
(Fig. A1-3C).  The development of tolerance (or its absence) is also shown in the 
inset of Fig. A1-3C as the ratio of APs at 8 min over the number of APs 2 min 
after EtOH exposure.  In WT mice, the ratio was below 1 (broken line, Fig. A1-
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3C; inset) while it was significantly higher in MSNs from KO mice (~ 2, p < 
0.001).   
To further establish a functional a link between β4 expression and the 
development of tolerance of spike patterning, we exposed β4 KO neurons in slice 
and dissociated culture to 100 nM charybdotoxin (ChTx), known to block α and 
αβ1 BK, the two BK channel subtypes found in these KO mice.  In both slices (n 
= 2) and freshly isolated MSNs (n = 4), not only did 50 mM EtOH fail to decrease 
spiking, but it slightly increased it (n = 6; Fig. A1-3D).  Fig. A1-3E shows the 
average number of APs before (open circles) and during EtOH exposure in the 
presence of 100 nM ChTx.  We also tested the effect of 1.5 µM tetrandrine, a 
blocker of αβ4 BK channels.  Tetrandrine completely prevented EtOH from 
altering excitability of WT MSNs.  The number of APs remained unchanged up to 
3 min after EtOH exposure (data not shown), confirming that EtOH effects are 
mediated by αβ4 BK.   
Because striatum is a brain region known to be involved in both the 
motivational and locomotor properties of drugs of abuse (for reviews see (Everitt 
and Robbins, 2005; Hyman et al., 2006)) we wondered if the stark difference in 
physiology at the single channel and whole cell levels could also be observed in 
the behavioral response to EtOH.  Thus, we challenged β4 KO and WT mice with 
2g/kg EtOH once a day and monitored their ambulatory activity 5, 10 and 15 min 
after injection.  Following EtOH injection on day 1, WT mice showed a marked 
(70%) reduction of their activity levels 5 min after injection (Fig. A1-4A; black 
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square symbols, F1,22 = 25.0, p < 0.001) compared to a saline injection.  Activity 
remained depressed when monitored over the following 10 and 15 min time 
blocks.  On day 4, the response of WT mice to EtOH, 5 and 10 min after injection 
were comparable to that of Day 1, and only showed tolerance at the 15 min time 
point (Fig. A1-4A; open squares, F1,22 = 7.36, p < 0.05 Day 1 compared to Day 
4).  However, in sharp contrast to WT mice, ambulatory activity in KO mice 
displayed rapid tolerance to the locomotor suppressing effects of EtOH.  Thus, 
on day 1, although EtOH significantly depressed locomotor activity (Fig. A1-4B; 
Day 1) 5 minutes after injection compared to control (F1,22 = 9.27, p < 0.01), when 
tested at 10 and at 15 minutes after EtOH injection on day 1, ambulatory activity 
had returned to control levels (Fig. A1-4B; filled squares).  In the same KO mice, 
by the fourth day of ethanol challenge, nearly complete tolerance to ethanol-
induced hypolocomotion was observed.  In addition, we compared summed 
locomotor activity 15 min after EtOH injection on days 1, 4, 7 and 10 between β4 
and WT mice.  On Day 1 (first injection), the activity of both WT and KO mice 
decreased (Fig. A1-4C).  However, by the fourth injection day (Day 4), complete 
tolerance to ethanol-induced hypolocomotion developed in β4 KO mice (Fig. A1-
4C; Day 4 significance between genotypes, F1,22 = 7.1, p < 0.05), whereas 
suppression remained evident in WT mice through the 10
th
 day of injection (Fig. 
A1-4C).  The difference in acute locomotor tolerance could not be explained by a 
difference in the pharmacokinetics of ethanol between β4 KO and WT mice 
because the peak blood ethanol concentration (BEC), as well as the clearance 
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rate of ethanol after an i.p. injection of 2 g/kg was identical in the two genotypes 
(Fig. A1-4D).   
Because rapid tolerance is predictive of increased alcohol consumption, 
we compared voluntary ethanol intake in WT and β4 KO mice, utilizing a 
restricted access EtOH self-administration paradigm termed “drinking in the dark” 
(Rhodes et al., 2005; Rhodes et al., 2007).  This assay produces robust EtOH 
intake in C57BL/6J mice, the background strain of the β4 KOs.  Remarkably, β4 
KO mice consumed significantly greater levels of EtOH compared to 
consumption in WT mice during each of the first 3 nights of the assay (Fig. A1-
5A).  In addition, the ethanol intake averaged over four nights was significantly 
higher in β4 KO mice (Fig. A1-5B, F1,81 = 19.7, p < 0.001).  We measured blood 
alcohol levels (BAL) immediately following ethanol exposure on night 2 of the 
DID assay, where we observed the largest difference in intake between 
genotypes.  As expected, BALs of KO mice (26.62 ± 7.53; n = 4) were much 
higher than that of WT mice (5.85 ± 0.53 mM, n = 4).  Water intake between WT 
and KO mice was not different (Fig. A1-5C), suggesting that changes in ethanol 
consumption were not due to differences in drinking volume.  Importantly, there 
was also no significant difference between genotypes in sucrose intake, 
indicating that changes in ethanol drinking were specific for the drug (Fig. A1-
5D).  WT and KO mice had similar aversion for quinine, suggesting that the 
difference of EtOH intake was not due to aversive taste (Fig. A1-5D; n = 5).   
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A1.C. DISCUSSION  
Our results suggest remarkable parallels in the effects of the BK β4 
subunit on acute alcohol tolerance at the level of single channel recording, 
spike patterning, and behavioral studies.  The development of tolerance 
was apparent within a few minutes at each level of analysis in β4 KO but 
not WT mice.   
The bridge between molecular events and behavioral outcome is always 
difficult to establish.  We believe that our finding of β4-dependent tolerance at the 
single channel and action potential levels is a compelling candidate for mediating 
effects we see on behavior (locomotor tolerance and alcohol consumption).  
Because the β4 subunit is expressed in a number of brain regions (Gribkoff et al., 
2001; Uebele et al., 2000), we cannot rule out that regions outside the striatum 
may participate in the changes in ethanol-related behavior.  However, our focus 
on striatum is based, in part, on the known role this circuitry plays in these 
behavioral outcomes.  Ethanol, via both direct and indirect activation of DAergic 
neurons in the ventral tegmental area (Blomqvist et al., 1993; Ericson et al., 
1998; Larsson et al., 2002; Okamoto et al., 2006), increases dopamine release in 
the striatum, which is associated with both the motivational and locomotor 
properties of most abused drugs.  In addition, our data are consistent with recent 
reports in c-elegans indicating a role for BK channels in depression of locomotor 
effects of alcohol (Kaczorowski et al., 1996).  MSNs make up ~95 % of neurons 
in striatum and receive inputs from DAergic neurons in the VTA and substantia 
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nigra pars compacta.  MSNs express BK channels consisting of α and β4 
subunits that are potentiated by ethanol, an effect that develops little tolerance in 
response to acute alcohol.  In the absence of the β4 subunit, the rate of tolerance 
to ethanol potentiation is dramatically enhanced at both the single channel and 
whole cell level.  This is associated with an increase in the rate of tolerance to 
locomotor suppression elicited by both acute and chronic ethanol exposure in β4 
KO mice compared to WT mice.  The fact that β4 KO mice also self-administer 
more alcohol than WT animals, corroborates the important role β4 subunit 
expression has on alcohol tolerance.  This dramatic difference in tolerance and 
alcohol consumption is specific for ethanol because β4 KO mice consume equal 
amounts of water, quinine, and sucrose solution compared to WT mice.  In 
addition, the pharmacokinetics of ethanol does not differ between genotypes.   
At the macroscopic level, the influence of the BK channel in shaping APs 
in MSNs of the dorsal striatum is not surprising.  Studies carried out in CA1 
pyramidal neurons from the hippocampus (Gu et al., 2007; Shao et al., 1999), 
dorsal vagal neurons (Pedarzani et al., 2000), lateral amygdala (Faber and 
Sah, 2002) and purkinje cells (Edgerton and Reinhart, 2003; Sausbier et al., 
2004), report that toxin-mediated BK channel blockade widens APs, suggesting 
that BK channels facilitate repolarization.  In striatal interneurons and MSNs, 
BK contributions to shaping APs has also been reported (Bennett et al., 2000).  
Interestingly, our data showing that spike frequency is significantly higher in β4 
KO mice compared to WT mice, is consistent with a recent study in CA1 
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neurons by Brenner et al (2005) (Brenner et al., 2005) with the same knockout 
animals.  The similarity with the Brenner study confirms the role of β4 subunit 
mRNA, since it is highly expressed in both striatum and hippocampus (Behrens 
et al., 2000).  Although MSNs express other channels involved in shaping APs 
and neuronal excitability, the effects of EtOH on MSN excitability are likely 
mediated by BK channels.  First, delayed-rectifier and rapidly inactivating IA K
+
 
channels, the two other main potassium channels activated by depolarization in 
striatal MSNs, have been shown in other preparations to be insensitive to 50 
mM EtOH (Camacho-Nasi and Treistman, 1986), the concentration tested here.  
Additionally, tolerance to EtOH-mediated effects of AP patterns in MSNs 
observed in KO mice occurs over a similar time course to tolerance to EtOH-
mediated potentiation of BK single channel activity in the same mice.  Finally, 
the effects of ethanol on AP spike patterns are inhibited by charybdotoxin in β4 
KO mice suggesting a BKα dependent mode of drug action.   
Our data indicate that the BK β4 subunit controls tolerance to alcohol at 
both the molecular and behavioral levels.  Since a dramatic association between 
tolerance to alcohol and the propensity to develop alcoholism exists, our data 
suggest that the gene encoding the BK channel β4 subunit, KCNMB4 should be 
evaluated as a candidate gene for susceptibility to alcohol abuse and alcoholism.   
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A1.D. MATERIAL AND METHODS  
Cell culture: Our methods are essentially the same as previously published 
(Feinberg-Zadek and Treistman, 2007).  Briefly, α BK channels were derived 
from stable cell lines (Tseng-Crank et al., 1996), a gift from Peter Ahring (Ahring 
et al., 1997).  αβ4 channels were derived from cell lines stably expressing α and 
transiently expressing β4.   
Slice preparation and freshly isolated striatal neurons:  This is described in 
detail in Martin et al. (Martin et al., 2002).  Briefly, mouse brains were sliced 
(350 µm) using a Vibratome 3000 (USA) and incubated for up to 6 h at room 
temp (20-22
o
C) in a gassed (95% O2 and 5% CO2) saline solution.  Following 
enzymatic digestion with protease XIV (1 mg/ml), the tissue was mechanically 
triturated using fire-polished Pasteur pipettes, and cells were plated into a 35 
mm Petri dish.   
Electrophysiological recording: Single-cell cell-attached patch clamp recording 
used standard methods (Hamill et al., 1981).  We pulled patch electrodes from 
1.5 mm OD borosilicate capillary glass (Warner Instrument, CT) to a resistance 
of 4-6 MΩ.  The recording pipette solution was (in mM): 130 K2MeSO4, 2 MgCl2, 
2 CaCl2, 15 HEPES.  We set sampling rate and low-pass filter at 10 and 2 kHz, 
respectively, using an EPC10 double amplifier (HEKA Electronics, Germany).  
Voltage and current were digitized and stored using PatchMaster 2.1 (HEKA 
Electronics, Germany).  We recorded BK activity for 20 sec, every minute, three 
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times to ensure a stable baseline.  We averaged the open probability of these 
three controls, and all subsequent NPo values were expressed relative to this 
average.  Drugs were applied and BK channel activity was recorded in 
successive blocks of 20 sec, every minute, for up to 10 min.  Data were 
expressed as mean ± SEM (with the number of cells or patches in parentheses).  
For whole cell recording in slices, MSNs were visually identified, and 
characterized electrophysiologically.  Series resistance (Rs) was monitored 
throughout experiments.  Recordings showing Rs changes of more than 15-20% 
were discarded.  We used MultiClamp 700 B and EPC10 double amplifiers, at a 
rate of 20 kHz, to record APs.  Voltage and current traces were acquired and 
analyzed with pClamp 10 (Molecular Devices; CA USA) and FitMaster 2.15 
(HEKA Elektronik, Germany) software packages.   
Charybdotoxin treatment: To ensure we recorded exclusively αβ4 channels in 
HEK-293 cells and in WT striatal neurons, we added low concentrations of 
charybdotoxin (ChTx), a toxin that rapidly and selectively inhibits activity of α and 
αβ1 BK channels at 100 nM (Behrens et al., 2000).  Calculation of the steady-
state channel activity, NPo.  We used all-points amplitude histograms to calculate 
BK activity, determined from the product of the total number of functional 
channels present in the membrane patch (N) and the probability that a particular 
channel was open under steady-state conditions (Po).  Calculations of NPo were 
performed with TAC analysis software (Bruxton Inc, OR, USA).  NPo ratios 
generated from the first ethanol exposure were used for normalization of the 
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data.  BK activity was measured as NPo ratio percent ((NPo ethanol / NPo 
control) X 100).   
Behavioral experiments:  Male and female C57BL/6J mice (Jackson Laboratory) 
between 8-14 weeks of age were housed 3-4 animals per cage until the start of 
each experiment.  For drinking in the dark, mice purchased from Jackson Labs 
were habituated to BNRI colony rooms for at least 2 weeks and the DID 
procedure room for at least 1 wk prior to the start of experiments.  Mice used for 
locomotor studies were bred and raised at the BNRI.  β4 KO mice were back-
crossed at least ten generations to the C57BL/6J strain.  We kept mice on a 
standard 12 h light/dark cycle with lights on at 7:00am and off at 7:00pm, and 
given food and water ad libitum.  We conducted all experiments in accordance 
with the guidelines for care and use of animals provided by the National Institute 
of Health, as well as with an approved animal protocol from the Institutional 
Animal Care and Use Committee of the UMass Medical School.   
Drugs and drinking solutions: Ethanol solution was prepared from 190 proof 
absolute anhydrous ethanol (Pharmco-Aaper brand, Brookfield, CT) diluted to 10 
% ethanol (v/v) using tap water.  Sucrose (EMD) and quinine hydrochloride 
(Sigma-Aldrich, St. Louis, MO) was dissolved in tap water to make a 10 % (w/v) 
and 1 mM concentration solution, respectively.   
Drinking in the dark (DID): Two hours after lights out, water bottles were removed 
and replaced with 10 % ethanol bottles and left in place for two hours.  Control 
animals had water replaced with another water bottle or 10 % sucrose or 1 mM 
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quinine solution.  An empty cage was set up and a water bottle was replaced with 
ethanol to control for evaporation.   
Activity Monitoring: Locomotor activity was measured by a photobeam system 
(San Diego Instruments).  Mice were placed in activity cages and allowed to 
habituate for 90 minutes prior to first i.p. injection of either saline or ethanol (2 
g/kg, 20 % v/v with saline, 10 ml/g body weight).   
Ethanol metabolism: Prior to an ethanol injection, blood was obtained from the 
tail vein (~30uL each time point) to provide a zero point.  After a 2 g/kg i.p. 
injection of EtOH, blood samples were taken at 30, 60, 90, and 120 min.  For 
BEC measurements after DID, mice were culled immediately after a 2 hr EtOH 
exposure on night 2 and trunk blood was collected in heparinized capillary tubes.  
Blood was centrifuged (1500Xg for 5 min) and analyzed using an alcohol 
oxidase-based assay.  BECs were measured on a GM7 Micro-Stat Analyzer 
(Analox Inst Ltd.)  
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Fig. A1-1. BK β4 subunit influences tolerance: A) αβ4 BK Single channel activity recorded at 
hyperpolarized potentials from HEK293 cells.  B) EtOH’s effects on αβ4 BK channel activity 
averaged over several cells (n values indicated in graphs).  Panel C shows α BK single channel 
activity before (control) and during EtOH exposure.  D) Magnitude of EtOH’s effects on α BK 
activity averaged over several cells (n values are indicated in graphs).  Representative traces of 
BK activity before (control) and during EtOH exposure (EtOH).  ‘C’ and ‘O’ refer to BK closed and 
open states, respectively.  NPo indicates BK channel open probability under each experimental 
condition.  In graphs (B and D) lightly shaded areas indicate where BK channel potentiation 
typically occurs, while the darker shaded areas show where tolerance is observed.  EtOH effects 
are expressed as % of baseline.   
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Fig. A1-2: β4 subunit controls tolerance of BK single channel activity in 
freshly isolated striatal MSNs.  A) DNA agarose gel shows that only β4 
expression is lacking in striatum isolated from β4 KO mice; whereas β1 mRNA is 
present in both WT and KO animals.  “L” denotes the 100 bp marker on 
molecular weight ladder.  Base pair number is indicated in the left hand margin.  
“B1” and “B4” refer to BK β1 and β4 subunits, respectively.  “NORT” are negative 
controls with omitted reverse transcriptase and “X” indicates columns where no 
material was loaded.  Single channel activity recorded from striatal MSNs acutely 
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isolated from WT (B and C) or β4 KO (D and E) mice, respectively.  B and D) 
Representative traces of BK activity from WT and KO mice, before (control) and 
during EtOH exposure (EtOH).  ‘C’ and ‘O’ refer to closed and open states.  NPo 
indicates BK channel open probability.  C and E) graphs show magnitude of 
EtOH’s effects averaged over several cells (n values are indicated in graphs).  
Lightly shaded areas indicate where BK channel potentiation typically occurs, 
while the darker shaded areas show where tolerance is observed.  EtOH effects 
are expressed as % of baseline.    
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Fig. A1-3.
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Fig. A1-3: EtOH-mediated decrease of MSN excitability exhibits tolerance in 
KO, but not WT mice.  A) Number of APs recorded from WT (filled columns) 
and KO (open columns) MSNs following a series of incremental (50 pA) current 
steps (50 to 300 pA).  B) Representative action potential trains evoked in a slice 
preparation (Slices) by a single 100 pA current step in WT (left panel) and KO 
(middle panel) mice before (control) and after 50 mM EtOH exposure (2 or 8 
min).  Two min after EtOH, the number of APs is smaller in both WT and KO 
mice.  While KO mice MSN excitability partially recovers 8 min after EtOH 
exposure (bottom trace; right panel), WT neuronal excitability remains depressed 
(left panel, bottom trace).  Results obtained in slices were reproduced on freshly 
isolated neurons from KO mice (right panel; β4 KO / F.I. cells).  C) Averaged 
change in action potential number recorded in MSNs in slices and freshly 
isolated after 2 or 8 minutes EtOH exposure, presented as percent of control 
before EtOH exposure in MSNs from WT and β4 KO striatal slices.  5/7 neurons 
were ethanol sensitive and developed tolerance in β4 KO MSNs, whereas 7/9 
MSNs from WT were ethanol sensitive and did not develop tolerance (*p < 0.05).  
The inset shows the ratio of AP number at 2 and 8 min reported as fold recovery 
from ethanol; value below the broken bar indicates a further decrease of APs 
number at 8 min compared to 2 min EtOH (solid column; WT), while value above 
the line indicate a recovery (KO); F1,10 = 27.6, p < 0.001.  D) 100 nM ChTx blocks 
EtOH effects on striatal MSNs AP patterns in slices (left panel) and freshly 
isolated neurons (F.I cells, right panel).  E) Number of APs measured every 
minute before (open circles) and during 50 mM EtOH exposure (solid circles) in 
presence of 100 nM ChTx.  Data from slices and freshly isolated MSNs were 
combined.  
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Fig. A1-4: Effects of EtOH on locomotor activity in WT and β4 KO mice.  A) 
Ambulatory activity of WT mice 5, 10 and 15 min after a 2 g/kg i.p. EtOH injection 
on day 0, 1 and 4.  Each data point represents 5 minutes summed activity.  
Asterisks above symbols indicate significant locomotor activity on both day 1 and 
4 of EtOH injection at each time point (5, 10 and 15 min) compared to saline 
injection baseline (represented by the dashed line).  Asterisk next to bracket 
indicates difference between day 1 and 4 at 15 min time point only.  B) Effects of 
the same EtOH dose at the same time points in KO mice.  C) Fifteen minute 
summed activity immediately after a daily ethanol injection.  Note the rapid 
development of tolerance for KO mice upon repeated injections of 2 g/kg EtOH, 
compared to WT mice.  D) Blood alcohol concentration in WT and KO mice 
before (time 0) and at 30 min after a single i.p. injection of 2 g/kg ethanol.  One-
way ANOVA, Tukey post-hoc, * p < 0.05, *** p < 0.001.  
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Fig. A1-5: EtOH consumption is higher in β4 KO.  A) EtOH consumption of 
WT (black squares) and β4 KO mice (white squares) using a restricted access 
single bottle self-administration assay.  Measurements were taken every day for 
four days for two hours after lights were turned off.  B) Average daily EtOH intake 
in WT and KO mice.  C and D illustrate water, sucrose and quinine intake of WT 
(black squares and circles) and KO (white squares and circles) mice, 
respectively.  No significant difference was observed in either condition. One 
Way ANOVA, Tukey post-hoc, * p < 0.05, ** p < 0.01, *** p < 0.001.  
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